ATAXIA-TELANGIECTASIA GENE

Abstract: A purified and isolated gene, designated ATM, mutations of which cause ataxia-telangiectasia.

Description: ATAXIA-TELANGIECTASIA GENE TECHNICAL FIELD The present invention relates to the determination of the gene sequence, mutations of which cause ataxia- telangiectasia (A-T) , designated ATM, and the use of the gene and gene products in detection of carriers of the A-T gene, and preparing native and transgenic organisms in which the gene products encoded by the ATM gene or its homolog in other species are artificially produced, or the expression of the native ATM gene is modified. BACKGROUND OF THE INVENTION Ataxia-telangiectasia (A-T) is a progressive genetic disorder affecting the central nervous and immune systems, and involving chromosomal instability, cancer predisposition, radiation sensitivity, and cell cycle abnormalities. Studies of the cellular phenotype of A-T have pointed to a defect in a putative system that processes a specific type of DNA damage and initiates a signal transduction pathway controlling cell cycle progression and repair. For a general review of Ataxia-telangiectasia, reference is hereby made to the review Ataxia- Telanqiectasis: Closer to Unraveling the Mystery, Eur. J. Hum. Genet. (Shiloh, 1995) which, along with its cited references, is hereby incorporated by reference as well as to the reviews by Harnden (1994) and Taylor et al (1994) . Despite extensive investigation over the last two decades, A-T has remained a clinical and molecular enigma. A-T is a multi-system disease inherited in an autosomal recessive manner, with an average worldwide frequency of 1:40,000 - 1:100,000 live births and an estimated carrier frequency of 1% in the American population. Notable concentrations of A-T patients outside the United States are in Turkey, Italy and Israel. Israeli A-T patients are Moroccan Jews, Palestinian Arabs, Bedouins and Druzes. Cerebellar ataxia that gradually develops into general motor dysfunction is the first clinical hallmark and results from progressive loss of Purkinje cells in the cerebellum. Oculocutaneous telangiectasia (dilation of blood vessels) develops in the bulbar conjunctiva and facial skin, and is later accompanied by graying of the hair and atrophic changes in the skin. The co-occurrence of cerebellar ataxia and telangiectases in the conjunctivae and occasionally on the facial skin - the second early hallmark of the disease - usually establishes the differential diagnosis of A-T from other cerebellar ataxias. Somatic growth is retarded in most patients, and ovarian dysgenesis is typical for female patients. Among occasional endocrine abnormalities, insulin-resistant diabetes is predominant, and serum levels of alpha-fetoprotein and carcinoembryonic antigen are elevated. The thymus is either absent or vestigial, and other immunological defects include reduced levels of serum IgA, IgE or IgG2, peripheral lymphopenia, and reduced responses to viral antigens and allogeneic cells, that cause many patients to suffer from recurrent sinopulmonary infections. Cancer predisposition in A-T is striking: 38% of patients develop malignancies, mainly lymphoreticular neoplasms and leukemias. But, A-T patients manifest acute radiosensitivity and must be treated with reduced radiation doses, and not with radiomimetic chemotherapy. The most common cause of death in A-T, typically during the second or third decade of life, is sinopulmonary infections with or without malignancy. The complexity of the disease is reflected also in the cellular phenotype. Chromosomal instability is expressed as increased chromosomal breakage and the appearance in lymphocytes of clonal translocations specifically involving the loci of the immune system genes. Such clones may later become predominant when a lymphoreticular malignancy appears. Primary fibroblast lines from A-T patients show accelerated senescence, increased demand for certain growth factors, and defective cytoskeletal structure. Most notable is the abnormal response of A-T cells to ionizing radiation and certain radiomimetic chemicals. While hypersensitive to the cytotoxic and clastogenic effects of these agents, DNA synthesis is inhibited by these agents to a lesser extent than in normal cells. The concomitant lack of radiation-induced cell cycle delay and reduction of radiation-induced elevation of p53 protein are evidence of defective checkpoints at the Gl, S and G2 phases of the cell cycle. The Gl and G2 checkpoint defects are evident as reduced delay in cell cycle progression following treatment with ionizing radiation or radiomimetic chemicals, while the rise in the p53 protein level usually associated in normal cells with radiation-induced Gl arrest is delayed in A-T cells. The defective checkpoint at the S phase is readily observed as radioresistant DNA synthesis (RDS) . Increased intrachromosomal recombination in A-T cells was also noted recently. Cellular sensitivity to DNA damaging agents and RDS are usually considered an integral part of the A-T phenotype. Although these clinical and cellular features are considered common to all "classical" A-T patients, variations have been noted. Milder forms of the disease with later onset, slower clinical progression, reduced radiosensitivity and occasional absence of RDS have been described in several ethnic groups (Fiorilli, 1985; Taylor et al., 1987; Ziv et al. , 1989; Chessa et al. , 1992). Additional phenotypic variability possibly related to A-T is suggested by several disorders that show "partial A-T phenotype" with varying combinations of ataxia, immunodeficiency and chromosomal instability without telangiectases (12-16) (Ying & Decoteau, 1983; Byrne et al. , 1984; Aicardi et al. , 1988; Maserati et a;., 1988; Friedman & Weitberg, 1993) . Still, other disorders display the A-T phenotype and additional features; most notable is the Nijmegen breakage syndrome that combines A-T features with microcephaly, sometimes with mental retardation, but without telangiectases (Weemaes et al., 1994). Prenatal diagnoses of A-T using cytogenetic analysis or measurements of DNA synthesis have been reported, but these tests are laborious and subject to background fluctuations and, therefore, not widely used. A-T homozygotes have two defective copies of the A-T gene and are affected with the disease. A-T heterozygotes (carriers) have one normal copy of the gene and one defective copy of the gene and are generally healthy. When two carriers have children, there is a 25% risk in every pregnancy of giving birth to an A-T affected child. A-T heterozygotes show a significant excess of various malignancies, with a 3- to 4-fold increased risk for all cancers between the ages of 20 and 80, >and a 5-fold increased risk of breast cancer in women. These observations turn A-T into a public health problem and add an important dimension to A-T research, particularly to heterozygote identification. Cultured cells from A-T heterozygotes indeed show an intermediate degree of X-ray sensitivity, but the difference from normal cells is not always large enough to warrant using this criterion as a laboratory assay for carrier detection. The main reason for the unreliability of this assay is the various degrees of overlap between A-T heterozygotes and non-heterozygotes with respect to radiosensitivity. Cytogenetic assays for carriers have the same problems as for prenatal diagnosis, they are labor intensive and not always consistent. The nature of the protein missing in A-T is unknown. Cell fusion studies have established four complementation groups in A-T, designated A, C, D and E, suggesting the probable involvement of at least four genes or four types of mutations in one gene, with inter-allelic complementation. These four groups are clinically indistinguishable and were found to account for 55%, 28%, 14% and 3% of some 80 patients typed to date. In Israel, several Moroccan Jewish patients were assigned to group C, while Palestinian Arab patients were assigned to group A. The general chromosomal localization of the putative A- T gene(s) has been determined, but not the sequence. An A-T locus containing the A-T(A) mutations was localized by Gatti et al. (1988) to chromosome 11, region q22-23, using linkage analysis. The A-T(C) locus was localized by applicant to the same region of chromosome 11, region q22-23, by linkage analysis of an extended Jewish Moroccan A-T family (Ziv et al., 1991). Further studies, conducted by an international consortium in which applicant participated (McConville et al., 1990; Foroud et al. , 1991; Ziv et al. , 1992), reconfirmed this localization in a series of studies and gradually narrowed the A-T locus to an interval estimated at 4 centimorgan, which probably contains also the A-T(E) mutations. A proposed gene for complementation group D is disclosed in United States patent 5,395,767 to Murnane et al., issued March 7, 1995. This sequence was found not to be mutated in any complementation group of A-T. Further, the gene sequence was mapped physically distant from the presumptive A-T locus. Therefore, in order to better understand the nature and effects of A-T, as well as to more accurately and consistently determine those individuals who may carry the defective gene for A-T, it would be advantageous to isolate and determine the gene sequence, mutations of which are responsible for causing A-T, and utilize this sequence as a basis for detecting carriers of A-T and thereby be able to more beneficially manage the underlying conditions and predispositions of those carriers of the defective gene. SUMMARY OF THE INVENTION AND ADVANTAGES According to the present invention, a gene designated ATM and mutations of this gene which cause ataxia- telangiectasia (A-T) , has been purified, isolated and determined as well as mutations of the gene. The present invention further includes the method for identifying carriers of the defective A-T gene in a population and defective A-T gene products. Further, the present invention provides transgenic and knockout nonhuman animal and cellular models. The role of the ATM gene in cancer predisposition makes this gene an important target for screening. The detection of A-T mutation carriers is particularly significant in light of their radiation-sensitivity so that carrier exposure to radiation can be properly monitored and avoided. BRIEF DESCRIPTION OF THE DRAWINGS Other advantages of the present invention will be readily appreciated as the same becomes better understood by reference to the following detailed description when considered in connection with the accompanying drawings wherein: FIGURES 1A-E illustrate the positional cloning steps to identify the A-T gene(s) wherein Figure 1A is a high-density marker map of the A-T region on chromosome llq22-23 (Vanagaite et al., 1995), constructed by generating microsatellite markers within genomic contigs spanning the region and by physical mapping of available markers using the same contigs, the prefix "Dll" has been omitted from the marker designations, FDX: the adrenal ferredoxin gene, ACAT: the acetoacetyl-coenzyme A thiolase gene, the stippled box denotes the A-T interval, defined recently by individual recombinants between the markers S1818 and S1819 in a consortium linkage study (Lange et al., 1995), the solid .box indicates the two-lod confidence interval for A-T obtained in that study, between S1294 and S384; Figure IB illustrates a part of a YAC contig constructed across this region (Rotman et al. , 1994c) ; Figure 1C illustrates part of a cosmid contig spanning the S384-S1818 interval, generated by screening a chromosome-11 specific cosmid library with YAC clones Y16 and Y67, and subsequent contig assembly of the cosmid clones by physical mapping (Shiloh, 1995) ; Figure ID illustrates products of gene hunting experiments wherein solid boxes denote cDNA fragments obtained by using cosmid and YAC clones for hybrid selection of cDNAs (Lovett et al. 1991; Tagle et al. , 1993) from a variety of tissues, open boxes denote putative exons isolated from these cosmids by exon trapping (Church et al. , 1993) , these sequences hybridized back to specific cosmids (broken lines) , which allowed their physical localization to specific subregions of the contig (dotted frames) ; and Figure IE illustrates a 5.9 kb cDNA clone, designated 7-9 (SEQ ID No:l) , identified in a fibroblast cDNA library- using the cDNA fragments and exons in ID as a probe wherein the open box denotes an open reading frame of 5124 nucleotides, solid lines denote untranslated regions, striped arrowheads denote two Alu elements at the 3' end, and wherein dotted lines drawn between cDNA fragments and exons the cDNA indicate colinearity of sequences; FIGURE 2 is a diagram of the physical map of the ATM region and relationship to the cDNA wherein the top line represents a linear map of the region containing known genetic markers (the prefix Dll has been omitted from marker designations) and shown below the linear map is a portion of a cosmid contig spanning the region with the arch between ends of cosmids A12 and B4 represents a genomic PCR product, a contig of cDNA clones which span the ATM ORF is shown at the bottom of the figure, broken lines denote the position of specific cDNA sequences with the cosmid contig; FIGURE 3 is a diagram of the molecular cloning of the coding region of the Atm transcript wherein the top bar depicts the entire length of the cloned sequence, double crosshatched bars are cDNA clones, dotted bars are RT-PCR products, and bars with diagonal lines are PCR products obtained from a cDNA library; FIGURE 4 is a diagram of the comparison of amino acid sequences of the human ATM and mouse Atm proteins wherein the alignment of amino acid sequences spanning the carboxy terminal portions that contain the PI 3-kinase domains of the two proteins are depicted with identical amino acids aligned by vertical bars, and similar amino acids by one or two dots; and FIGURE 5A-B diagrams the chromosomal location of Atm in the mouse genome with (A) showing the segregation patterns of Atm and flanking genes wherein each column represents the chromosome identified in the backcross progeny that was inherited from the (C57BL/6J x M. spretus) F 1 parent, and shaded boxes represent the presence of a C57BL/6J allele and empty boxes represent the presence of a M. spretus allele, the number of offspring inheriting each type of chromosome is listed at the bottom of each column, and (B) is a diagram of a partial chromosome 9 linkage map showing the location of Atm in relation to linked genes with the number of recombinant N 2 animals over the total number of N 2 animals typed plus the recombination frequencies, expressed as genetic distance in centimorgans (± one standard error) is shown for each pair of loci to the left of the map, where no recombinants were found between loci, the upper 95% confidence limit of the recombination distance is given in parentheses, the positions of loci in human chromosomes are shown to the right of the map. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT The present invention consists of a purified, isolated and cloned nucleic acid sequence encoding a gene, designated ATM, mutations in which cause ataxia-telangiectasia and genetic polymorphisms thereof. The nucleic acid can be genomic DNA, cDNA or mRNA. The complete coding sequence of the ATM gene is set forth in SEQ ID No:2 and was submitted to the GenBank database under accession number U33841. There is extensive alternate splicing at the 5' untranslated region (5'UTR) of the ATM transcript giving rise to twelve different 5' UTRs. The sequence of the longest 5'UTR is set forth in SEQ ID No:9. The first exon in this sequence is designated lb. There is an alternative leader exon, designated la (SEQ ID No:10) . The sequence of the complete 3'UTR is set forth in SEQ ID No:8. Together these sequences contain the complete sequence of the ATM transcript. Polymorphisms are variants in the sequence generally found between different ethnic and geographic locations which, while having a different sequence, produce functionally equivalent gene products. Current mutation data (as shown in Tables 1 and 2) indicate that A-T is a disease characterized by considerable allelic heterogenicity. Mutations imparting defects into the A-T gene can be point mutations, deletions, insertions or rearrangements. The mutations can be present within the nucleotide sequence of either/or both alleles of the ATM gene such that the resulting amino acid sequence of the ATM protein product is altered in one or both copies of the gene product; when present in both copies imparting ataxia- telangiectasia. Alternatively, a mutation event selected from the group consisting of point mutations, deletions, insertions and rearrangements could have occurred within the flanking sequences and/or regulatory sequences of ATM such that regulation of ATM is altered imparting ataxia- telangiectasia. Table 1 illustrates several mutations in the ATM gene found in A-T patients. Mutations in the ATM gene were found in all of the complementation groups suggesting that ATM is the sole gene responsible for all A-T cases. Table 2 illustrates the 44 mutations identified to date in applicant's patient cohort and include 34 new ones and 10 previously listed in Table 1. These mutations were found amongst 55 A-T families: many are unique to a single family, while others are shared by several families, most notably the 4 nt deletion, 7517del4, which is common to 6 A-T families from South-Central Italy. The nature and location of A-T mutations, as set forth in Table 2, provide insight into the function of the ATM protein and the molecular basis of this pleiotropic disease. This series of 44 A-T mutations is dominated by deletions and insertions. The smaller ones, of less than 12 nt, reflect identical sequence alterations in genomic DNA. Deletions spanning larger segments of the ATM transcript were found to reflect exon skipping, not corresponding genomic deletions. Of the 44 A-T mutations identified, 39 (89%) are expected to inactivate the ATM protein by truncating it, by abolishing correct initiation or termination of translation, or by deleting large segments. Additional mutations are four smaller in-frame deletions and insertions, and one substitution of a highly conserved amino acid at the PI 3-kinase domain. The emerging profile of mutations causing A-T is thus dominated by those expected to completely inactivate the ATM protein. ATM mutations with milder effects appear to result in phenotypes related, but not identical, to A-T. In view of the pleiotropic nature of the ATM gene, the range of phenotypes associated with various ATM genotypes may be even broader, and include mild progressive conditions not always defined as clear clinical entities as discussed herein below in Example 3. Screening for mutations in this gene in such cases will reveal wider boundaries for the molecular pathology associated with the ATM gene. The present invention therefore allows the identification of these mutations in subjects with related phenotypes to A-T. The ATM gene leaves a great deal of room for mutations: it encodes a large transcript . The variety of mutations identified in this study indeed indicates a rich mutation repertoire. Despite this wealth of mutations, their structural characteristics point to a definite bias towards those that inactivate or eliminate the ATM protein. The nature or distribution of the genomic deletions among these mutations do not suggest a special preponderance of the ATM gene for such mutations, such as that of the dystrophin (Anderson and Kunkel, 1992) or steroid sulfatase (Ballabio et al., 1989) genes which are particularly prone to such deletions. Thus, one would have expected also a strong representation of missense mutations, which usually constitute a significant portion of the molecular lesions in many disease genes (Cooper and Krawczak, 1993; Sommer, 1995) . However, only one such mutation was identified in the present study. Other point mutations reflected in this series are those that probably underlie the exon skipping deletions observed in many patients, again, exerting a severe structural effect on the ATM protein. In cloning the gene for A-T (Example 2) , the strategy used was a standard strategy in identifying a disease gene with an unknown protein product known as positional cloning, as is well known in the art. In positional cloning, the target gene is localized to a specific chromosomal region by establishing linkage between the disease and random genetic markers defined by DNA polymorphisms. Definition of the smallest search interval for the gene by genetic analysis is followed by long-range genomic cloning and identification of transcribed sequences within the interval. The disease gene is then identified among these sequences, mainly by searching for mutations in patients. Several important and long sought disease genes were isolated recently in this way (Collins, 1992; Attree et al. , 1992; Berger et al. , 1992; Chelly et al. , 1993; Vetrie et al., 1993; Trofatter et al. , 1993; The Huntington's Disease Collaborative Research Group, 1993; The European Polycystic Kidney Disease Consortium, 1994; Miki et al. , 1994). Two complementary methods were used for the identification of transcribed sequences (gene hunting) : hybrid selection based on direct hybridization of genomic DNA with cDNAs from various sources (Parimoo et al. , 1991; Lovett et al., 1991); and exon trapping (also called exon amplification) , which identifies putative exons in genomic DNA by virtue of their splicing capacity (Church et al. , 1993) . In hybrid selection experiments, cosmid and YAC clones served to capture cross-hybridizing sequences in cDNA collections from placenta, thymus and fetal brain, using the magnetic bead capture protocol (Morgan et al. , 1992; Tagle et al., 1993). In parallel experiments, YAC clones were bound to a solid matrix and used to select cDNA fragments from a heterogeneous cDNA collection representing several human tissues (Parimoo et al. , 1993). The cosmids were also used for exon trapping with the pSPL3 vector (Church et al., 1994) . The captured cDNA fragments and trapped exons were mapped back to the A-T region by hybridization to several radiation hybrids containing various portions of the llq22- 23 region (Richard et al., 1993; James et al. , 1994), and to high-density grids containing all the YACs and cosmids spanning this interval. An extensive transcriptional map of the A-T region was thus constructed (Shiloh et al., 1994) . Pools of adjacent cDNA fragments and exons, expected to converge into the same transcriptional units, were used to screen cDNA libraries. A cluster of 5 cDNA fragments and 3 exons mapped in close proximity to the marker D11S535, where the location score for A-T had peaked (Lange et al. , 1995). All these sequences hybridized to the same 5.9 kb of the cDNA clone, 7-9, (SEQ ID No:l) obtained from a fibroblast cDNA library. Hybridization of the 7-9 cDNA clone to the radiation hybrid panel indicated that the entire transcript was derived from the chromosome 11 locus. The full sequence of this clone (SEQ ID No:l) was obtained using a shotgun strategy, and found to contain 5921 bp which includes an open reading frame (ORF) of 5124 nucleotides, a 538 bp 3' untranslated region (3' UTR) , and a 259 bp 5' non-coding sequence containing stop codons in all reading frames. (Genbank Accession No. U26455) . Two Alu repetitive elements were observed at the 3' end of this clone and in nine smaller clones representing this gene from the same cDNA library. Since no polyadenylation signal was identified in these cDNA clones, their poly(A) tracts were assumed to be associated with the Alu element rather than being authentic poly(A) tails of these transcripts. This assumption was later supported when applicants identified a cDNA clone derived from the same gene in a leukocyte cDNA library, with an alternative 3' UTR containing a typical polyadenylation signal. Alignment of the cDNA with the genomic physical map showed that the corresponding gene is transcribed from centromere to telomere. Hybridization of a probe containing the entire ORF of clone 7-9 to northern blots from various tissues and cell lines revealed a major transcript of 12 kb, later shown to be 13 kb, in all tissues and cell types examined, and minor species of various sizes in several tissues, possibly representing alternatively spliced transcripts of the corresponding gene or other homologous sequences. Genomic sequencing later identified the 5' non-coding region of clone 7-9 as sequences of the unspliced adjacent intron. Two other cDNA clones from a leukocyte cDNA library were found to contain this intronic sequence in their 5' ends. These clones may represent splicing intermediates. The 7-9 cDNA clone represents only part of the ATM gene transcript. Successive screening of randomly-primed cDNA libraries identified a series of partly overlapping cDNA clones and enabled the construction of a cDNA contig of about 10 Kb (Fig. 2) . The gene coding for this transcript spans about 150 Kb of genomic DNA. The composite cDNA of 9860 bp (GenBank Accession No. U33841; SEQ ID No:2) includes an open reading frame of 9168 nucleotides, a 538 bp 3' untranslated region (UTR) , and a 164 bp 5' UTR containing stop codons in all reading frames. The sequence surrounding the first in-frame initiation codon (ACCATGA) resembles the consensus sequence proposed by Kozak for optimal initiation of translation, (A/G) CCATGG (ref. 20 in Savitsky et al, 1995b) . No polyadenylation signal was found at the 3' UTR. The same poly(A) tail was found in all cDNA clones and 3' RACE products isolated to date in applicant's laboratory, however, this poly(A) tail most likely belongs to the Alu element contained in the 3' UTR. Sequencing and PCR analysis of 32 partial ATM cDNA clones, obtained from 11 cDNA libraries representing 8 different tissues, did not show coding sequences in addition to those presented herein. The invention further provides a purified protein as encoded by the ATM gene (SEQ ID No:2) and analogs thereof. A consensus complete sequence is set forth in SEQ ID No:3. The present invention further provides for mutations in SEQ ID No:2 and SEQ ID No:3 which cause ataxia-telangiectasia, for example, as set forth in Tables 1 and 2. This product (SEQ ID No:3) of the ATM Open Reading Frame (SEQ ID No:2) is a large protein of 3056 amino acids, with an expected molecular weight of 350.6 kDa. The ATM gene product (SEQ ID No:3) contains a PI-3 kinase signature at codons 2855-2875, and a potential leucine zipper at codons 1217-1238. The presence of this leucine zipper may suggest possible dimerization of the ATM protein or interaction with additional proteins. No nuclear localization signal, transmembrane domains or other motifs were observed in this protein sequence. The ATM gene product is a member of a family of large proteins that share a highly conserved carboxy-terminal region of about 300 amino acids showing high sequence homology to the catalytic domain of PI-3 kinases. Among these proteins are Tellp and Meclp in budding yeast, rad3p in fission yeast, the TOR proteins in yeast and their mammalian counterpart, FRAP (RAFT1) , MEI-41 in Drosophila melanogaster, and the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs) in mammals. All of these proteins are implicated in cell cycle control and some of them, like Meclp, rad3p and DNA-PKcs are involved in response to DNA damage (Table 3) . The central core of the PI-3 kinase-like domain contains two subdomains with highly conserved residues present in nearly all kinases, including protein and PI-3 kinases. The residues Asp and Asn (at positions 2870 and 2875 in ATM) , and the triplet Asp-Phe-Gly (at positions 2889-2891) , which represents the most highly conserved short stretch in the protein kinase catalytic domain, have been implicated in the binding of ATP and phosphotransferase activity. Mutations in the genes encoding these proteins result in a variety of phenotypes that share features with A-T, such as radiosensitivity, chromosomal instability, telomere shortening, and defective cell cycle checkpoints (reviewed by Savitsky et al., 1995a and b; Zakian, 1995) . A possible working model for the ATM protein's function is DNA-PK, a serine/threonine protein kinase that is activated in vitro by DNA double-strand breaks and responds by phosphorylating several regulatory proteins (Gottlieb and Jackson, 1994) . The ATM protein may be responsible for conveying a signal evoked by a specific DNA damage to various checkpoint systems, possibly via lipid or protein phosphorylation. The present invention further includes a recombinant protein encoded by SEQ ID No:3. This recombinant protein is isolated and purified by techniques known to those skilled in the art. An analog will be generally at least 70% homologous over any portion that is functionally relevant. In more preferred embodiments, the homology will be at least 80% and can approach 95% homology to the ATM protein. The amino acid sequence of an analog may differ from that of the ATM protein when at least one residue is deleted, inserted or substituted but the protein remains functional and does not cause A-T. Differences in glycosylation can provide analogs. The present invention provides an antibody, either polyclonal or monoclonal, which specifically binds to a polypeptide/protein encoded by the ATM gene and/or mutant epitopes on the protein. Examples of such antibodies are set forth in Example 5. In preparing the antibody, the protein (with and without mutations) encoded by the ATM gene and polymorphisms thereof is used as a source of the immunogen. Peptide amino acid sequences isolated from the amino acid sequence as set forth in SEQ ID No:3 or mutant peptide sequences can also be used as an immunogen. The antibodies may be either monoclonal or polyclonal. Conveniently, the antfibodies may be prepared against a synthetic peptide based on the sequence, or prepared recombinantly by cloning techniques or the natural gene product and/or portions thereof may be isolated and used as the immunogen. Such proteins or peptides can be used to produce antibodies by standard antibody production technology well known to those skilled in the art as described generally in Harlow and Lane, Antibodies : A Laboratory Manual , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1988. For producing polyclonal antibodies a host, such as a rabbit or goat, is immunized with the protein or peptide, generally with an adjuvant and, if necessary, coupled to a carrier; antibodies to the protein are collected from the sera. For producing monoclonal antibodies, the technique involves hyperimmunization of an appropriate donor, generally a mouse, with the protein or peptide fragment and isolation of splenic antibody producing cells. These cells are fused to a cell having immortality, such as a myeloma cell, to provide a fused cell hybrid which has immortality and secretes the required antibody. The cells are then cultured, in bulk, and the monoclonal antibodies harvested from the culture media for use. The antibody can be bound to a solid support substrate or conjugated with a detectable moiety or be both bound and conjugated as is well known in the art. (For a general discussion of conjugation of fluorescent or enzymatic moieties see Johnstone and Thorpe, Immuno chemistry in Practice, Blackwell Scientific Publications, Oxford, 1982.) The binding of antibodies to a solid support substrate is also well known in the art. (see for a general discussion Harlow and Lane Antibodies : A Laboratory Manual , Cold Spring Harbor Laboratory Publications, New York, 1988) The detectable moieties contemplated with the present invention can include, but are not limited to, fluorescent, metallic, enzymatic and radioactive markers such as biotin, gold, ferritin, alkaline phosphatase, β-galactosidase, peroxidase, urease, fluorescein, rhodamine, tritium, 14 C and iodination. The present invention provides vectors comprising an expression control sequence operatively linked to the nucleic acid sequence of the ATM gene, SEQ ID No:2 and portions thereof as well as mutant sequences which lead to the expression of A-T. The present invention further provides host cells, selected from suitable eucaryotic and procaryotic cells, which are transformed with these vectors. Using the present invention, it is possible to transform host cells, including E. coli , using the appropriate vectors so that they carry recombinant DNA sequences derived from the ATM transcript or containing the entire ATM transcript in its normal form or a mutated sequence containing point mutations, deletions, insertions, or rearrangements of DNA which lead to the expression of A- T. Such transformed cells allow the study of the function and the regulation of the A-T gene. Use of recombinantly transformed host cells allows for the study of the mechanisms of A-T and, in particular it will allow for the study of gene function interrupted by the mutations in the A-T gene region. Vectors are known or can be constructed by those skilled in the art and should contain all expression elements necessary to achieve the desired transcription of the sequences. Other beneficial characteristics can also be contained within the vectors such as mechanisms for recovery of the nucleic acids in a different form. Phagemids are a specific example of such beneficial vectors because they can be used either as plasmids or as bacteriophage vectors. Examples of other vectors include viruses such as bacteriophages, baculoviruses and retroviruses, DNA viruses, cosmids, plasmids and other recombination vectors. The vectors can also contain elements for use in either procaryotic or eucaryotic host systems. One of ordinary skill in the art will know which host systems are compatible with a particular vector. The vectors can be introduced into cells or tissues by any one of a variety of known methods within the art. Such methods can be found generally described in Sambrook et al., Molecular Cloning: A Laboratory Manual , Cold Springs Harbor Laboratory, New York (1992), in Ausubel et al. , Current Protocols in Molecular Biology, John Wiley and Sons, Baltimore, Maryland (1989), Chang et al. , Somatic Gene Therapy, CRC Press, Ann Arbor, MI (1995), Vega et al. , Gene Targeting, CRC Press, Ann Arbor, MI (1995) and Gilboa et al (1986) and include, for example, stable or transient transfection, lipofection, electroporation and infection with recombinant viral vectors. Introduction of nucleic acids by infection offers several advantages over the other listed methods. Higher efficiency can be obtained due to their infectious nature. See also United States patents 5,487,992 and 5,464,764. Moreover, viruses are very specialized and typically infect and propagate in specific cell types. Thus, their natural specificity can be used to target the vectors to specific cell types in vivo or within a tissue or mixed culture of cells. Viral vectors can also be modified with specific receptors or ligands to alter target specificity through receptor mediated events. Recombinant methods known in the art can also be used to achieve the sense, antisense or triplex inhibition of a target nucleic acid. For example, vectors containing antisense nucleic acids can be employed to express protein or antisense message to reduce the expression of the target nucleic acid and therefore its activity. A specific example of DNA viral vector for introducing and expressing antisense nucleic acids is the adenovirus derived vector Adenop53TK. This vector expresses a herpes virus thymidine kinase (TK) gene for either positive or negative selection and an expression cassette for desired recombinant sequences such as antisense sequences. This vector can be used to infect cells that have an adenovirus receptor which includes most cancers of epithelial origin as well as others. This vector as well as others that exhibit similar desired functions can be used to treat a mixed population of cells include, for example, an in vi tro or ex vivo culture of cells, a tissue or a human subject. Additional features can be added to the vector to ensure its safety and/or enhance its therapeutic efficacy. Such features include, for example, markers that can be used to negatively select against cells infected with the recombinant virus. An example of such a negative selection marker is the TK gene described above that confers sensitivity to the anti-viral gancyclovir. Negative selection is therefore a means by which infection can be controlled because it provides inducible suicide through the addition of antibiotic. Such protection ensures that if, for example, mutations arise that produce altered forms of the viral vector or sequence, cellular transformation will not occur. Features that limit expression to particular cell types can also be included. Such features include, for example, promoter and regulatory elements that are specific for the desired cell type. Recombinant viral vectors are another example of vectors useful for in vivo expression of a desired nucleic acid because they offer advantages such as lateral infection and targeting specificity. Lateral infection is inherent in the life cycle of, for example, retrovirus and is the process by which a single infected cell produces many progeny virions that bud off and infect neighboring cells. The result is that a large area becomes rapidly infected, most of which was not initially infected by the original viral particles. This is in contrast to vertical-type of infection in which the infectious agent spreads only through daughter progeny. Viral vectors can also be produced that are unable to spread laterally. This characteristic can be useful if the desired purpose is to introduce a specified gene into only a localized number of targeted cells. As described above, viruses are very specialized infectious agents that have evolved, in many cases, to elude host defense mechanisms. Typically, viruses infect and propagate in specific cell types. The targeting specificity of viral vectors utilizes its natural specificity to specifically target predetermined cell types and thereby introduce a recombinant gene into the infected cell. The vector to be used in the methods of the invention will depend on desired cell type to be targeted. For example, if breast cancer is to be treated, then a vector specific for such epithelial cells should be used. Likewise, if diseases or pathological conditions of the hematopoietic system are to be treated, then a viral vector that is specific for blood cells and their precursors, preferably for the specific type of hematopoietic cell, should be used. Retroviral vectors can be constructed to function either as infectious particles or to undergo only a single initial round of infection. In the former case, the genome of the virus is modified so that it maintains all the necessary genes, regulatory sequences and packaging signals to synthesize new viral proteins and RNA. Once these molecules are synthesized, the host cell packages the RNA into new viral particles which are capable of undergoing further rounds of infection. The vector's genome is also engineered to encode and express the desired recombinant gene. In the case of non-infectious viral vectors, the vector genome is usually mutated to destroy the viral packaging signal that is required to encapsulate the RNA into viral particles. Without such a signal, any particles that are formed will not contain a genome and therefore cannot proceed through subsequent rounds of infection. The specific type of vector will depend upon the intended application. The actual vectors are also known and readily available within the art or can be constructed by one skilled in the art using well-known methodology. If viral vectors are used, for example, the procedure can take advantage of their target specificity and consequently, do not have to be administered locally at the diseased site. However, local administration may provide a quicker and more effective treatment, administration can also be performed by, for example, intravenous or subcutaneous injection into the subject. Injection of the viral vectors into a spinal fluid can also be used as a mode of administration, especially in the case of neuro- degenerative diseases. Following injection, the viral vectors will circulate until they recognize host cells with the appropriate target specificity for infection. Transfection vehicles such as liposomes can also be used to introduce the non-viral vectors described above into recipient cells within the inoculated area. Such transfection vehicles are known by one skilled within the art. The present invention includes the construction of transgenic and knockout organisms that exhibit the phenotypic manifestations of A-T. The present invention provides for transgenic ATM gene and mutant ATM gene animal and cellular (cell lines) models as well as for knockout ATM models. The transgenic models include those carrying the sequence set forth SEQ ID Nos :2, 8, 9 (or 10) . These models are constructed using standard methods known in the art and as set forth in United States Patents 5,487,992, 5,464,764, 5,387,742, 5,360,735, 5,347,075, 5,298,422, 5,288,846, 5,221,778, 5,175,385, 5,175,384,5,175,383, 4,736,866 as well as Burke and Olson, (1991), Capecchi, (1989), Davies et al. , (1992), Dickinson et al. , (1993), Huxley et al. , (1991) , Jakobovits et al. , (1993), Lamb et al. , (1993), Rothstein, (1991), Schedl et al. , (1993) , Strauss et al. , (1993) . Further, patent applications WO 94/23049, WO 93/14200, WO 94/06908, WO 94/28123 also provide information. See also in general Hogan et al "Manipulating the Mouse Embryo" Cold Spring Harbor Laboratory Press, 2nd Edition (1994) . Further, the mouse homolog of the A-T gene, designated Atm, has been identified as set forth in detail in Example 4, hereinbelow. The coding sequence of Atm (SEQ ID No:ll), the mouse homolog of the human gene ATM defective in A-T, was cloned and found to contain an open reading frame encoding a protein of 3,066 amino acids (SEQ ID No:12) with 84% overall identity and 91% similarity to the human ATM protein (SEQ ID No:3) . Variable levels of expression of Atm were observed in different tissues. Fluorescence in si tu hybridization and linkage analysis located the Atm gene on mouse chromosome 9, band 9C, in a region homologous to the ATM region on human chromosome llq22-23. The present invention includes the construction of mice in which the mouse homolog of the A-T gene has been knocked out. According to the present invention, there is provided a method for diagnosing and detecting carriers of the defective gene responsible for causing A-T. The present invention further provides methods for detecting normal copies of the ATM gene and its gene product. Carrier detection is especially important since A-T mutations underlie certain cases of cancer predisposition in the general population. Identifying the carriers either by their defective gene or by their missing or defective protein(s) encoded thereby, leads to earlier and more consistent diagnosis of A-T gene carriers. Thus, since carriers of the disease are more likely to be cancer-prone and/or sensitive to therapeutic applications of radiation, better surveillance and treatment protocols can be initiated for them. Conversely, exclusion of A-T heterozygotes from patients undergoing radiotherapy can allow for establishing routinely higher dose schedules for other cancer patients thereby improving the efficacy of their treatment. Briefly, the methods comprise the steps of obtaining a sample from a test subject, isolating the appropriate test material from the sample and assaying for the target nucleic acid sequence or gene product. The sample can be tissue or bodily fluids from which genetic material and/or proteins are isolated using methods standard in the ar . For example, DNA can be isolated from lymphocytes, cells in amniotic fluid and chorionic villi (Llerena et al.,. 1989). More specifically, the method of carrier detection is carried out by first obtaining a sample of either cells or bodily fluid from a subject. Convenient methods for obtaining a cellular sample can include collection of either mouth wash fluids or hair roots. A cell sample could be amniotic or placental cells or tissue in the case of a prenatal diagnosis. A crude DNA could be made from the cells (or alternatively proteins isolated) by techniques well known in the art. This isolated target DNA is then used for PCR analysis (or alternatively, Western blot analysis for proteins from a cell line established from the subject) with appropriate primers derived from the gene sequence by techniques well known in the art. The PCR product would then be tested for the presence of appropriate sequence variations in order to assess genotypic A-T status of the subject. The specimen can be assayed for polypeptides/proteins by immunohistochemical and immunocytochemical staining (see generally Stites and Terr, Basic and Clinical Immunology, Appleton and Lange, 1994) , ELISA, RIA, immunoblots, Western blotting, immunoprecipitation, functional assays and protein truncation test. In preferred embodiments, Western blotting, functional assays and protein truncation test (Hogervorst et al., 1995) will be used. mRNA complementary to the target nucleic acid sequence can be assayed by in si tu hybridization, Northern blotting and reverse transcriptase - polymerase chain reaction. Nucleic acid sequences can be identified by in si tu hybridization, Southern blotting, single strand conformational polymorphism, PCR amplification and DNA-chip analysis using specific primers. (Kawasaki, 1990; Sambrook, 1992; Lichter et al, 1990; Orita et al, 1989; Fodor et al. , 1993; Pease et al., 1994) ELISA assays are well known to those skilled in the art. Both polyclonal and monoclonal antibodies can be used in the assays. Where appropriate other immunoassays, such as radioimmunoassays (RIA) can be used as are known to those in the art. Available immunoassays are extensively described in the patent and scientific literature. See, for example, United States patents 3,791,932; 3,839,153; 3,850,752; 3,850,578; 3,853,987; 3,867,517; 3,879,262; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; 4,098,876; 4,879,219; 5,011,771 and 5,281,521 as well as Sambrook et al, 1992. Current mutation data (as shown in Tables 1 and 2) indicate that A-T is a disease characterized by considerable allelic heterogenicity. It is not surprising that there are hundreds (or even thousands) of ATM mutations (as is the case for cystic fibrosis and BRCAI) as shown in Table 2. Thus, it will be important for a successful mutation screen to be able to detect all possible nucleotide alterations in the ATM gene, rather than being focused on a limited subset. Methods including direct sequencing of PCR amplified DNA or RNA or DNA chip hybridization (Fodor et al. , 1993; Pease et al., 1994) can be applied along with other suitable methods known to those skilled in the art. In order to use the method of the present invention for diagnostic applications, it is advantageous to include a mechanism for identifying the presence or absence of target polynucleotide sequence (or alternatively proteins) . In many hybridization based diagnostic or experimental procedures, a label or tag is used to detect or visualize for the presence or absence of a particular polynucleotide sequence. Typically, oligomer probes are labelled with radioisotopes such as 32 P or 35 S (Sambrook, 1992) which can be detected by methods well known in the art such as autoradiography. Oligomer probes can also be labelled by non-radioactive methods such as chemiluminescent materials which can be detected by autoradiography (Sambrook, 1992) . Also, enzyme-substrate based labelling and detection methods can be used. Labelling can be accomplished by mechanisms well known in the art such as end labelling (Sambrook, 1992) , chemical labelling, or by hybridization with another labelled oligonucleotide. These methods of labelling and detection are provided merely as examples and are not meant to provide a complete and exhaustive list of all the methods known in the art. The introduction of a label for detection purposes can be accomplished by attaching the label to the probe prior to hybridization. An alternative method for practicing the method of the present invention includes the step of binding the target DNA to a solid support prior to the application of the probe. The solid support can be any material capable of binding the target DNA, such as beads or a membranous material such as nitrocellulose or nylon. After the target DNA is bound to the solid support, the probe oligomers is applied. Functional assays can be used for detection of A-T carriers or affected individuals. For example, if the ATM protein product is shown to have PI 3-kinase biochemical activity which can be assayed in an accessible biological material, such as serum, peripheral leukocytes, etc., then homozygous normal individuals would have approximately normal biological activity and serve as the positive control. A-T carriers would have substantially less than normal biological activity, and affected (i.e. homozygous) individuals would have even less biological activity and serve as a negative control. Such a biochemical assay currently serves as the basis for Tay-Sachs carrier detection. The present invention also provides a kit for diagnosis and detection of the defective A-T gene in populations. The kit includes a molecular probe complementary to genetic sequences of the defective gene which causes ataxia- telangiectasia (A-T) and suitable labels for detecting hybridization of the molecular probe and the defective gene thereby indicating the presence of the defective gene. The molecular probe has a DNA sequence complementary to mutant sequences in the population. Alternatively, the kit can contain reagents and antibodies for detection of mutant proteins. The above discussion provides a factual basis for the use and identification of the ataxia-telangiectasia gene and gene products and identification of carriers as well as construction of transgenic organisms. The methods used in the present invention can be shown by the following non- limiting example and accompanying figures. EXAMPLES Materials and Methods; General methods in molecular biology: Standard molecular biology techniques known in the art and not specifically described were generally followed as in Sambrook et al., Molecular Cloning: A Laboratory Manual , Cold Springs Harbor Laboratory, New York (1989, 1992) , and in Ausubel et al. , Current Protocols in Molecular Biology, John Wiley and Sons, Baltimore, Maryland (1989) and methodology as set forth in United States patents 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057. Polymerase chain reaction (PCR) was carried out generally as in PCR Protocols : A Guide To Methods And Applications , Academic Press, San Diego, CA (1990) . Protein analysis techniques were as described in Coligan et al. , Current Protocols in Immunology, John Wiley and Sons, Baltimore, Maryland (1992, 1994) . Patient and family resources: A cell line repository was established containing 230 patient cell lines and 143 cell lines from healthy members of Moroccan Jewish, Palestinian Arab and Druze families. Some of these pedigrees are highly inbred and unusually large (Ziv et al., 1991; Ziv, 1992) . In view of the large number of meiotic events required for high-resolution linkage analysis, applicants collaborated with Dr. Carmel McConville (University of Birmingham, UK) and Dr. Richard Gatti (UCLA, Los Angeles, CA) , who have also established extensive repositories of A-T families. Linkage analysis was conducted on a pool of 176 families. EXAMPLE 1 Definition of the A-T interval by genetic analysis: Studies based only on analysis of Israeli A-T families enabled localization of the A-T(C) gene at llq22-23 (Ziv, 1991), and confirmed the localization of A-T(A) mutation in Palestinians to the same region (Ziv et al. , 1992) . Studies with the Birmingham group further narrowed the major A-T interval to 4 centimorgans, between D11S611 and D11S1897 (McConville et al. , 1993), and subsequently to 3 centimorgans, between GRIA4 and D11S1897 (Ambrose et al. , 1994; McConville et al. , 1994; Shiloh, 1995, and Figure 1). All these studies were conducted with biallelic markers, whose power is limited by their low polymorphic information content (PIC) . The recently discovered microsatellite markers based on variable numbers of tandem simple repeats (Litt and Luty, 1989; Weber and May, 1989) are much more powerful due to their high degree of polymorphism. Microsatellite markers were used to saturate the A-T region using two approaches. The first, was based on physical mapping of microsatellite markers generated by others which were loosely linked to chromosome llq. Mapping experiments were conducted using YAC and cosmid contigs which allowed precise, high-resolution localization of DNA sequences in this region of chromosome 11. Twelve microsatellites were localized at the A-T region (Vanagaite et al., 1994a; Vanagaite et al. , 1995). The second approach was based on generating new microsatellites within the YAC contig. A rapid method for the identification of polymorphic CA-repeats in YAC clones was set up (Rotman, 1995) resulting in the generation of twelve new markers within the A-T locus (Vanagaite et al. , 1995; Rotman et al. , 1995; Rotman et al. , 1994b). Hence, the high-density microsatellite map constructed in this manner contained a total of 24 new microsatellite markers and spans the A-T locus and flanking sequences, over a total of six megabases (Vanagaite et al. , 1995). Repeated linkage analysis on the entire cohort of A-T families indicated that the A-T(A) locus was definitely located within a 1.5 megabase region between D11S1819 and D11S1818 (Gatti et al., 1994) as shown in Figure 1 and in Shiloh (1995) , with a clear peak of the cumulative lod score under D11S535 (Lange et al., 1994). Concomitant with these studies, linkage disequilibrium (LD) analysis of Moroccan-Jewish A-T patients was conducted. LD refers to the non-random association between alleles at two or more polymorphic loci (Chakravarti et al., 1984) . LD between disease loci and linked markers is a useful tool for the fine localization of disease genes (Chakravarti et al. , 1984; Kerem et al. 1989; Ozelius et al., 1992; Sirugo et al. , 1992; Hastbacka et al. , 1992; Mitchison et al. , 1993) . LD is particularly powerful in isolated ethnic groups, where the number of different mutations at a disease locus is likely to be low (Hastbacka et al., 1992; Lehesjoki et al. , 1993; Aksentijevitch et al., 1993) . Early on, applicants observed very significant LD (p<0.02-p<0.001) between A-T and markers along the D11S1817-D11S927 region in the patients of the sixteen Moroccan-Jewish A-T families identified in Israel (Oskato et al., 1993) . Further analysis with the new markers narrowed the peak of linkage disequilibrium to the D11S384-D11S1818 region as shown in Figure 1. Haplotype analysis indicated that all of the mutant chromosomes carry the same D11S384-D11S1818 haplotype, suggesting a founder effect for A-T in this community, with one mutation predominating. EXAMPLE 2 SEQUENCING THE ATM GENE Cloning the disease locus in a contig (set of overlapping clones) was essential in isolating the A-T disease gene. The entire A-T locus and flanking region in a contig of yeast artificial chromosomes (YACs) was cloned by methods well known in the art (Rotman et al. 1994c; Rotman et al., 1994d) . This contig was instrumental in the construction of the microsatellite map of the region (Vanagaite et al., 1995) and subsequently enabled construction of cosmid contigs extending over most of the interval D11S384-D11S1818. Cosmids corresponding to the YAC clones were identified in a chromosome 11-specific cosmid library supplied by Dr. L. Deaven (Los Alamos National Laboratory) and were ordered into contigs by identifying overlaps as shown in Figure 1. Isolation of the A-T gene: Transcribed sequences were systematically identified based on two complementary methods: 1. Use of an improved direct selection method based on magnetic bead capture (MBC) of cDNAs corresponding to genomic clones (Morgan et al. , 1992; Tagle et al., 1993). In several, large-scale experiments YAC or cosmid DNA was biotinylated and hybridized to PCR-amplified cDNA from thymus, brain and placenta. Genomic DNA-cDNA complexes were captured using streptavidin-coated magnetic beads which was followed with subsequent elution, amplification, and cloning of captured cDNAs. The cDNA inserts were excised from a gel, self-ligated to form concatamers and sonicated to obtain random fragments. These fragments were size fractionated by gel electrophoresis, and the 1.0-1.5 Kb fraction was extracted from the gel and subcloned in a plasmid vector. The end portions of individual clones were sequenced using vector-specific primers, in an automated sequencer (Model 373A, Applied Biosystems) , and the sequences were aligned using the AutoAssembler program (Applied Biosystems Division, Perkin-Elmer Corporation) . In the final sequence each nucleotide position represents at least 3 independent overlapping readings. YACs were also used and were no less efficient than cosmids as starting material for MBC, with more than 50% of the products mapping back to the genomic clones. However, when a small panel of radiation hybrids spanning the A-T region was used to test the cDNA fragments, it was found that some clones that hybridized back to the YACs and cosmids were not derived from this region. This pitfall probably stems from limited homology between certain portions of different genes, and points up the necessity to use radiation hybrid mapping when testing the authenticity of the captured sequences, and not to rely solely on cloned DNA for this purpose. Homology searches in sequence databases showed that only one of the first 105 cDNA fragments mapped to the A-T region was homologous to a sequence previously deposited in one of the databases, as an expressed sequence tag (EST) . 2. Exon amplification, also termed "exon trapping" (Duyk et al. , 1990; Buckler et al. , 1991), is based on cloning genomic fragments into a vector in which exon splice sites are flagged by splicing to their counterpart sites in the vector. This method of gene identification was expected to complement the MBC strategy, since it does not depend on the constitution of cDNA libraries or on the relative abundance of transcripts, and is not affected by the presence of repetitive sequences in the genomic clones. An improved version of this system (Church et al., 1993) that eliminated problems identified in an earlier version, including a high percentage of false positives and the effect of cryptic splice sites was utilized. Each experiment ran a pool of three to five cosmids with an average of two to five exons identified per cosmid. A total of forty five exons were identified. Sequence analysis and physical mapping indicated that MBC and exon amplification were complementary in identifying transcribed sequences. The availability of a deep cosmid contig enabled rapid and precise physical localization of the cDNA fragments and captured exons, leading to a detailed transcriptional map of the A-T region. Both MBC and exon amplification yielded short (100-1000 bp) transcribed sequences. Those sequences were used as anchor points in isolating full-length clones from twenty eight cDNA libraries currently at applicants disposal and which represented a variety of tissues and cell lines. Initial screening of the cDNA libraries by polymerase chain reaction (PCR) using primer sets derived from individual cDNA fragments or exons aided in the identification of the libraries most likely to yield corresponding cDNA clones. Large scale screening experiments were carried out in which most of the cDNA fragments and exons were used in large pools. In addition to the mass screening by hybridization, PCR-based screening methods and RACE (rapid amplification of cDNA ends) (Frohman et al. , 1988; Frohman et al., 1994) was employed to identify full-length cDNAs. The above experiments resulted in the initial identification and isolation of a cDNA clone designated 7-9 (Savitsky et al, 1995a), the complete sequence of which is set forth in SEQ ID No:1 and which is derived from a gene located under the peak of cumulative location score obtained by linkage analysis as shown in Figure 1. The gene extends over some 300 kilobases (kb) of genomic DNA and codes for two major mRNA species of 12 kb and 10.5 kb in length. The 7-9 clone is 5.9 kb in length and, therefore, is not a full length clone. An open reading frame of 5124 bp within this cDNA encodes a protein with signature motifs typical of a group of signal transduction proteins known as phosphatidylinositol 3-kinases (PI 3-kinases) . PI 3-kinases take part in the complex system responsible for transmitting signals from the outer environment of a cell into the cell. It is not clear yet whether the protein product of the corresponding gene encodes a lipid kinase or a protein kinase. The gene encoding the 7-9 cDNA clone was considered a strong A-T candidate and mutations were sought in patients. Southern blotting analysis revealed a homozygous deletion in this gene in affected members of Family N. , an extended Palestinian Arab A-T family which has not been assigned to a specific complementation group. All the patients in this family are expected to be homozygous by descent for a single A-T mutation. The deletion includes almost the entire genomic region spanned by transcript 7-9, and was found to segregate in the family together with the disease. This finding led to a systematic search for mutations in the 7-9 transcript in additional patients, especially those previously assigned to specific complementation groups. The restriction endonuclease fingerprinting (REF) method (Liu and Sommer 1995) was applied to reverse-transcribed and PCR-amplified RNA (RT-PCR) from A-T cell lines. Observation of abnormal REF patterns was followed by direct sequencing of the relevant portion of the transcript and repeated analysis of another independent RT product. In compound heterozygotes, the two alleles were separated by subcloning of RT-PCR products and individually sequenced. Genomic sequencing was conducted in some cases to confirm the sequence alteration at the genomic level. Additional family members were studied when available. Ten sequence alterations (Table 1) were identified in the 7-9 transcript in 13 A-T patients including two sibling pairs. Most of these sequence changes are expected to lead to premature truncation of the protein product, while the rest are expected to create in-frame deletions of 1-3 amino acid residues in this protein. While the consequences of the in-frame deletions remain to be investigated, it is reasonable to assume that they result in impairment of protein function. In one patient, AT3NG, the loss of a serine residue at position 1512 occurs within the PI3-kinase signature sequence. This well conserved domain is distantly related to the catalytic site of protein kinases, hence this mutation is likely to functionally affect the 7-9 protein. In view of the strong evidence that mutations in this gene are responsible for A-T, it was designated ATM (A-T. Mutated) . Since these patients represent all complementation groups of the disease and considerable ethnic variability, these results indicate that the ATM gene alone is responsible for all A-T cases. In order to complete the cloning of the entire ATM open reading frame, fetal brain and colon random-primed libraries obtained from Stratagene (San Diego, CA) and an endothelial cell random-primed library (a gift of Dr. David Ginsburg, University of Michigan) were screened. A total of lxlO 6 pfu were screened at a density of 40,000 pfu per 140mm plate, and replicas were made on Qiabrane filters (Qiagen) , as recommended by the manufacturer. Filters were prehybridized in a solution containing 6xSSC, 5x Denhardt's, 1% N-laurylsarcosyl, 10% dextran sulfate and lOOμg/ml salmon sperm DNA for 2 hours at 65°C. Hybridization was performed for 16 hrs under the same conditions with lxl0 6 cpm/ml of 32 P-labelled probe, followed by final washes of 30 minutes in 0.25xSSC, 0.1%SDS at 60°C. Positive clones were plaque-purified using standard techniques and sequenced. DNA sequencing was performed using an automated DNA sequencer (Applied Biosystems, model 373A) , and the sequence was assembled using the AutoAssembler program (Applied Biosystems Division, Perkin-Elmer Corporation) . In the final sequence, each nucleotide represents at least four independent readings in both directions. Database searches for sequence similarities were performed using the BLAST network service. Alignment of protein sequences and pairwise comparisons were done using the MACAW program, and the PILEUP and BESTFIT programs in the sequence analysis software package developed by the Genetics Computer Group at the University of Wisconsin. EXAMPLE 3 DETECTION OF MUTATIONS Determination of mutations: The recently discovered ATM gene is probably involved in a novel signal transduction system that links DNA damage surveillance to cell cycle control. A-T mutations affect a variety of tissues and lead to cancer predisposition. This striking phenotype together with the existence of "partial A-T phenotypes" endow the study of ATM mutations with special significance. MATERIALS AND METHODS. RT-PCR: Total RNA was extracted from cultured fibroblast or lymphoblast cells using the Tri-Reagent system (Molecular research Center, Cincinnati, OH) . Reverse transcription was performed on 2.5 ug of total RNA in a final volume of 10 ul, using the Superscript II Reverse Transcriptase (Gibco BRL, Gaithersburg, MD) in the buffer recommended by the supplier, and in the presence of 125 U/ml of RNAsin (Promega) and ImM dNTPs (Pharmacia) . Primers were either oligo(dT) (Pharmacia) or a specifically designed primer. The reaction products were used as templates for PCR performed with specific primers. These reactions were carried out in 50 μl containing 2 units of Taq DNA Polymerase (Boehringer Mannheim, Mannheim, Germany) , 200 μM dNTPs, 0.5μM of each primer, and one tenth of the RT-PCR products. The products were purified using the QIA-quick spin system (Qiagen, Hilden, Germany) . Restriction endonuclease fingerprinting: The protocol of Liu and Sommer (1995) was followed with slight modifications. RT-PCR was performed as described above, using primers defining PCR products of 1.0-1.6 kb. One hundred ng of amplified DNA was digested separately with 5 or 6 restriction endonucleases in the presence of 0.2 units of shrimp alkaline phosphatase (United States Biochemicals, Cleveland, OH) . Following heat inactivation at 65°C for 10 minutes, the digestion products corresponding to the same PCR product were pooled, denatured at 96°C for 5 minutes and immediately chilled on ice. Ten ng of this fragment mixture was labeled in the presence of 6 μCi of [γ- 33 P]ATP and 1 unit of T4 polynucleotide kinase (New England Biolabs, Beverly, MA) at 37°C for 45 minutes. Twenty μl of stop solution containing 95% formamide, 20mM EDTA, 0.05% bromophenol blue, 0.05% xylene cyanol, and lOmM NaOH were added, and the samples were boiled for 3 minutes and quick-chilled on ice. Electrophoresis was performed in 5.6% polyacrylamide gels in 50mM Tris-borate, pH 8.3, ImM EDTA at constant power of 12 W for 3 hours at room temperature, with a fan directed to the glass plates, keeping them at 22-24°C. The gels were dried and subjected to autoradiography. Direct sequencing of PCR products: Five hundred ng of PCR products was dried under vacuum, resuspended in reaction buffer containing the sequencing primer, and the mixture was boiled and snap-frozen in liquid nitrogen. The Sequenase II system (Unites States Biochemicals) was used to carry out the sequencing reaction in the presence of 0.5 μg of single-strand binding protein (T4 gene 32 protein, United States Biochemicals) . The reaction products were treated with 0.1 μg of proteinase K at 65°C for 15 minutes, separated on a 6% polyacrylamide gel, and visualized by autoradiography. Using the methods described herein above the ATM transcript was scanned for mutations in fibroblast and lymphoblast cell lines derived from an extended series of A-T patients from 13 countries, all of whom were characterized by the classical A-T phenotype. The analysis was based on RT-PCR followed by restriction endonuclease fingerprinting (REF) . REF is a modification of the single-strand conformation polymorphism (SSCP) method, and enables efficient detection of sequence alterations in DNA fragments up to 2 kb in length (Liu and Sommer, 1995) . Briefly, after PCR amplification of the target region, multiple restriction endonuclease digestions are performed prior to SSCP analysis, in order to increase the sensitivity of the method and enable precise localization of a sequence alteration within the analyzed fragment. The coding sequence of the ATM transcript, which spans 9168 nucleotides (SEQ ID No:2) (Savitsky et al. , 1995b), was thus divided into 8 partly overlapping portions of 1.0-1.6 Kb, and each one was analyzed separately. Sequence alterations causing abnormal REF patterns were located and disclosed by direct sequencing. Mutations identified in this way were reconfirmed by repeating the RT-PCR and sequencing, or by testing the presence of the same mutations in genomic DNA. In compound heterozygotes, the two alleles were separated by subcloning and individually sequenced. In some cases, agarose gel electrophoresis showed large deletions in the ATM transcript manifested as RT-PCR products of reduced sizes. The breakpoints of such deletions were delineated by direct sequencing of these products. The 44 mutations identified to date in our patient cohort (Table 2) include 34 new ones and 10 previously published ones (Table 1) . (Mutations in Table 2 are presented according to the nomenclature proposed by Beaudet & Tsui (1993) ; nucleotide numbers refer to their positions in the sequence of the ATM transcript (accession number U33841) ; the first nucleotide of the open reading frame was designated +1.) These mutations were found amongst 55 A-T families: many are unique to a single family, while others are shared by several families, most notably the 4 nt deletion, 7517del4, which is common to 6 A-T families from South-Central Italy (Table 2) . According to this sample, there is a considerable heterogeneity of mutations in A-T, and most of them are "private". The proportion of homozygotes in this sample is relatively high due to a high degree of consanguinity the populations studied. It should be noted, however, that apparently homozygous patients from non-consanguineous families may in fact be compound heterozygotes with one allele not expressed. This series of 44 A-T mutations is dominated by deletions and insertions. The smaller ones, of less than 12 nt, reflect identical sequence alterations in genomic DNA. Deletions spanning larger segments of the ATM transcript were found to reflect exon skipping, not corresponding genomic deletions. This phenomenon usually results from sequence alterations at splice junctions or within introns, or mutations within the skipped exons, mainly of the nonsense type (Cooper and Krawczak, 1993; Sommer, 1995; Steingrimsdottir et al. , 1992; Gibson et al. , 1993; Dietz and Kendzior, 1994). One large deletion spans about 7.5 Kb of the transcript and represents a genomic deletion of about 85 Kb within the ATM gene. Of these deletions and insertions, 25 are expected to result in frameshifts. Together with the 4 nonsense mutations, truncation mutations account for 66% of the total number of mutations in this sample. Seven in-frame deletions span long segments (30-124 aa) of the protein, and similarly to the truncation mutations, are expected to have a severe effect on the protein's structure. It should be noted that two base substitutions abolish the translation initiation and termination codons. The latter is expected to result in an extension of the ATM protein by an additional 29 amino acids. This mutation may affect the conformation of the nearby PI 3-kinase-like domain. While the effect of the 4 small (1-3 aa) in-frame deletions and insertions on the ATM protein remains to be studied, it should be noted that one such deletion (8578del3) leads to a loss of a serine residue at position 2860. This amino acid is part of a conserved motif within the PI 3-kinase-like domain typical of the protein family to which ATM is related, and is present in 7 of 9 members of this family. The single missense mutation identified in this study, which leads to a Glu2904Gly substitution, results in a nonconservative alteration of another extremely conserved residue within this domain, which is shared by all of these proteins. The patient homozygous for this mutation, AT41RM, shows the typical clinical A-T phenotype. Measurement of radioresistant DNA synthesis in the patient's cell line revealed a typical A-T response, demonstrating that this patient has the classical A-T cellular phenotype. As discussed herein above, the ATM gene of the present invention is probably involved in a novel signal transduction system that links DNA damage surveillance to cell cycle control. A-T mutations affect a variety of tissues and lead to cancer predisposition. This striking phenotype together with the existence of "partial A-T phenotypes" endow the study of ATM mutations with special significance. The ATM gene leaves a great deal of room for mutations: it encodes a large transcript. The variety of mutations identified in this study indeed indicates a rich mutation repertoire. Despite this wealth of mutations, their structural characteristics point to a definite bias towards those that inactivate or eliminate the ATM protein. The nature or distribution of the genomic deletions among these mutations do not suggest a special preponderance of the ATM gene for such mutations, such as that of the dystrophin (Anderson and Kunkel, 1992) or steroid sulfatase (Ballabio et al., 1989) genes which are particularly prone to such deletions. Thus, one would have expected also a strong representation of missense mutations, which usually constitute a significant portion of the molecular lesions in many disease genes (Cooper and Krawczak, 1993; Sommer, 1995) . However, only one such mutation was identified in the present study. Other point mutations reflected in this series are those that probably underlie the exon skipping deletions observed in many patients, again, exerting a severe structural effect on the ATM protein. A technical explanation for this bias towards deletions and insertions could be a greater ability of the REF method to detect such lesions versus its ability to detect base substitution. Liu and Sommer (1995) have shown, however, that the detection rate of this method in a sample of 42 point mutations in the factor IX gene ranged between 88% and 100%, depending on the electrophoresis conditions. The 7 base substitutions detected directly by the REF method in the present study (Table 2) , indicate that such sequence alterations are detected in our hands as well. Since the expected result of most of these mutations is complete inactivation of the protein, this skewed mutation profile might represent a functional bias related to the studied phenotype, rather than a structural feature of the ATM gene that lends itself to a particular mutation mechanism. The classical A-T phenotype appears to be caused by homozygosity or compound heterozygosity for null alleles, and hence is probably the most severe expression of defects in the ATM gene. The plethora of missense mutations expected in the large coding region of this gene is probably rarely represented in patients with classical A-T, unless such a mutation results in complete functional inactivation of the protein. By inference, the only missense identified in this study, Glu2940Gly, which substitutes a conserved amino acid at the PI 3-kinase domain and clearly gives rise to a classical A-T phenotype, points to the importance of this domain for the biological activity of the ATM protein. Mutations in this domain abolish the telomere-preserving function of the TEL1 protein in S. cerevisiae (Greenwell et al., 1995), a protein which shows a particularly high sequence similarity to ATM (Savitsky et al., 1995b; Zakian, 1995) . Another member of the family of PI 3-kinase-related proteins that includes ATM is the mammalian FRAP. Mutations in the PI 3-kinase domain abolish its autophosphorylation ability and biological activity (Brown et al. , 1995). These observations, together with the mutation shown here, suggest that this domain in ATM is also likely to include the catalytic site, which may function as a protein kinase. Genotype-phenotype relationships associated with the ATM gene appear therefore to extend beyond classical A-T. There are several examples of genes in which different mutations lead to related but clinically different phenotypes. For example, different combinations of defective alleles of the ERCC2 gene may result in xeroderma pigmentosum (group D) , Cockayne's syndrome or trichothiodystrophy - three diseases with different clinical features involving UV sensitivity (Broughton et al. , 1994, 1995) . Different mutations in the CFTR gene may lead to full-fledged cystic fibrosis, or only to congenital bilateral absence of the vas deferens which is one feature of this disease (Chillon et al., 1995; Jarvi et al. , 1995) . A particularly interesting example is the X-linked WASP gene responsible for Wiskott Aldrich syndrome (WAS) , characterized by immunodeficiency, eczema and thrombocytopenia. Most of the mutations responsible for this phenotype cause protein truncations; however, certain missense mutations may result in X-linked thrombocytopenia, which represents a partial WAS phenotype, while compound heterozygosity for a severe and mild mutation results in females in an intermediate phenotype (Kolluri et al. , 1995; Derry et al. , 1995) . In a similar manner, genotypic combinations of mutations with different severities create a continuous spectrum of phenotypic variation in many metabolic diseases. Which phenotypes are most likely to be associated with milder ATM mutations? Since cerebellar damage is the early and severe manifestation of A-T, it is reasonable to assume that the cerebellum might also be affected to some extent in phenotypes associated with milder ATM mutations. Such phenotypes may include cerebellar ataxia, either isolated {Harding, 1993) or coupled with various degrees of immunodeficiency. The latter combination has indeed been described, sometimes with chromosomal instability, and is often designated "ataxia without telangiectasia" (Ying and Decoteau, 1983; Byrne et al. , 1984; Aicardi et al. , 1988; Maserati, 1988; Friedman and Weitberg, 1993) . Friedman and Weitberg (1993) recently suggested a new clinical category of "ataxia with immune deficiency" that would include A-T as well as other cases of cerebellar degeneration with immune deficits. Evaluation of patients with cerebellar disorders with the present invention may reveal a higher frequency of such cases than previously estimated. However, in view of the pleiotropic nature of the ATM gene, the range of phenotypes associated with various ATM genotypes may be even broader, and include mild progressive conditions not always defined as clear clinical entities. Screening for mutations in this gene in such cases may reveal wider boundaries for the molecular pathology associated with the ATM gene. EXAMPLE 4 Identification of the Mouse Atm Gene MATERIALS AND METHODS Library screening: An oligo(dT) -primed mouse brain cDNA library in a Uni-Zap XR vector, a mouse 129Sv genomic library (Stratagene, San Diego, CA) and a randomly primed mouse brain cDNA library in lambda-gtlO (Clontech, Palo Alto, CA) were used. 10 6 pfu were screened with each probe. The libraries were plated at a density of 5xl0 4 pfu per 140 mm plate, and two sets of replica filters were made using Qiabrane nylon membranes (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Filters were prehybridized for 2 hours at 65°C in 6xSSC, 5χ Denhardt's, 1% N-laurylsarcosyl, 10% dextran sulfate and 100 μg/ml sheared salmon sperm DNA. Hybridization was performed at 65°C for 16-18 hours in the same solution containing 10 6 cpm/ml of probe labeled with 32 P-dCTP by random priming. Final washes were made for 30 minutes in 0.5xSSC, 0.1% SDS at 50°C. Positive clones were plaque-purified using standard techniques. RT-PCR: First strand synthesis was performed using 2 μg of total RNA from mouse 3T3 cells with an oligo (dT) primer and Superscript II (Gibco-BRL, Gaithersburg, MD) . The reaction products served as templates for PCR with gene-specific primers. Sequence analysis: The insert of cDNA clone 15-1 (see below) was excised from a gel, self-ligated to form concatamers, and sonicated to obtain random fragments. These fragments were size-fractionated by gel electrophoresis, and the 1.0- to 1.5-kb fraction was extracted from the gel and subcloned in a pBluescript vector (Stratagene) . The end portions of individual clones were sequenced with vector-specific primers in an automated sequencer (Model 373A, Applied Biosystems Division, Perkin Elmer) , and the sequences were aligned with the AutoAssembler program (Applied Biosystems) . In the final sequence, each nucleotide position represents at least three independent overlapping readings. In smaller cDNA inserts, sequencing was initiated with vector-specific primers, and additional sequencing primers were designed for both strands as sequencing progressed. Sequencing of RT-PCR products . was performed with the PCR primers. Fluorescence in-situ hybridization (FISH) : Preliminary chromosomal localization of the Atm gene was determined by FISH analysis. Mouse metaphase chromosomes were prepared from concanavalin A (conA) stimulated lymphocytes obtained after splenectomy as described by Boyle at al. (1992), with slight modifications. Briefly, homogenized spleen tissue was cultured for 48 hours in RPMI 1640 medium supplemented with 20% fetal bovine serum, 6 μg/ml concanavalin A, and 86.4 μM β-mercaptoethanol. The cell cycle was synchronized by incubation with methotrexate (17 hours, 4.5 mM) . The S-phase block was released with BrdU (30 μM) and FUdR (0.15 μg/ml) for 5 hours. Colcemid was added for 10 minutes; the cells were incubated in KC1 (0.55%) and fixed with methanol/acetic acid (3:1) . The mouse Atm genomic clone used for FISH analysis was obtained by screening the mouse 129Sv genomic library with a human 236 bp PCR probe corresponding to nt 5381-5617 of the human ATM cDNA. Sequence analysis confirmed that this clone contains a 177 bp exon corresponding to nt 5705-5881 of the mouse Atm cDNA. The mouse Atm genomic clone was labeled by nick-translation with digoxigenin-lldUTP (Boehringer Mannheim, Indianapolis, IN) . To facilitate chromosome identification, a biotinylated mouse chromosome 9-specific painting probe (Vector Laboratories, Burlingame, CA) was used for cohybridization. The probe sequences and metaphase chromosomes were heat denatured separately. Hybridization was performed for 15 hours at 37°C in a solution containing 50% formamide, 2xSSC, and 10% dextran sulfate. Post-hybridization washes were performed as described by Ried et al. (1992) . The biotinylated probe sequences were detected by incubation with avidin conjugated to FITC (Vector Laboratories) , and the digoxigenin labeled sequences by incubation with mouse anti-digoxin and goat anti-mouse conjugated to TRITC (Sigma Chemicals, St. Louis, MO) . Chromosomes were counterstained with DAPI. The fluorescent signals were sequentially acquired using a cooled CCD camera (Photometries, Tucson, AZ) coupled to a Leica DMRBE microscope. Gray scale images were converted to tintscale using Gene Join (Ried et al., 1992) . Linkage analysis: Interspecific backcross progeny were generated by mating (C57BL/6J x M. spretus) Fl females and C57BL/6J males, as described by Copeland and Jenkins (1991) . A total of 205 N 2 mice were used to map the Atm locus as described herein below. Southern blot analysis was performed (Jenkins et al. , 1982) . All blots were prepared with Hybond-N + membrane (Amersham) . The Atm probe, REF3, a PCR-amplified fragment from the Atm mouse cDNA representing nt 6000-7264 was labeled with [α 32 P] dCTP using a random priming labeling kit (Stratagene) ; washing was done to a final stringency of 0.5xSSCP, 0.1% SDS, 65°C. Fragments of 4.9, 3.6, and 1.4 kb were detected in Hindlll-digested C57BL/6J DNA and fragments of 5.6 and 4.3 kb were detected in Hindlll-digested M. spretus DNA. The presence or absence of the 5.6 and 4.3 kb M. spretus-specific fragments, which cosegregated, were followed in the backcross mice. A description of the probes and RFLPs for the loci linked to Atm, including glutamate receptor, ionotropic, kainate 4 (Grik4) ; thymus cell antigen-1 theta (Thyl) ; Casitas B-lineage lymphoma (Cbl) ,* CD3 antigen, gamma polypeptide (Cd3g) ; and dopamine receptor 2 (Drd2) , has been reported previously (Kingsley at al. , 1989; Regnier et al., 1989; Szpirer et al. , 1994) . The mouse chromosomal locations of mitochondrial acetoacetyl-CoA thiolase (Acatl) and src-kinase (Csk) were determined for the first time, herein. Recombination distances were calculated as described (Green, 1981) , using the computer program SPRETUS MADNESS. Gene order was determined by minimizing the number of recombination events required to explain the allele distribution patterns. The Csk probe, a 2.2 kb EcoRI/XhoI fragment derived from the mouse cDNA (Thomas et al. , 1991), was labeled with [α 32 P]dCTP using a nick] translation labeling kit (Boehringer Mannhein) ; washing was done to a final stringency of O.lxSSPE, 0.1% SDS, 65°C. A fragment of 9.4 kb was detected in Hindlll-digested C57BL/6J DNA and a fragment of 5.8 kb was detected in Hindlll-digested M. spretus DNA. The presence or absence of the 5.8 kb M. spretus-specific fragment was followed in the backcross mice. The Acatl probe, a 1.4 kb fragment from the Acat rat cDNA (Fukao et al. , 1990), was labeled by nick translation and washed from the blots to a final stringency of O.δxSSCP, 0.1% SDS, 65°C. A fragment of 23 kb was detected in EcoRI-digested C57BL/6J DNA, and fragments of 22 and 5.4 kb were detected in EcoRI-digested M. spretus DNA. The presence or absence of the 22 and 5.4 kb . spretus-specific fragments, which cosegregated, were followed in the backcross mice. RESULTS Molecular cloning of the coding sequence of Atm gene: In search of a cDNA clone derived from a murine gene corresponding to the human ATM, 10 6 pfu from a mouse brain cDNA library were screened with a PCR product corresponding to nt 4021-8043 of the human ATM cDNA (Savistky et al. , 1995b; the first nucleotide of the open reading frame was numbered 1) . Fifteen positive clones were identified, and the longest one, of 8.5 kb (designated 15-1; Fig. 3) , was further analyzed. High-stringency hybridization of this clone to panels of radiation hybrids, YAC and cosmid clones representing the human ATM locus (Rotman et al.,1994; Shiloh, 1994; Savitsky et al., 1995a,b) showed strongly hybridizing sequences within the ATM locus. Northern blotting analysis and subsequent sequencing and alignment with the human ATM transcript confirmed that 15-1 corresponded throughout its length to the human gene but was missing the 5' end of the corresponding mouse transcript. Screening of a randomly primed mouse brain cDNA library with a probe corresponding to the 5' region of the human ATM transcript (nt 1-2456) identified 2 clones, MRP1 and MRP2, of 1.3 and 0.6 kb, respectively (Fig. 3) . The gap between clones 15-1 and MRP1 was subsequently bridged using RT-PCR with primers derived from these clones, which produced the fragment m4m5 of 840 bp. Finally, a primer derived from the MRP1 sequence was designed and used with vector-specific primers to obtain two PCR products, 23m9 and 24m9, from the randomly primed brain cDNA library. All these clones and PCR products hybridized exclusively to the ATM locus in the human genome. Their sequences were assembled and formed a contig of 9620 nucleotides (Fig. 3; GenBank accession no. U43678) . Sequence comparisons: The sequence of the contig shown in Fig. 3 shows an open reading frame (ORF) of 9201 nt, and includes a 41 nt 5' UTR and a 378 nt 3' UTR. These UTRs are probably not complete, in view of the length of the UTRs of the ATM transcript and the lack of a poly(A) tail in 15-1. The ORF encodes a putative protein of 3,066 amino acids with a molecular weight of 349.5 kDa (SEQ ID No:3) . When the nucleotide and amino acid sequences corresponding to the coding regions of the mouse and human ATM transcripts were aligned, there was an overall identity of 85% at the nucleotide sequence level, and an 84% identity and 91% similarity at the amino acid level. The difference of 10 amino acids between the human and mouse proteins is the net sum of several insertions and deletions in both proteins, when compared to each other. The PI 3-kinase domain found in ATM and other related proteins was identified in the mouse sequence (SEQ ID No:12, aa residues 2750 - 3055) , as was the leucine zipper (SEQ ID No:12, aa residues 1211 to 1243) present in the human ATM protein (SEQ ID No:3, aa residues 2855-2875 and 1217-1238 respectively) . These results indicated that applicants had obtained the entire coding sequence of Atm, the murine homolog of the human ATM gene. It is noteworthy that the human and mouse proteins were most similar within the PI 3-kinase domain at the carboxy terminus (94% identity, 97% similarity) , while the other portions of these proteins show variable identity and similarity reaching a minimum of 70% and 82%, respectively, in some regions (Fig. 4) . Expression pattern: A Northern blot representing several mouse tissues (Clontech) was probed with a fragment representing nt 2297-5311 of the Atm transcript. This probe identified a message of about 13 kb in brain, skeletal muscle and testis, which was barely detectable in heart, spleen, lung and kidney. In the testis, another band of about 10.5 kb was observed at about 50% intensity compared to the 13 kb band. This pattern seems to represent greater differences in expression levels between tissues, compared to the more uniform pattern observed in human tissues (Savitsky et al. , 1995a) . In addition, the 10.5 kb band, which may represent mRNA species with alternative polyadenylation, was not detected in any of 16 human tissues tested previously, but was clearly observed in cultured human fibroblasts (Savitsky et al., 1995a) . Chromosomal localization of the Atm gene by FISH: Initial chromosomal localization of the mouse Atm gene was determined by dual-color FISH. A digoxigenin-labeled probe was cohybridized with a chromosome painting probe specific for mouse chromosome 9, that confirms the identification of DAPI-stained mouse chromosomes. Mouse chromosome 9 contains homologous regions of human chromosomes llq, including llq22-23, the region to which the human ATM gene was assigned. Twelve randomly selected metaphases were analyzed. Signals were observed in 90% of the cells on mouse chromosome 9C. Other chromosomal positions were not observed. Genetic mapping of the Atm gene: The Atm gene was further localized on the genetic map of mouse chromosome 9 using interspecific backcross analysis using progeny derived from matings of [ (C57BL/6J x M. spretus) F x C57BL/6J] mice. This interspecific backcross mapping panel has been typed for over 2000 loci which are well distributed among all the autosomes as well as the X chromosome (Copeland and Jenkins, 1991) . C57BL/6J and M. spretus DNAs were digested with several enzymes and analyzed by Southern blot hybridization for informative restriction fragment length polymorphisms (RFLPs) , using a probe representing nt 6000-7264 of the Atm transcript. The results indicated that Atm is located in the proximal region of mouse chromosome 9 linked to Grik4, Thyl, Cbl, C3g, Drd2, Acatl and Csk (Fig. 5B) . Ninety-one mice were analyzed for every marker and are shown in the segregation analysis (Fig. 5A) , however up to 203 mice were typed for some pairs of markers. Each locus was analyzed in pairwise combinations for recombination frequencies using the additional data. The ratios of the total number of mice analyzed for each pair of loci and the recombination frequencies between the loci are shown in Fig. 5B. Two mapping methods were used to assign the Atm gene to chromosome 9, band 9C. Comparative gene mapping in mouse and human has revealed numerous regions of homology between the two species (Copeland et al., 1993). (References for the human map positions of loci cited in this study can be obtained from GDB (Genome Database) , a computerized database of human linkage information maintained by The William H. Welch Medical Library of The Johns Hopkins University (Baltimore, MD) . ) This is clearly demonstrated between this portion of mouse chromosome 9 and human chromosome llq22-23. The human homologs of Grik4, Thyl, Cbl, Cd3g, Drd2, Acatl and Atm map to llq22-23. It is noteworthy that, similarly to the close map locations of Atm and Acatl in the mouse, ATM and ACAT1 lie about 200 kb apart in the human genome. The mapping of Atm refines the distal end of the human llq22-23 homology unit. Csk, 1.1 cM distal to Acat and Atm, maps to human chromosome 15q23-q25. The average length of a conserved autosomal segment in mice was estimated at 8.1 cM (Nadeau and Taylor, 1984) . The conserved segment on mouse chromosome 9 which corresponds to llq22-23 in humans, extends centromeric to Grik4 and spans approximately 19 cM. The high degree of conservation between the human and mouse proteins suggests similar roles; however, the difference in expression patterns between mice and humans suggested by these northern results may lead to differences between the phenotypes associated with these proteins in the two organisms. To date, no phenotype identical to A-T has been reported in the mouse. The derived chromosome 9 interspecific map of the present invention was compared with a composite mouse linkage map from Mouse Genome Database (The Jackson Laboratory, Bar Harbor, ME) , that reports location of many uncloned mouse mutations. Only one uncloned mouse mutation, luxoid (lu) , lies in the vicinity of Atm, but this skeletal abnormality is highly unlikely to represent a mouse disorder corresponding to A-T. The mouse phenotype closest to A-T is severe combined immune deficiency (SCID) on mouse chromosome 16. It is characterized by a deficiency in mature B and T lymphocytes, radiation sensitivity, chromosomal instability, defective rejoining of DNA double-strand breaks and defective V(D)J recombination (Bosma and Carroll, 1991) . This phenotype is caused by defects in one of the proteins with a PI 3-kinase domain, the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs) (Blunt et al. , 1995; Hartley et al., 1995) . The reason for lack of a mouse phenotype associated with the Atm gene may be that, unlike in humans, such a phenotype is either embryonic lethal, or considerably milder than in humans. As described herein below, a knockout mouse for the Atm gene in mice has been generated and the phenotype appears in young mice to be somwhat milder than in humans. Using a 200 bp PCR product from the human ATM sequence, mouse genomic clones were screened and isolated. The sequence of the 200 bp PCR product corresponds approximately to ATM exons 40 and 41 as set forth in SEQ ID No:24. The targeted disruption of the homologous mouse gene (Atm) involves insertion of a neomycin cassette in the targeted exon and homologous recombination in 129/Sv-ES cells. Generation and analysis of knockout mice were done in collaboration with Dr. Anthony Wynshaw-Boris at the NIH. Neomycin resistant clones were analyzed by PCR and Southern, and injected into blastocysts. Targeted ES cells showed moderate radiosensitivity. No outward phenotypic differences were observed in the heterozygous progenies thus far. Heterozygous matings resulted in homozygote nulls whose preliminary analysis are shown to be infertile, are radiosensitive and show stunted growth. Techniques used are as described in Hogan et al. , Manipulating the Mouse Embryo : A Laboratory Manual , Cold Spring Harbor Laboratory, New York, (1994) . EXAMPLE 5 Generation of antibodies against the ATM protein Antibodies, both polyclonal and monoclonal, were generated against peptide sequences based on the human ATM sequence as set forth in SEQ ID Nos:4-7, 13-15 : HEPANSSASQSTDLC (SEQ ID No:4), CKRNLSDIDQSFDKV (SEQ ID No:5), PEDETELHPTLNADDQEC (SEQ ID No:6), CKSLASFIKKPFDRGEVESMEDDTNG (SEQ ID No:7), CRQLEHDRATERRKKEVEKFK (SEQ ID No:13) CLRIAKPNVSASTQASRQKK (SEQ ID No:14) CARQEKSSSGLNHILAA (SEQ ID No:15) Two rabbits each and six mice each were immunized with each of the antigens. Additional peptide sequences based on the mouse atm sequence to which polyclonal antibodies were raised includes: CRQLEHDRATERKKEVDKF (SEQ ID No:16) CFKHSSQASRSATPANSD (SEQ ID No:17) RPEDESDLHSTPNADDQEC (SEQ ID No:18) Glutathione S-transferase recombinant fusions with the ATM fragments from which polyclonals and monoclonals have been raised are set forth in SEQ ID Nos:19-23. Antibodies raised against the ATM protein detect mono- specifically a high molecular weight of the expected size of 350 kDa on Western blots of protein lysates derived from fibroblast and lymphoblastoid cell lines. Because of the high frequency of truncation mutations in the ATM gene, mutated ATM protein can be identified if such proteins are stable. Indirect immunofluorescence showed the ATM protein to be predominantly nuclear. Cell-fractionation studies of normal fibroblast cells identified the presence of the ATM protein in both the nuclear and microsomal fractions. Throughout this application various publications and patents are referenced by citation or number, respectively. Full citations for the publications referenced are listed below. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains. The invention has been described in an illustrative manner, and it is to be understood that the terminology which has been used is intended to be in the nature of words of description rather than of limitation. Obviously, many modifications and variations of the present invention are possible in light of the above teachings. It is, therefore, to be understood that within the scope of the appended claims, the invention may be practiced otherwise than as specifically described. Table 1 illustrate* several Mutations found in A-T patients H t l o n Ethnic/ Complemen¬ mPNA sequence change Protein alteration Codon 9 Patient • β Patient geographic tation genotype' 0 origin group* AT2RO Arab Deletion of 11 nt 5 Prameshift, truncation 499 Homozygote AT3NO Dutch Deletion of 3 nt Deletion, 1 residue" 1512 Compound heterozygote AT15 A Philippine Insertion, +A Frameahift, truncation 557 Compound heterozygote AT3LΛ African-American Deletion of 139 nt'/ Frameahift, trunction 1196 Compound AT4LA 2 Deletion of 298 nt 6 heterozygote AT2BR Celtic/Irish Deletion, 9 nt Deletion, 3 residues 1198- Homozygote 1200 AT1ABR Australian Deletion, 9 nt Deletion, 3 residues 1198- Homozygote AT2ABR (Irish/British) 1200 AT5BX' Indian/English Deletion, 6 nt Deletion, 2 residues 1079- Compound AT6BI 2 1080 heterozygote F-2079 3 Turkish ND Insertion, +C 5 Frameahift, truncation 504 Homozygote AT29RM Italian ND Deletion of 175 nt Frameahift, truncation 132 Homozygote AT103LO Canadian ND Insertion, +A Frameahift, truncation 1635 Homozygote F-596 3 Palestinian Arab ND Deletion' Truncation Host Homozygote of ORF (Table 1 - continued) 1 Cell line deaignation. 2 Sibling patientβ in both of whom the βame mutation was identified. 3 Patient expected to be homozygous by descent for an A-T mutation. 4 According to the methods of Jaβperβ et al. (1988) NDi not determined. 5 An identical sequence change was observed in genomic DNA 6 No evidence for deletion waβ observed in genomic DNA. In both siblings, a normal mRNA waβ observed in addition to the two deleted βpecieβ. The two deleted mRNAs may represent abnormal splicing events caused by a splice βite mutation. 7 Reflects a genomic deletion segregating with the disease in Family N. 8 The deleted serine residue iβ located within the PI3-kinase signature sequence (1507 - 1527 of SEQ ID No:2). 9 Numbers refer to residue positions in SEQ ID Not2. 10 In all the compound heterozygoteβ, the second mutation iβ still unidentified. Table 2. Mutations in the ATM gene in patients with classical A-T. mRNA Predicted Ethnic/ sequence protein geographical change 1 alteration Codon* Patient origin Genotype 1 Truncations and exon skipping deletions: 9001delAG 8946insA 8307G->A 8283delTC 8269del403 2 8269dell503 81 0C->T 7883del5 7789dell39/7630del29l 7630dell59 3 7517del4 Truncation 2506 6573del5 Truncation 2192 6348dell05 3 Del, 35 aa 2116 6199dell49 3 Truncation 2067 5979del5 Truncation 1994 5712insA Truncation 1905 5554insC Truncation 1852 5539delll Truncation 1847 5320del355 ε Truncation 1774 Table 2 (continued) mRNA Predicted Ethnic/ sequence protein geographical change 1 alteration Codon" Patient origin Genotype 11 5320del7 Truncation 5178dell42 3 Truncation 4612dell65 3 Del, 55 aa 44437dell75 3 Truncation 4110dell27 3 Truncation 3403dell74 3 Del, 58 aa 2839del83 3 Truncation 2467del372 3 ' 5 Del, 124 aa 2 ' 377del90 3 Del, 30 aa 22284delCT Truncation 2125dell25 3 Truncation 2113delT Truncation 1563delAG 5 Truncation 1339C->T Arg->ter; truncation 1240C->T Gln->ter; truncation 755delGT Truncation 497del7514 7 Truncation -30del215 Incorrect ' initiation In-frame genomic deletions and insertions: 8578del3 Del, 1 aa 2860 AT3NG Dutch Compd Htz 7636del9 Del, 3 aa 2547 AT2BR Celtic/Irish Hmz AT1ABR Australian (Irish) Hmz AT1SF American Compd Htz 7278del6 5 Del, 2 aa 2427 AT5BI Indian/English Compd Htz GM5823 English Compd Htz Table 2 (continued) mRNA Predicted Ethnic/ sequence protein geographical change 1 alteration Codon* Patient origin Genotype 1 5319ins9 Ins, 3 aa 1774 251075-008T Finnish Compd Htz Other base substitutions 9170G->C ter->Ser ter F-2089 9 Turkish Hmz Extension of protein by 29 amino acids 8711A->G Glu2904Gly 2904 AT41RM Italian Hmz 2T->C Met->Thr 1 AT8BI British Compd Htz Initiation codon abolished 1 Presented according to the nomenclature proposed by Beaudet & Tsui (1993) . Nucleotide numbers refer to their positions in the sequence of the ATM transcript (accession number U33841) . The first nucleotide of the open reading rame was designated +1. 3 Three adjacent exons skipped. 3 One exon skipped. 4 This allele produces two transcripts, with one or two ajacent exons skipped. 5 The same mutation was found in two affected siblings. 6 Two exons skipped. I This transcript is produced by an allele containing a large genomic deletion spanning approximately 85 Kb within the ATM gene in Family ISAT 9 (Savitsky, et al., 1995a) . * For deletions, the number of the first codon on the amino terminus side is indicated. Codon numbers are according to the ATM protein sequence published by Savitsky et al. (1995b) . In each section of the table, the mutations are ordered according to the codon numbers in this column, beginning with the one closest to the carboxyl terminus. 9 Consanguineous family. 10 All patients are from the same region. II Genotypic combinations in which the mutation was found. Hmz: homozygote; Compd Htz: compound heterozygote. Each patient represents one family. 19/44 20/46 21/46 22/47 19/45 20/45 18/44 18/43 *350 aa of the carboxy terminus, containing the PI-3 kina.se-likc domain. **The entire protein excluding the carboxy terminal 350 aa. An average value is given, since the values obtained for different parts of the proteins vary only by 1-3%. REFERENCES Aicardi et al. , "Ataxia-ocularmotor apraxia: A syndrome mimicking ataxia-telangiectasia" Ann. Neurol. 24:497-502 (1988) . Aksentijevitch et al. , "Familial mediterranean fever in Moroccan Jews : Demonstration of a founder effect by extended haplotype analysis" Am. J. Hu . Genet. , 53:644-651 (1993) . Ambrose et al., "A physical map across chromosome llq22-23 containing the major locus for ataxia-telangiectasia. Genomics. 21:612-619 (1994) . Anderson and Kunkel, "The molecular and biochemical basis of Duchenne muscular dystrophy" Trends Biochem. Sci. 17:289-292 (1992) . Attree et al. , "The Lowe's oculocerebrorenal syndrome gene encodes protein highly homologous to inositol polyphosphate- 5-phosphatase" Nature. 358:239-242 (1992) . Ballabio et al. , "Molecular heterogeneity of steroid sulfatase deficiency: a multicenter study on 57 unrelated patients, at DNA and protein levels" Genomics 4:36-40 (1989) . Barker, "A more robust, rapid alkaline denaturation sequencing method", BioTechniσues, Vol. 14, No. 2, pp. 168- 169 (1993) . Berger et al., "Isolation of a candidate gene for Norrie disease by positional cloning" Nature Genet. 1:199-203, (1992) Beaudet and Tsui, "A suggested nomenclature for designating mutations" Hum. Mutat. 2:245-248 (1993) . Blunt et al. , 1995. Defective DNA-dependent protein kinase activity is linked to V(D)J recombination and DNA repair defects associated with the murine scid mutation. Cell 80:813-823. Bosma and Carroll, 1991. The SCID mouse mutant: definition, characterization, and potential uses. Rev. Immunol. 9:323-350. Boyle et al . , 1992. Rapid physical mapping of cloned DNA on banded mouse chromosomes by fluorescence in situ hybridization. Genomics 12:106-115. Broughton et al., "Mutations in the xeroderma pigmentosum group D DNA repair/transcription gene in patients with trichothiodystrophy" Nature Genet. 7:189-194 (1994) . Broughton et al., "Molecular and cellular analysis of the DNA repair defect in a patient in xeroderma pigmentosum group D who has the clinical features of xeroderma pigmentosum and Cockayne's syndrome" Am. J. Hum. Genet. 56:167-174 (1995) . Brown et al. , "Control of p70 S6 kinase by kinase activity of FRAP in vivo" Nature 377:441-446 (1995) . Buckler et al. , "Exon amplification: a strategy to isolate mammalian genes based on RNA splicing" Proc. Natl. Acad. Sci. USA, 88:4005-4009 (1991) . Burke and Olson, "Preparation of Clone Libraries in Yeast Artificial-Chromosome Vectors" in Methods in Enzymolocrv, Vol. 194, "Guide to Yeast Genetics and Molecular Biology", eds. C. Guthrie and G. Fink, Academic Press, Inc., Chap. 17, pp. 251-270 (1991) . Byrne et al., "Ataxia-without-telangiectasia" J Neurol. Sci. 66:307-317 (1984) . Capecchi, "Altering the genome by homologous recombination" Science 244:1288-1292 (1989) . Chakravarti et al. , "Nonuniform recombination within the human beta-globin gene cluster" Am. J. Hum. Genet.. 36:1239-1258 (1984) . Chelly et al. , "Isolation of a candidate gene for Menkes disease that encodes a potential heavy metal binding protein" Nature Genet. 3:14-19 (1993) . Chessa et al. , "Heterogeneity in ataxia telangiectasia: classical phenotype associated with intermediate cellular radiosensitivity" Am. J. Med. Genet. 42:741-746 (1992) . Chillon et al. , "Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens" New Enσl. J. Med. 332:1475-1480 (1995) . Church et al. , "Isolation of genes from complex sources of mammalian genomic DNA using exon amplification" Nature Genet. 6:98-104 (1993) . Collins, F.S. "Positional cloning: let's not call it reverse anymore" Nature Genet.. 1:3-6 (1992) . Cooper and Krawczak, Human gene mutation. BIOS Scientific Publishers, London (1993) . Copeland and Jenkins, 1991. Development and applications of a molecular genetic linkage map of the mouse genome. Trends Genet. 7:113-118. Copeland et al. , 1993. A genetic linkage map of the mouse: current applications and future prospects. Science 262:57-66. Davies et al., "Targeted alterations in yeast artificial chromosomes for inter-species gene transfer", Nucleic Acids Research, Vol. 20, No. 11, pp. 2693-2698 (1992) . Derry et al. , "WSP gene mutations in Wiskott-Aldrich syndrome and X-linked thrombocytopenia" Hum. Mol . Genet. 4:1127-1135 (1995) . Dickinson et al. , "High frequency gene targeting using insertional vectors", Human Molecular Genetics, Vol. 2, No. 8, pp. 1299-1302 (1993) . Dietz and Kendzior, "Maintenance of an open reading frame as an additional level of scrutiny during splice site selection" Nature Genet . 8:183-188 (1994) . Duyk et al. , "Exon trapping: A genetic screen to identify candidate transcribed sequences in cloned mammalian genomic DNA" Proc. Natl. Acad. Sci. USA. 87:8995-8999 (1990) . Fiorilli et al. , "Variant of ataxia-telangiectasia with low-level radiosensitivity" Hum. Genet. 70:274-277 (1985) . Fodor et al, "Multiplexed biochemical assays with biological chips", Nature 364:555-556 (1993) Foroud et al. "Localization of the AT locus to an 8 cM interval defined by STMY and S132" Am. J. Hum. Genet.. 49:1263-1279 (1991) . Friedman and Weitberg, "Ataxia without telangiectasia" Movement Disorders 8:223-226 (1993) . Frohman, M.A. "On beyond classic RACE (rapid amplification of cDNA ends)" PCR Methods and Applications, 4:S40-S58 (1994) . Frohman et al., "Rapid production of full-length cDNAs from rare transcripts: Amplification using a single gene-specific oligonucleotide primer" Proc. Natl. Acad. Sci. USA, 85:8998-9002 (1988) . Fukao et al. , 1990. Molecular cloning and sequence of the complementary DNA encoding human mitochondrial acetoacrtyl-coenzyme A thiolase and study of the variant enzymes in cultured fibroblasts from patients with 3-ketothiolase deficiency. J. Clin. Invest. 86:2086-2092. Gatti et al., "Genetic haplotyping of ataxia-telangiectasia families localizes the major gene to an 850 kb region on chromosome llq23.1" Int. J. Radiat. Biol. (1994) . Gatti et al. "Localization of an ataxia- telangiectasia gene to chromosome llq22-23" Nature, 336: 577-580 (1988) . Gibson et al. , "A nonsense mutation and exon skipping in the Fanconi anaemia group C gene" Hum. Mol. Genet. 2:797-799 (1993) . Gilboa et al. "Transfer and expression of cloned genes using retroviral vectors" BioTechnicrues 4(6) :504-512 (1986) . Gottlieb and Jackson, "Protein kinases and DNA damage" Trends Biochem. Sci. 19:500-503 (1994) . Green, 1981. Linkage, recombination and mapping. In: Genetics and Probability in Animal Breeding Experiments. Oxford University Press, New York, pp. 77-113. Greenwell et al., "TELl, a gene involved in controlling telomere length in Saccharomyces cerevisiae, is homologous to the human ataxia telangiectasia (ATM) gene" Cell 82:823-829 (1995) . Harding, "Clinical features and classification of inherited ataxias" Adv. Neurol. 61:1-14 (1993) . Harnden, "The nature of ataxia-telangiectasia: problems and perspectives" Int. J. Radiat. Biol. 66:S13-S19 (1994) . Hartley et al. , 1995. DNA-dependent protein kinase catalytic subunit: a relative of phosphatidylinositol 3-kinase and the ataxia telangiectasia gene product. Cell 82:849-856. Hastbacka et al. , "Linkage disequilibrium mapping in isolated founder populations: diastrophic dysplasia in Finland" Nature Genet. , 2:204-211 (1992) . Hogervorst et al., "Rapid detection of BRCA1 mutations by the protein truncation test" Nature Genetics 10:208-212 (1995) . Huxley et al., "The human HPRT gene on a yeast artificial chromosome is functional when transferred to mouse cells by cell fusion", Genomics, 9:742-750 (1991) . Jakobovits et al. , "Germ-line transmission and expression of a human-derived yeast artificial chromosome", Nature, Vol. 362, pp. 255-261 (1993) . James et al., "A radiation hybrid map of 506 STS markers spanning human chromosome 11", Nature Genet . 8:70 (1994) . Jarvi et al., "Cystic fibrosis transmembrane conductance regulator and obstructive azoospermia" The Lancet 345:1578 (1995) . Jaspers et al., "Genetic complementation analysis of Ataxia- Telangiectasia and Nijmegen breakage syndrome: A survey of 50 patients", Cvtogenet. Cell Genet .. 49:259 (1988) . Jenkins et al., 1982. "Organization, distribution and stability of endogenous ecotropic murine leukemia virus DNA sequences in chromosomes of Mus musculus" . J. Virol. 43:26-36. Kawasaki ES. Amplification of RNA. In: PCR protocols: A Guide to Methods and Applications, Innis MA, Gelfand DH, Sninsky JJ, White TJ, eds. Academic Press, 1990, pp21-27. Kerem et al., "Identification of the cystic fibrosis gene: genetic analysis" Science, 245:1073-1080 (1989) . Kingsley et al. , 1989. A molecular genetic linkage map of mouse chromosome 9 with new regional localizations for Gsta, T3g, Ets-1, and Ldlr loci. Genetics 123:165-172. Kolluri et al. , "Identification of WASP mutations in patients with Wiskott-Aldrich syndrome and isolated thrombocytopenia reveals allelic heterogeneity at the WAS locus" Hum. Mol. Genet. 4:1119-1126 (1995) . Lamb et al., "Introduction and expression of the 400 kilobase precursor amyloid protein gene in transgenic mice", Nature Genetics, Vol. 5, pp. 22-29 (1993) . Lange et al., "Localization of an ataxia-telangiectasia gene to a 850 kb interval on chromosome llq23.1 by linkage analysis of 176 families in an international consortium" Am. J. Hum. Genet. (1995) . Lehesjoki et al., "Localization of the EPM1 gene for progressive myoclonus epilepsy on chromosome 21: linkage disequilibrium allows high resolution mapping" Hum. Mol. Genet. ■ 2:1229-1234 (1993) . Lichter et al. , "High-resolution mapping of human chromosome 11 by in situ hybridization with cosmid clones" Science 247:64-69 (1990) . Litt and Luty, "A hypervariable microsatellite revealed by in vitro amplification of a dinucleotide repeat within the cardiac muscle actin gene" Am. J. Hum. Genet. , 44:397-401 (1989) . Liu and Sommer, "Restriction endonuclease fingerprinting (REF) : a sensitive method for screening mutations in long, contiguous segments of DNA" BioTechniσues 18:470-477 (1995) . Llerena et al. , "Spontaneous and induced chromosome breakage in chorionic villus samples: a cytogenetic approach to first trimester prenatal diagnosis of ataxia-telangiectasia syndrome" J. Med. Genet.. 26:174-178 (1989) . Lovett et al., "Direct selection: A method for the isolation of cDNA encoded by large genomic regions", Proc. Natl. Acad. Sci. USA 88, 9628 (1991) . Maserati et al., "Ataxia-without-telangiectasia in two sisters with rearrangements of chromosomes 7 and 14" Clin. Genet. 34:283-287 (1988) . McConville et al., "Genetic and physical mapping of the ataxia-telangiectasia locus on chromosome llq22-23" Int. J. Radiat. Biol. (1994) . McConville et al. , "Paired STSs amplified from radiation hybrids, and from associated YACs, identify highly polymorphic loci flanking the ataxia-telangiectasia locus on chromosome llq22-23" Hum. Mol. Genet.. 2:969-974 (1993) . McConville et al., "Fine mapping of the chromosome llq22-23 region using PFGE, linkage and haplotype analysis; localization of the gene for ataxia telangiectasia to a 5cM region flanked by NCAM/DRD2 and STMY/CJ52.75, phi2.22" Nucleic Acids Res.. 18:4335-4343 (1990) . Miki et al. "A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1" Science, 266:66-71 (1994) . Mitchison et al., "Fine genetic mapping of the Batten Disease locus (CLN3) by haplotype analysis and demonstration of allelic association with chromosome 16p microsatellite loci" Genomics, 16:455-460 (1993) . Morgan et al. , "The selective isolation of novel cDNAs encoded by the regions surrounding the human interleukin 4 and 5 genes" Nucleic Acids Res.. 20:5173-5179 (1992) . Nadeau and Taylor 1984. Lengths of chromosomal segments conserved since divergence of man and mouse. Proc. Natl. Acad. Sci. USA 81:814-818. Orita et al. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 1989; 86:2766-2770 Oskato et al. , "Ataxia-telangiectasia: allelic association with llq22-23 markers in Moroccan-Jewish patients. 43rd Annual Meeting of the American Society of Human Genetics, New Orleans, LA (1993) . Ozelius et al., "Strong alleleic association between the torsion dystonia gene (DYTl) and loci on chromosome 9q34 in Ashkenazi Jews" Am. J. Hum. Genet. 50:619-628 (1992) . Parimoo et al., "cDNA selection: Efficient PCR approach for the selection of cDNAs encoded in large chromosomal DNA fragments" Proc. Natl. Acad. Sci. USA. 88:9623-9627 (1991) . Pease et al., "Light-generated oligonucleotide arrays for rapid DNA sequence analysis", Proc. Natl. Acad. Sci. USA 91(11) :5022-5026 (1994) Regnier et al., 1989. Identification of two murine loci homologous to the v-abl oncogene. J. Virol. 63:3678-3682. Richard et al. , "A radiation hybrid map of human chromosme llq22-23 containing the Ataxia-Telangiectasia disease locus", Genomics 17, 1 (1993) . Ried et al., 1992. Simultaneous visualization of seven different DNA probes using combinatorial labeling and digital imaging microscopy. Proc. Natl. Acad. Sci. USA 89:1388-1392. Rothstein, "Targeting, disruption, replacement, and allele rescue: integrative DNA transformation in yeast" in Methods in Enzvmology, Vol. 194, "Guide to Yeast Genetics and Molecular Biology", eds. C. Guthrie and G. Fink, Academic Press, Inc., Chap. 19, pp. 281-301 (1991) . Rotman et al. , "Three dinucleotide repeat polymorphisms at the ataxia-telangiectasia locus" Human Molecular Genetics (1994b) . Rotman et al. , "A YAC contig spanning the ataxia- telangiectasia locus (groups A and C) on chromosome llq22-23. Genomics (1994c) . Rotman et al., "Physical and genetic mapping of the ATA/ATC locus in chromosome llq22-23" Int. J. Radiat. Biol. (1994d) . Rotman et al., "Rapid identification of polymorphic CA-repeats in YAC clones" Molecular Biotechnology (1995) . Savitsky et al. , "A single gene with homologies to phosphatidylinositol 3-kinases and rad3+ is Mutated in all complementation groups of ataxia-telangiectasia" Science, 268:1749-1753 (June 23, 1995a) Savitsky et al. , "The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species" Hum. Mol. Genet. 4:2025-2032 (1995b) . Schedl et al . , "A yeast artificial chromosome covering the tyrosinase gene confers copy number-dependent expression in transgenic mice", Nature, Vol. 362, pp. 258-261 (1993) . Sirugo et al. , "Friedreich ataxia in Louisiana Acadians: Demonstration of a founder effect by analysis of microsatellite-generated extended haplotypes" Am. J.Hum. Genet. , 50:559-566 (1992) . Shiloh, "Ataxia-telangiectasia: closer to unraveling the mystery" European Journal of Human Genetics (1995) Shiloh et al., Am. J. Hum. Genet. 55 (suppl.), A49 (1994) Sommer, "Recent human germ-line mutation: Inferences from patients with hemophilia B" Trends Gene. 11:141-147 (1995) . Steingrimsdottir et al., "Mutations which alter splicing in the human hypoxanthine-guanine phosphoribosyl-transferase gene" Nucleic Acids Res. 6:1201-1208 (1992) . Strauss et al. , "Germ line transmission of a yeast artificial chromosome spanning the murine a x (I) collagen locus", Science, Vol. 259, pp. 1904-1907 (1993) . Szpirer et al. , 1994. The genes encoding the glutamate receptor subunits KAl and KA2 (GRIK4 and GRIK5) are located on separate chromosomes in human, mouse and rat. Proc. Natl. Acad. Sci. USA 91:11849-11853. Tagle et al. , "Magnetic capture of expressed sequences encoded within large genomic segments" Nature, 361:751-753 (1993) . Taylor et al., "Genetic and cellular features of ataxia telangiectasia" Int. J. Radiat. Biol. 65:65-70 (1994) . Taylor et al. , Variant forms of ataxia telangiectasia. J. Med. Genet. 24, 669-677 (1987) . The European Polycystic Kidney Disease Consortium, "The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16" Cell, 77:881-894 (1994) . The Huntington's Disease Collaborative Research Group, "A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes" Cell, 72:971-983 (1993) . Thomas et al. , 1991. Phosphorylation of c-Src on tyrosine 527 by anchor protein tyrosine kinase. Science 254:568-571. Trofatter et al. , "A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor" Cell, 72:791-800 (1993) . Vanagaite et al. , "Physical localization of microsatellite markers at the ataxia-telangiectasia locus at llq22-23. Genomics, 22:231-233 (1994a) . Vanagaite et al., "High-density microsatellite map of ataxia-telangiectasia locus" Human Genetics 95:451-453 (1995) . Vetrie et al., "The gene involved in X-linked agammaglobulinemia is a member of the src family of protein- tyrosine kinases" Nature, 361:226-233 (1993) . Weber and May, "Abundant class of human DNA polymorphisms which can be typed using the polymerase chain reaction" Am. J. Hum. Genet., 44:388-396 (1989) . Weemaes et al. , "Nijmegen breakage syndrome: A progress report" Int. J. Radiat. Biol. 66:S185-S188 (1994) . Ying and Decoteau, "Cytogenetic anomalies in a patient with ataxia, immune deficiency, and high alpha-fetoprotein in the absence of telangiectasia" Cancer Genet . Cvtogenet. 4:311-317 (1983) . Zakian, "ATM-related genes: What do they tell us about functions of the human gene?" Cell 82:685-687 (1995) . Ziv et al., "Ataxia-telangiectasia: linkage analysis in highly inbred Arab and Druze families and differentiation from an ataxia-microcephaly-cataract syndrome" Hum. Genet. , 88:619-626 (1992) . Ziv et al., "The ATC (ataxia-telangiectasia complementation group C) locus localizes to Ilq22-q23. Genomics, 9:373-375 (1991) . Ziv et al. , "Ataxia telangiectasia: a variant with altered in vi tro phenotype of fibroblast cells" Mutation Res. 210:211-219 (1989) . SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: Shiloh, Yosef Tagle, Danilo A. Collins, Francis S. (ii) TITLE OF INVENTION: ATAXIA-TELANGIECTASIA GENE (iii) NUMBER OF SEQUENCES: 24 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Kohn & Associates (B) STREET: 30500 Northwestern Hwy. , Suite 410 (C) CITY: Farmington Hills (D) STATE: Michigan (E) COUNTRY: U.S. (F) ZIP: 48334 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentln Release #1.0, Version #1.30 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Kohn, Kenneth I. (B) REGISTRATION NUMBER: 30,995 (C) REFERENCE/DOCKET NUMBER: 2290.00029 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 810-539-5050 (B) TELEFAX: 810-539-5055 (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 5912 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (vii) IMMEDIATE SOURCE: (B) CLONE: 7-9 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: CATACTTTTT CCTCTTAGTC TACAGGTTGG CTGCATAGAA GAAAAAGGTA GAGTTATTTA 60 TAATCTTGTA AATCTTGGAC TTTGAGTCAT CTATTTTCTT TTACAGTCAT CGAATACTTT 120 TGGAAATAAG GTAATATATG CCTTTTGAGC TGTCTTGACG TTCACAGATA TAAAATATTA 180 AATATATTTT AATTTTGTGC CCTTGCAGAT TGATCACTTA TTCATTAGTA ATTTACCAGA 240 GATTGTGGTG GAGTTATTGA TGACGTTACA TGAGCCAGCA AATTCTAGTG CCAGTCAGAG 300 CACTGACCTC TGTGACTTTT CAGGGGATTT GGATCCTGCT CCTAATCCAC CTCATTTTCC 360 ATCGCATGTG ATTAAAGCAA CATTTGCCTA TATCAGCAAT TGTCATAAAA CCAAGTTAAA 420 AAGCATTTTA GAAATTCTTT CCAAAAGCCC TGATTCCTAT CAGAAAATTC TTCTTGCCAT 480 ATGTGAGCAA GCAGCTGAAA CAAATAATGT TTATAAGAAG CACAGAATTC TTAAAATATA 540 TCACCTGTTT GTTAGTTTAT TACTGAAAGA TATAAAAAGT GGCTTAGGAG GAGCTTGGGC 600 CTTTGTTCTT CGAGACGTTA TTTATACTTT GATTCACTAT ATCAACCAAA GGCCTTCTTG 660 TATCATGGAT GTGTCATTAC GTAGCTTCTC CCTTTGTTGT GACTTATTAA GTCAGGTTTG 720 CCAGACAGCC GTGACTTACT GTAAGGATGC TCTAGAAAAC CATCTTCATG TTATTGTTGG 780 TACACTTATA CCCCTTGTGT ATGAGCAGGT GGAGGTTCAG AAACAGGTAT TGGACTTGTT 840 GAAATACTTA GTGATAGATA ACAAGGATAA TGAAAACCTC TATATCACGA TTAAGCTTTT 900 AGATCCTTTT CCTGACCATG TTGTTTTTAA GGATTTGCGT ATTACTCAGC AAAAAATCAA 960 ATACAGTAGA GGACCCTTTT CACTCTTGGA GGAAATTAAC CATTTTCTCT CAGTAAGTGT 1020 TTATGATGCA CTTCCATTGA CAAGACTTGA AGGACTAAAG GATCTTCGAA GACAACTGGA 1080 ACTACATAAA GATCAGATGG TGGACATTAT GAGAGCTTCT CAGGATAATC CGCAAGATGG 1140 GATTATGGTG AAACTAGTTG TCAATTTGTT GCAGTTATCC AAGATGGCAA TAAACCACAC 1200 TGGTGAAAAA GAAGTTCTAG AGGCTGTTGG AAGCTGCTTG GGAGAAGTGG GTCCTATAGA 1260 TTTCTCTACC ATAGCTATAC AACATAGTAA AGATGCATCT TATACCAAGG CCCTTAAGTT 1320 ATTTGAAGAT AAAGAACTTC AGTGGACCTT CATAATGCTG ACCTACCTGA ATAACACACT 1380 GGTAGAAGAT TGTGTCAAAG TTCGATCAGC AGCTGTTACC TGTTTGAAAA ACATTTTAGC 1440 CACAAAGACT GGACATAGTT TCTGGGAGAT TTATAAGATG ACAACAGATC CAATGCTGGC 1500 CTATCTACAG CCTTTTAGAA CATCAAGAAA AAAGTTTTTA GAAGTACCCA GATTTGACAA 1560 AGAAAACCCT TTTGAAGGCC TGGATGATAT AAATCTGTGG ATTCCTCTAA GTGAAAATCA 1620 TGACATTTGG ATAAAGACAC TGACTTGTGC TTTTTTGGAC AGTGGAGGCA CAAAATGTGA 1680 AATTCTTCAA TTATTAAAGC CAATGTGTGA AGTGAAAACT GACTTTTGTC AGACTGTACT 1740 TCCATACTTG ATTCATGATA TTTTACTCCA AGATACAAAT GAATCATGGA GAAATCTGCT 1800 TTCTACACAT GTTCAGGGAT TTTTCACCAG CTGTCTTCGA CACTTCTCGC AAACGAGCCG 1860 ATCCACAACC CCTGCAAACT TGGATTCAGA GTCAGAGCAC TTTTTCCGAT GCTGTTTGGA 1920 TAAAAAATCA CAAAGAACAA TGCTTGCTGT TGTGGACTAC ATGAGAAGAC AAAAGAGACC 1980 TTCTTCAGGA ACAATTTTTA ATGATGCTTT CTGGCTGGAT TTAAATTATC TAGAAGTTGC 2040 CAAGGTAGCT CAGTCTTGTG CTGCTCACTT TACAGCTTTA CTCTATGCAG AAATCTATGC 2100 AGATAAGAAA AGTATGGATG ATCAAGAGAA AAGAAGTCTT GCATTTGAAG AAGGAAGCCA 2160 GAGTACAACT ATTTCTAGCT TGAGTGAAAA AAGTAAAGAA GAAACTGGAA TAAGTTTACA 2220 GGATCTTCTC TTAGAAATCT ACAGAAGTAT AGGGGAGCCA GATAGTTTGT ATGGCTGTGG 2280 TGGAGGGAAG ATGTTACAAC CCATTACTAG ACTACGAACA TATGAACACG AAGCAATGTG 2340 GGGCAAAGCC CTAGTAACAT ATGACCTCGA AACAGCAATC CCCTCATCAA CACGCCAGGC 2400 AGGAATCATT CAGGCCTTGC AGAATTTGGG ACTCTGCCAT ATTCTTTCCG TCTATTTAAA 2460 AGGATTGGAT TATGAAAATA AAGACTGGTG TCCTGAACTA GAAGAACTTC ATTACCAAGC 2520 AGCATGGAGG AATATGCAGT GGGACCATTG CACTTCCGTC AGCAAAGAAG TAGAAGGAAC 2580 CAGTTACCAT GAATCATTGT ACAATGCTCT ACAATCTCTA AGAGACAGAG AATTCTCTAC 2640 ATTTTATGAA AGTCTCAAAT ATGCCAGAGT AAAAGAAGTG GAAGAGATGT GTAAGCGCAG 2700 CCTTGAGTCT GTGTATTCGC TCTATCCCAC ACTTAGCAGG TTGCAGGCCA TTGGAGAGCT 2760 GGAAAGCATT GGGGAGCTTT TCTCAAGATC AGTCACACAT AGACAACTCT CTGAAGTATA 2820 TATTAAGTGG CAGAAACACT CCCAGCTTCT CAAGGACAGT GATTTTAGTT TTCAGGAGCC 2880 TATCATGGCT CTACGCACAG TCATTTTGGA GATCCTGATG GAAAAGGAAA TGGACAACTC 2940 ACAAAGAGAA TGTATTAAGG ACATTCTCAC CAAACACCTT GTAGAACTCT CTATACTGGC 3000 CAGAACTTTC AAGAACACTC AGCTCCCTGA AAGGGCAATA TTTCAAATTA AACAGTACAA 3060 TTCAGTTAGC TGTGGAGTCT CTGAGTGGCA GCTGGAAGAA GCACAAGTAT TCTGGGCAAA 3120 AAAGGAGCAG AGTCTTGCCC TGAGTATTCT CAAGCAAATG ATCAAGAAGT TGGATGCCAG 3180 CTGTGCAGCG AACAATCCCA GCCTAAAACT TACATACACA GAATGTCTGA GGGTTTGTGG 3240 CAACTGGTTA GCAGAAACGT GCTTAGAAAA TCCTGCGGTC ATCATGCAGA CCTATCTAGA 3300 AAAGGCAGTA GAAGTTGCTG GAAATTATGA TGGAGAAAGT AGTGATGAGC TAAGAAATGG. 3360 AAAAATGAAG GCATTTCTCT CATTAGCCCG GTTTTCAGAT ACTCAATACC AAAGAATTGA 3420 AAACTACATG AAATCATCGG AATTTGAAAA CAAGCAAGCT CTCCTGAAAA GAGCCAAAGA 3480 GGAAGTAGGT CTCCTTAGGG AACATAAAAT TCAGACAAAC AGATACACAG TAAAGGTTCA 3540 GCGAGAGCTG GAGTTGGATG AATTAGCCCT GCGTGCACTG AAAGAGGATC GTAAACGCTT 3600 CTTATGTAAA GCAGTTGAAA ATTATATCAA CTGCTTATTA AGTGGAGAAG AACATGATAT 3660 GTGGGTATTC CGACTTTGTT CCCTCTGGCT TGAAAATTCT GGAGTTTCTG AAGTCAATGG 3720 CATGATGAAG AGAGACGGAA TGAAGATTCC AACATATAAA TTTTTGCCTC TTATGTACCA 3780 ATTGGCTGCT AGAATGGGGA CCAAGATGAT GGGAGGCCTA GGATTTCATG AAGTCCTCAA 3840 TAATCTAATC TCTAGAATTT CAATGGATCA CCCCCATCAC ACTTTGTTTA TTATACTGGC 3900 CTTAGCAAAT GCAAACAGAG ATGAATTTCT GACTAAACCA GAGGTAGCCA GAAGAAGCAG 3960 AATAACTAAA AATGTGCCTA AACAAAGCTC TCAGCTTGAT GAGGATCGAA CAGAGGCTGC 4020 AAATAGAATA ATATGTACTA TCAGAAGTAG GAGACCTCAG ATGGTCAGAA GTGTTGAGGC 4080 ACTTTGTGAT GCTTATATTA TATTAGCAAA CTTAGATGCC ACTCAGTGGA AGACTCAGAG 4140 AAAAGGCATA AATATTCCAG CAGACCAGCC AATTACTAAA CTTAAGAATT TAGAAGATGT 4200 TGTTGTCCCT ACTATGGAAA TTAAGGTGGA CCACACAGGA GAATATGGAA ATCTGGTGAC 4260 TATACAGTCA TTTAAAGCAG AATTTCGCTT AGCAGGAGGT GTAAATTTAC CAAAAATAAT 4320 AGATTGTGTA GGTTCCGATG GCAAGGAGAG GAGACAGCTT GTTAAGGGCC GTGATGACCT 4380 GAGACAAGAT GCTGTCATGC AACAGGTCTT CCAGATGTGT AATACATTAC TGCAGAGAAA 4440 CACGGAAACT AGGAAGAGGA AATTAACTAT CTGTACTTAT AAGGTGGTTC CCCTCTCTCA 4500 GCGAAGTGGT GTTCTTGAAT GGTGCACAGG AACTGTCCCC ATTGGTGAAT TTCTTGTTAA 4560 CAATGAAGAT GGTGCTCATA AAAGATACAG GCCAAATGAT TTCAGTGCCT TTCAGTGCCA 4620 AAAGAAAATG ATGGAGGTGC AAAAAAAGTC TTTTGAAGAG AAATATGAAG TCTTCATGGA 4680 TGTTTGCCAA AATTTTCAAC CAGTTTTCCG TTACTTCTGC ATGGAAAAAT TCTTGGATCC 4740 AGCTATTTGG TTTGAGAAGC GATTGGCTTA TACGCGCAGT GTAGCTACTT CTTCTATTGT 4800 TGGTTACATA CTTGGACTTG GTGATAGACA TGTACAGAAT ATCTTGATAA ATGAGCAGTC 4860 AGCAGAACTT GTACATATAG ATCTAGGTGT TGCTTTTGAA CAGGGCAAAA TCCTTCCTAC 4920 TCCTGAGACA GTTCCTTTTA GACTCACCAG AGATATTGTG GATGGCATGG GCATTACGGG 4980 TGTTGAAGGT GTCTTCAGAA GATGCTGTGA GAAAACCATG GAAGTGATGA GAAACTCTCA 5040 GGAAACTCTG TTAACCATTG TAGAGGTCCT TCTATATGAT CCACTCTTTG ACTGGACCAT 5100 GAATCCTTTG AAAGCTTTGT ATTTACAGCA GAGGCCGGAA GATGAAACTG AGCTTCACCC 5160 TACTCTGAAT GCAGATGACC AAGAATGCAA ACGAAATCTC AGTGATATTG ACCAGAGTTT 5220 CGACAAAGTA GCTGAACGTG TCTTAATGAG ACTACAAGAG AAACTGAAAG GAGTGGAAGA 5280 AGGCACTGTG CTCAGTGTTG GTGGACAGGT GAATTTGCTC ATACAGCAGG CCATAGACCC 5340 CAAAAATCTC AGCCGACTTT TCCCAGGATG GAAAGCTTGG GTGTGATCTT CAGTATATGA 5400 ATTACCCTTT CATTCAGCCT TTAGAAATTA TATTTTAGCC TTTATTTTTA ACCTGCCAAC 5460 ATACTTTAAG TAGGGATTAA TATTTAAGTG AACTATTGTG GGTTTTTTTG AATGTTGGTT 5520 TTAATACTTG ATTTAATCAC CACTCAAAAA TGTTTTGATG GTCTTAAGGA ACATCTCTGC 5580 TTTCACTCTT TAGAAATAAT GGTCATTCGG GCTGGGCGCA GCGGCTCACG CCTGTAATCC 5640 CAGCACTTTG GGAGGCCGAG GTGAGCGGAT CACAAGGTCA GGAGTTCGAG ACCAGCCTGG 5700 CCAAGAGACC AGCCTGGCCA GTATGGTGAA ACCCTGTCTC TACTAAAAAT ACAAAAATTA 5760 GCCGAGCATG GTGGCGGGCA CCTGTAGTCC CAGCTACTCG AGAGGCTGAG GCAGGAGAAT 5820 CTCTTGAACC TGGGAGGTGA AGGTTGCTGT GGGCCAAAAT CATGCCATTG CACTCCAGCC 5880 TGGGTGACAA GAGCGAAACT CCATCTCAAA AA 5912 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9171 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (viii) POSITION IN GENOME: (A) CHROMOSOME/SEGMENT: llq22-23 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: ATGAGTCTAG TACTTAATGA TCTGCTTATC TGCTGCCGTC AACTAGAACA TGATAGAGCT 60 ACAGAACGAA AGAAAGAAGT TGAGAAATTT AAGCGCCTGA TTCGAGATCC TGAAACAATT 120 AAACATCTAG ATCGGCATTC AGATTCCAAA CAAGGAAAAT ATTTGAATTG GGATGCTGTT 180 TTTAGATTTT TACAGAAATA TATTCAGAAA GAAACAGAAT GTCTGAGAAT AGCAAAACCA 240 AATGTATCAG CCTCAACACA AGCCTCCAGG CAGAAAAAGA TGCAGGAAAT CAGTAGTTTG 300 GTCAAATACT TCATCAAATG TGCAAACAGA AGAGCACCTA GGCTAAAATG TCAAGAACTC 360 TTAAATTATA TCATGGATAC AGTGAAAGAT TCATCTAATG GTGCTATTTA CGGAGCTGAT 420 TGTAGCAACA TACTACTCAA AGACATTCTT TCTGTGAGAA AATACTGGTG TGAAATATCT 480 CAGCAACAGT GGTTAGAATT GTTCTCTGTG TACTTCAGGC TCTATCTGAA ACCTTCACAA 540 GATGTTCATA GAGTTTTAGT GGCTAGAATA ATTCATGCTG TTACCAAAGG ATGCTGTTCT 600 CAGACTGACG GATTAAATTC CAAATTTTTG GACTTTTTTT CCAAGGCTAT TCAGTGTGCG 660 AGACAAGAAA AGAGCTCTTC AGGTCTAAAT CATATCTTAG CAGCTCTTAC TATCTTCCTC 720 AAGACTTTGG CTGTCAACTT TCGAATTCGA GTGTGTGAAT TAGGAGATGA AATTCTTCCC 780 ACTTTGCTTT ATATTTGGAC TCAACATAGG CTTAATGATT CTTTAAAAGA AGTCATTATT 840 GAATTATTTC AACTGCAAAT TTATATCCAT CATCCGAAAG GAGCCAAAAC CCAAGAAAAA 900 GGTGCTTATG AATCAACAAA ATGGAGAAGT ATTTTATACA ACTTATATGA TCTGCTAGTG 960 AATGAGATAA GTCATATAGG AAGTAGAGGA AAGTATTCTT CAGGATTTCG TAATATTGCC 1020 GTCAAAGAAA ATTTGATTGA ATTGATGGCA GATATCTGTC ACCAGGTTTT TAATGAAGAT 1080 ACCAGATCCT TGGAGATTTC TCAATCTTAC ACTACTACAC AAAGAGAATC TAGTGATTAC 1140 AGTGTCCCTT GCAAAAGGAA GAAAATAGAA CTAGGCTGGG AAGTAATAAA AGATCACCTT 1200 CAGAAGTCAC AGAATGATTT TGATCTTGTG CCTTGGCTAC AGATTGCAAC CCAATTAATA 1260 TCAAAGTATC CTGCAAGTTT ACCTAACTGT GAGCTGTCTC CATTACTGAT GATACTATCT 1320 CAGCTTCTAC CCCAACAGCG ACATGGGGAA CGTACACCAT ATGTGTTACG ATGCCTTACG 1380 GAAGTTGCAT TGTGTCAAGA CAAGAGGTCA AACCTAGAAA GCTCACAAAA GTCAGATTTA 1440 TTAAAACTCT GGAATAAAAT TTGGTGTATT ACCTTTCGTG GTATAAGTTC TGAGCAAATA 1500 CAAGCTGAAA ACTTTGGCTT ACTTGGAGCC ATAATTCAGG GTAGTTTAGT TGAGGTTGAC 1560 AGAGAATTCT GGAAGTTATT TACTGGGTCA GCCTGCAGAC CTTCATGTCC TGCAGTATGC 1620 TGTTTGACTT TGGCACTGAC CACCAGTATA GTTCCAGGAA CGGTAAAAAT GGGAATAGAG 1680 CAAAATATGT GTGAAGTAAA TAGAAGCTTT TCTTTAAAGG AATCAATAAT GAAATGGCTC 1740 TTATTCTATC AGTTAGAGGG TGACTTAGAA AATAGCACAG AAGTGCCTCC AATTCTTCAC 1800 AGTAATTTTC CTCATCTTGT ACTGGAGAAA ATTCTTGTGA GTCTCACTAT GAAAAACTGT 1860 AAAGCTGCAA TGAATTTTTT CCAAAGCGTG CCAGAATGTG AACACCACCA AAAAGATAAA 1920 GAAGAACTTT CATTCTCAGA AGTAGAAGAA CTATTTCTTC AGACAACTTT TGACAAGATG 1980 GACTTTTTAA CCATTGTGAG AGAATGTGGT ATAGAAAAGC ACCAGTCCAG TATTGGCTTC 2040 TCTGTCCACC AGAATCTCAA GGAATCACTG GATCGCTGTC TTCTGGGATT ATCAGAACAG 2100 CTTCTGAATA ATTACTCATC TGAGATTACA AATTCAGAAA CTCTTGTCCG GTGTTCACGT 2160 CTTTTGGTGG GTGTCCTTGG CTGCTACTGT TACATGGGTG TAATAGCTGA AGAGGAAGCA 2220 TATAAGTCAG AATTATTCCA GAAAGCCAAG TCTCTAATGC AATGTGCAGG AGAAAGTATC 2280 ACTCTGTTTA AAAATAAGAC AAATGAGGAA TTCAGAATTG GTTCCTTGAG AAATATGATG 2340 CAGCTATGTA CACGTTGCTT GAGCAACTGT ACCAAGAAGA GTCCAAATAA GATTGCATCT 2400 GGCTTTTTCC TGCGATTGTT AACATCAAAG CTAATGAATG ACATTGCAGA TATTTGTAAA 2460 AGTTTAGCAT CCTTCATCAA AAAGCCATTT GACCGTGGAG AAGTAGAATC AATGGAAGAT 2520 GATACTAATG GAAATCTAAT GGAGGTGGAG GATCAGTCAT CCATGAATCT ATTTAACGAT 2580 TACCCTGATA GTAGTGTTAG TGATGCAAAC GAACCTGGAG AGAGCCAAAG TACCATAGGT 2640 GCCATTAATC CTTTAGCTGA AGAATATCTG TCAAAGCAAG ATCTACTTTT CTTAGACATG 2700 CTCAAGTTCT TGTGTTTGTG TGTAACTACT GCTCAGACCA ATACTGTGTC CTTTAGGGCA 2760 GCTGATATTC GGAGGAAATT GTTAATGTTA ATTGATTCTA GCACGCTAGA ACCTACCAAA 2820 TCCCTCCACC TGCATATGTA TCTAATGCTT TTAAAGGAGC TTCCTGGAGA AGAGTACCCC 2880 TTGCCAATGG AAGATGTTCT TGAACTTCTG AAACCACTAT CCAATGTGTG TTCTTTGTAT 2940 CGTCGTGACC AAGATGTTTG TAAAACTATT TTAAACCATG TCCTTCATGT AGTGAAAAAC 3000 CTAGGTCAAA GCAATATGGA CTCTGAGAAC ACAAGGGATG CTCAAGGACA GTTTCTTACA 3060 GTAATTGGAG CATTTTGGCA TCTAACAAAG GAGAGGAAAT ATATATTCTC TGTAAGAATG 3120 GCCCTAGTAA ATTGCCTTAA AACTTTGCTT GAGGCTGATC CTTATTCAAA ATGGGCCATT 3180 CTTAATGTAA TGGGAAAAGA CTTTCCTGTA AATGAAGTAT TTACACAATT TCTTGCTGAC 3240 AATCATCACC AAGTTCGCAT GTTGGCTGCA GAGTCAATCA ATAGATTGTT CCAGGACACG 3300 AAGGGAGATT CTTCCAGGTT ACTGAAAGCA CTTCCTTTGA AGCTTCAGCA AACAGCTTTT 3360 GAAAATGCAT ACTTGAAAGC TCAGGAAGGA ATGAGAGAAA TGTCCCATAG TGCTGAGAAC 3420 CCTGAAACTT TGGATGAAAT TTATAATAGA AAATCTGTTT TACTGACGTT GATAGCTGTG 3480 GTTTTATCCT GTAGCCCTAT CTGCGAAAAA CAGGCTTTGT TTGCCCTGTG TAAATCTGTG 3540 AAAGAGAATG GATTAGAACC TCACCTTGTG AAAAAGGTTT TAGAGAAAGT TTCTGAAACT 3600 TTTGGATATA GACGTTTAGA AGACTTTATG GCATCTCATT TAGATTATCT GGTTTTGGAA 3660 TGGCTAAATC TTCAAGATAC TGAATACAAC TTATCTTCTT TTCCTTTTAT TTTATTAAAC 3720 TACACAAATA TTGAGGATTT CTATAGATCT TGTTATAAGG TTTTGATTCC ACATCTGGTG 3780 ATTAGAAGTC ATTTTGATGA GGTGAAGTCC ATTGCTAATC AGATTCAAGA GGACTGGAAA 3840 AGTCTTCTAA CAGACTGCTT TCCAAAGATT CTTGTAAATA TTCTTCCTTA TTTTGCCTAT 3900 GAGGGTACCA GAGACAGTGG GATGGCACAG CAAAGAGAGA CTGCTACCAA GGTCTATGAT 3960 ATGCTTAAAA GTGAAAACTT ATTGGGAAAA CAGATTGATC ACTTATTCAT TAGTAATTTA 4020 CCAGAGATTG TGGTGGAGTT ATTGATGACG TTACATGAGC CAGCAAATTC TAGTGCCAGT 4080 CAGAGCACTG ACCTCTGTGA CTTTTCAGGG GATTTGGATC CTGCTCCTAA TCCACCTCAT 4140 TTTCCATCGC ATGTGATTAA AGCAACATTT GCCTATATCA GCAATTGTCA TAAAACCAAG 4200 TTAAAAAGCA TTTTAGAAAT TCTTTCCAAA AGCCCTGATT CCTATCAGAA AATTCTTCTT 4260 GCCATATGTG AGCAAGCAGC TGAAACAAAT AATGTTTATA AGAAGCACAG AATTCTTAAA 4320 ATATATCACC TGTTTGTTAG TTTATTACTG AAAGATATAA AAAGTGGCTT AGGAGGAGCT 4380 TGGGCCTTTG TTCTTCGAGA CGTTATTTAT ACTTTGATTC ACTATATCAA CCAAAGGCCT 4440 TCTTGTATCA TGGATGTGTC ATTACGTAGC TTCTCCCTTT GTTGTGACTT ATTAAGTCAG 4500 GTTTGCCAGA CAGCCGTGAC TTACTGTAAG GATGCTCTAG AAAACCATCT TCATGTTATT 4560 GTTGGTACAC TTATACCCCT TGTGTATGAG CAGGTGGAGG TTCAGAAACA GGTATTGGAC 4620 TTGTTGAAAT ACTTAGTGAT AGATAACAAG GATAATGAAA ACCTCTATAT CACGATTAAG 4680 CTTTTAGATC CTTTTCCTGA CCATGTTGTT TTTAAGGATT TGCGTATTAC TCAGCAAAAA 4740 ATCAAATACA GTAGAGGACC CTTTTCACTC TTGGAGGAAA TTAACCATTT TCTCTCAGTA 4800 AGTGTTTATG ATGCACTTCC ATTGACAAGA CTTGAAGGAC TAAAGGATCT TCGAAGACAA 4860 CTGGAACTAC ATAAAGATCA GATGGTGGAC ATTATGAGAG CTTCTCAGGA TAATCCGCAA 4920 GATGGGATTA TGGTGAAACT AGTTGTCAAT TTGTTGCAGT TATCCAAGAT GGCAATAAAC 4980 CACACTGGTG AAAAAGAAGT TCTAGAGGCT GTTGGAAGCT GCTTGGGAGA AGTGGGTCCT 5040 ATAGATTTCT CTACCATAGC TATACAACAT AGTAAAGATG CATCTTATAC CAAGGCCCTT 5100 AAGTTATTTG AAGATAAAGA ACTTCAGTGG ACCTTCATAA TGCTGACCTA CCTGAATAAC 5160 ACACTGGTAG AAGATTGTGT CAAAGTTCGA TCAGCAGCTG TTACCTGTTT GAAAAACATT 5220 TTAGCCACAA AGACTGGACA TAGTTTCTGG GAGATTTATA AGATGACAAC AGATCCAATG 5280 CTGGCCTATC TACAGCCTTT TAGAACATCA AGAAAAAAGT TTTTAGAAGT ACCCAGATTT 5340 GACAAAGAAA ACCCTTTTGA AGGCCTGGAT GATATAAATC TGTGGATTCC TCTAAGTGAA 5400 AATCATGACA TTTGGATAAA GACACTGACT TGTGCTTTTT TGGACAGTGG AGGCACAAAA 5460 TGTGAAATTC TTCAATTATT AAAGCCAATG TGTGAAGTGA AAACTGACTT TTGTCAGACT 5520 GTACTTCCAT ACTTGATTCA TGATATTTTA CTCCAAGATA CAAATGAATC ATGGAGAAAT 5580 CTGCTTTCTA CACATGTTCA GGGATTTTTC ACCAGCTGTC TTCGACACTT CTCGCAAACG 5640 AGCCGATCCA CAACCCCTGC AAACTTGGAT TCAGAGTCAG AGCACTTTTT CCGATGCTGT 5700 TTGGATAAAA AATCACAAAG AACAATGCTT GCTGTTGTGG ACTACATGAG AAGACAAAAG 5760 AGACCTTCTT CAGGAACAAT TTTTAATGAT GCTTTCTGGC TGGATTTAAA TTATCTAGAA 5820 GTTGCCAAGG TAGCTCAGTC TTGTGCTGCT CACTTTACAG CTTTACTCTA TGCAGAAATC 5880 TATGCAGATA AGAAAAGTAT GGATGATCAA GAGAAAAGAA GTCTTGCATT TGAAGAAGGA 5940 AGCCAGAGTA CAACTATTTC TAGCTTGAGT GAAAAAAGTA AAGAAGAAAC TGGAATAAGT 6000 TTACAGGATC TTCTCTTAGA AATCTACAGA AGTATAGGGG AGCCAGATAG TTTGTATGGC 6060 TGTGGTGGAG GGAAGATGTT ACAACCCATT ACTAGACTAC GAACATATGA ACACGAAGCA 6120 ATGTGGGGCA AAGCCCTAGT AACATATGAC CTCGAAACAG CAATCCCCTC ATCAACACGC 6180 CAGGCAGGAA TCATTCAGGC CTTGCAGAAT TTGGGACTCT GCCATATTCT TTCCGTCTAT 6240 TTAAAAGGAT TGGATTATGA AAATAAAGAC TGGTGTCCTG AACTAGAAGA ACTTCATTAC 6300 CAAGCAGCAT GGAGGAATAT GCAGTGGGAC CATTGCACTT CCGTCAGCAA AGAAGTAGAA 6360 GGAACCAGTT ACCATGAATC ATTGTACAAT GCTCTACAAT CTCTAAGAGA CAGAGAATTC 6420 TCTACATTTT ATGAAAGTCT CAAATATGCC AGAGTAAAAG AAGTGGAAGA GATGTGTAAG 6480 CGCAGCCTTG AGTCTGTGTA TTCGCTCTAT CCCACACTTA GCAGGTTGCA GGCCATTGGA 6540 GAGCTGGAAA GCATTGGGGA GCTTTTCTCA AGATCAGTCA CACATAGACA ACTCTCTGAA 6600 GTATATATTA AGTGGCAGAA ACACTCCCAG CTTCTCAAGG ACAGTGATTT TAGTTTTCAG 6660 GAGCCTATCA TGGCTCTACG CACAGTCATT TTGGAGATCC TGATGGAAAA GGAAATGGAC 6720 AACTCACAAA GAGAATGTAT TAAGGACATT CTCACCAAAC ACCTTGTAGA ACTCTCTATA 6780 CTGGCCAGAA CTTTCAAGAA CACTCAGCTC CCTGAAAGGG CAATATTTCA AATTAAACAG 6840 TACAATTCAG TTAGCTGTGG AGTCTCTGAG TGGCAGCTGG AAGAAGCACA AGTATTCTGG 6900 GCAAAAAAGG AGCAGAGTCT TGCCCTGAGT ATTCTCAAGC AAATGATCAA GAAGTTGGAT 6960 GCCAGCTGTG CAGCGAACAA TCCCAGCCTA AAACTTACAT ACACAGAATG TCTGAGGGTT 7020 TGTGGCAACT GGTTAGCAGA AACGTGCTTA GAAAATCCTG CGGTCATCAT GCAGACCTAT 7080 CTAGAAAAGG CAGTAGAAGT TGCTGGAAAT TATGATGGAG AAAGTAGTGA TGAGCTAAGA 7140 AATGGAAAAA TGAAGGCATT TCTCTCATTA GCCCGGTTTT CAGATACTCA ATACCAAAGA 7200 ATTGAAAACT ACATGAAATC ATCGGAATTT GAAAACAAGC AAGCTCTCCT GAAAAGAGCC 7260 AAAGAGGAAG TAGGTCTCCT TAGGGAACAT AAAATTCAGA CAAACAGATA CACAGTAAAG 7320 GTTCAGCGAG AGCTGGAGTT GGATGAATTA GCCCTGCGTG CACTGAAAGA GGATCGTAAA 7380 CGCTTCTTAT GTAAAGCAGT TGAAAATTAT ATCAACTGCT TATTAAGTGG AGAAGAACAT 7440 GATATGTGGG TATTCCGACT TTGTTCCCTC TGGCTTGAAA ATTCTGGAGT TTCTGAAGTC 7500 AATGGCATGA TGAAGAGAGA CGGAATGAAG ATTCCAACAT ATAAATTTTT GCCTCTTATG 7560 TACCAATTGG CTGCTAGAAT GGGGACCAAG ATGATGGGAG GCCTAGGATT TCATGAAGTC 7620 CTCAATAATC TAATCTCTAG AATTTCAATG GATCACCCCC ATCACACTTT GTTTATTATA 7680 CTGGCCTTAG CAAATGCAAA CAGAGATGAA TTTCTGACTA AACCAGAGGT AGCCAGAAGA 7740 AGCAGAATAA CTAAAAATGT GCCTAAACAA AGCTCTCAGC TTGATGAGGA TCGAACAGAG 7800 GCTGCAAATA GAATAATATG TACTATCAGA AGTAGGAGAC CTCAGATGGT CAGAAGTGTT 7860 GAGGCACTTT GTGATGCTTA TATTATATTA GCAAACTTAG ATGCCACTCA GTGGAAGACT 7920 CAGAGAAAAG GCATAAATAT TCCAGCAGAC CAGCCAATTA CTAAACTTAA GAATTTAGAA 7980 GATGTTGTTG TCCCTACTAT GGAAATTAAG GTGGACCACA CAGGAGAATA TGGAAATCTG 8040 GTGACTATAC AGTCATTTAA AGCAGAATTT CGCTTAGCAG GAGGTGTAAA TTTACCAAAA 8100 ATAATAGATT GTGTAGGTTC CGATGGCAAG GAGAGGAGAC AGCTTGTTAA GGGCCGTGAT 8160 GACCTGAGAC AAGATGCTGT CATGCAACAG GTCTTCCAGA TGTGTAATAC ATTACTGCAG 8220 AGAAACACGG AAACTAGGAA GAGGAAATTA ACTATCTGTA CTTATAAGGT GGTTCCCCTC 8280 TCTCAGCGAA GTGGTGTTCT TGAATGGTGC ACAGGAACTG TCCCCATTGG TGAATTTCTT 8340 GTTAACAATG AAGATGGTGC TCATAAAAGA TACAGGCCAA ATGATTTCAG TGCCTTTCAG 8400 TGCCAAAAGA AAATGATGGA GGTGCAAAAA AAGTCTTTTG AAGAGAAATA TGAAGTCTTC 8460 ATGGATGTTT GCCAAAATTT TCAACCAGTT TTCCGTTACT TCTGCATGGA AAAATTCTTG 8520 GATCCAGCTA TTTGGTTTGA GAAGCGATTG GCTTATACGC GCAGTGTAGC TACTTCTTCT 8580 ATTGTTGGTT ACATACTTGG ACTTGGTGAT AGACATGTAC AGAATATCTT GATAAATGAG 8640 CAGTCAGCAG AACTTGTACA TATAGATCTA GGTGTTGCTT TTGAACAGGG CAAAATCCTT 8700 CCTACTCCTG AGACAGTTCC TTTTAGACTC ACCAGAGATA TTGTGGATGG CATGGGCATT 8760 ACGGGTGTTG AAGGTGTCTT CAGAAGATGC TGTGAGAAAA CCATGGAAGT GATGAGAAAC 8820 TCTCAGGAAA CTCTGTTAAC CATTGTAGAG GTCCTTCTAT ATGATCCACT CTTTGACTGG 8880 ACCATGAATC CTTTGAAAGC TTTGTATTTA CAGCAGAGGC CGGAAGATGA AACTGAGCTT 8940 CACCCTACTC TGAATGCAGA TGACCAAGAA TGCAAACGAA ATCTCAGTGA TATTGACCAG 9000 AGTTTCAACA AAGTAGCTGA ACGTGTCTTA ATGAGACTAC AAGAGAAACT GAAAGGAGTG 9060 GAAGAAGGCA CTGTGCTCAG TGTTGGTGGA CAAGTGAATT TGCTCATACA GCAGGCCATA 9120 GACCCCAAAA ATCTCAGCCG ACTTTTCCCA GGATGGAAAG CTTGGGTGTG A 9171 (2) INFORMATION FOR SEQ ID NO:3 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3056 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: Met Ser Leu Val Leu Asn Asp Leu Leu lie Cys Cys Arg Gin Leu Glu 1 5 10 15 His Asp Arg Ala Thr Glu Arg Lys Lys Glu Val Glu Lys Phe Lys Arg 20 25 30 Leu lie Arg Asp Pro Glu Thr lie Lys His Leu Asp Arg His Ser Asp 35 40 45 Ser Lys Gin Gly Lys Tyr Leu Asn Trp Asp Ala Val Phe Arg Phe Leu 50 55 60 Gin Lys Tyr lie Gin Lys Glu Thr Glu Cys Leu Arg lie Ala Lys Pro 65 70 75 80 Asn Val Ser Ala Ser Thr Gin Ala Ser Arg Gin Lys Lys Met Gin Glu 85 90 95 lie Ser Ser Leu Val Lys Tyr Phe lie Lys Cys Ala Asn Arg Arg Ala 100 105 110 Pro Arg Leu Lys Cys Gin Glu Leu Leu Asn Tyr lie Met Asp Thr Val 115 120 125 Lys Asp Ser Ser Asn Gly Ala lie Tyr Gly Ala Asp Cys Ser Asn He 130 135 140 Leu Leu Lys Asp He Leu Ser Val Arg Lys Tyr Trp Cys Glu He Ser 145 150 155 160 Gin Gin Gin Trp Leu Glu Leu Phe Ser Val Tyr Phe Arg Leu Tyr Leu 165 170 175 Lys Pro Ser Gin Asp Val His Arg Val Leu Val Ala Arg He He His 180 185 190 Ala Val Thr Lys Gly Cys Cys Ser Gin Thr Asp Gly Leu Asn Ser Lys 195 200 205 Phe Leu Asp Phe Phe Ser Lys Ala He Gin Cys Ala Arg Gin Glu Lys 210 215 220 Ser Ser Ser Gly Leu Asn His He Leu Ala Ala Leu Thr He Phe Leu 225 230 235 240 Lys Thr Leu Ala Val Asn Phe Arg He Arg Val Cys Glu Leu Gly Asp 245 250 255 Glu He Leu Pro Thr Leu Val Tyr He Trp Thr Gin His Arg Leu Asn 260 265 270 Asp Ser Leu Lys Glu Val He He Glu Leu Phe Gin Leu Gin He Tyr 275 280 285 He His His Pro Lys Gly Ala Lys Thr Gin Glu Lys Gly Ala Tyr Glu 290 295 300 Ser Thr Lys Trp Arg Ser He Leu Tyr Asn Leu Tyr Asp Leu Leu Val 305 310 315 320 Asn Glu He Ser His He Gly Ser Arg Gly Lys Tyr Ser Ser Gly Phe 325 330 335 Arg Asn He Ala Val Lys Glu Asn Leu He Glu Leu Met Ala Asp He 340 345 350 Cys His Gin Val Phe Asn Glu Asp Thr Arg Ser Leu Glu He Ser Gin 355 360 365 Ser Tyr Thr Thr Thr Gin Arg Glu Ser Ser Asp Tyr Ser Val Pro Cys 370 375 380 Lys Arg Lys Lys He Glu Leu Gly Trp Glu Val He Lys Asp His Leu 385 390 395 400 Gin Lys Ser Gin Asn Asp Phe Asp Leu Val Pro Trp Leu Gin He Ala 405 410 415 Thr Gin Leu He Ser Lys Tyr Pro Ala Ser Leu Pro Asn Cys Glu Leu 420 425 430 Ser Pro Leu Leu Met He Leu Ser Gin Leu Leu Pro Gin Gin Arg His 435 440 445 Gly Glu Arg Thr Pro Tyr Val Leu Arg Cys Leu Thr Glu Val Ala Leu 450 455 460 Cys Gin Asp Lys Arg Ser Asn Leu Glu Ser Ser Gin Lys Ser Asp Leu 465 470 475 480 Leu Lys Leu Trp Asn Lys He Trp Cys He Thr Phe Arg Gly He Ser 485 490 495 Ser Glu Gin Lys Gin Ala Glu Asn Phe Gly Leu Leu Gly Ala He He 500 505 510 Gin Gly Ser Leu Val Glu Val Asp Arg Glu Phe Trp Lys Leu Phe Thr 515 520 525 Gly Ser Ala Cys Arg Pro Ser Cys Pro Ala Val Cys Cys Leu Thr Leu 530 535 540 Ala Leu Thr Thr Ser He Val Pro Gly Ala Val Lys Met Gly He Glu 545 550 555 560 Gin Asn Met Cys Glu Val Asn Arg Ser Phe Ser Leu Lys Glu Ser He 565 570 575 Met Lys Trp Leu Leu Phe Tyr Gin Leu Glu Gly Asp Leu Glu Asn Ser 580 585 590 Thr Glu Val Pro Pro He Leu His Ser Asn Phe Pro His Leu Val Leu 595 600 605 Glu Lys He Leu Val Ser Leu Thr Met Lys Asn Cys Lys Ala Ala Met 610 615 620 Asn Phe Phe Gin Ser Val Pro Glu Cys Glu His His His Lys Asp Lys 625 630 635 640 Glu Glu Leu Ser Phe Ser Glu Val Glu Glu Leu Phe Leu Gin Thr Thr 645 650 655 Phe Asp Lys Met Asp Phe Leu Thr He Val Arg Glu Cys Gly He Glu 660 665 670 Lys His Gin Ser Ser He Gly Phe Ser Val His Gin Asn Leu Lys Glu 675 680 685 Ser Leu Asp Arg Cys Leu Leu Gly Leu Ser Glu Gin Leu Leu Asn Asn 690 695 700 Tyr Ser Ser Glu He Thr Asn Ser Glu Thr Leu Val Arg Cys Ser Arg 705 710 715 720 Leu Leu Val Gly Val Leu Gly Cys Tyr Cys Tyr Met Gly Val He Ala 725 730 735 Glu Glu Glu Ala Tyr Lys Ser Glu Leu Phe Gin Lys Ala Asn Ser Leu 740 745 750 Met Gin Cys Ala Gly Glu Ser He Thr Leu Phe Lys Asn Lys Thr Asn 755 760 765 Glu Glu Phe Arg He Gly Ser Leu Arg Asn Met Met Gin Leu Cys Thr 770 775 780 Arg Cys Leu Ser Asn Cys Thr Lys Lys Ser Pro Asn Lys He Ala Ser 785 790 795 800 Gly Phe Phe Leu Arg Leu Leu Thr Ser Lys Leu Met Asn Asp He Ala 805 810 815 Asp He Cys Lys Ser Leu Ala Ser Phe He Lys Lys Pro Phe Asp Arg 820 825 830 Gly Glu Val Glu Ser Met Glu Asp Asp Thr Asn Gly Asn Leu Met Glu 835 840 845 Val Glu Asp Gin Ser Ser Met Asn Leu Phe Asn Asp Tyr Pro Asp Ser 850 855 860 Ser Val Ser Asp Ala Asn Glu Pro Gly Glu Ser Gin Ser Thr He Gly 865 870 875 880 Ala He Asn Pro Leu Ala Glu Glu Tyr Leu Ser Lys Gin Asp Leu Leu 885 890 895 Phe Leu Asp Met Leu Lys Phe Leu Cys Leu Cys Val Thr Thr Ala Gin 900 905 910 Thr Asn Thr Val Ser Phe Arg Ala Ala Asp He Arg Arg Lys Leu Leu 915 920 925 Met Leu He Asp Ser Ser Thr Leu Glu Pro Thr Lys Ser Leu His Leu 930 935 940 His Met Tyr Leu Met Leu Leu Lys Glu Leu Pro Gly Glu Glu Tyr Pro 945 950 955 960 Leu Pro Met Glu Asp Val Leu Glu Leu Leu Lys Pro Leu Ser Asn Val 965 970 975 Cys Ser Leu Tyr Arg Arg Asp Gin Asp Val Cys Lys Thr He Leu Asn 980 985 990 His Val Leu His Val Val Lys Asn Leu Gly Gin Ser Asn Met Asp Ser 995 1000 1005 Glu Asn Thr Arg Asp Ala Gin Gly Gin Phe Leu Thr Val He Gly Ala 1010 1015 1020 Phe Trp His Leu Thr Lys Glu Arg Lys Tyr He Phe Ser Val Arg Met 1025 1030 1035 1040 Ala Leu Val Asn Cys Leu Lys Thr Leu Leu Glu Ala Asp Pro Tyr Ser 1045 1050 1055 Lys Trp Ala He Leu Asn Val Met Gly Lys Asp Phe Pro Val Asn Glu 1060 1065 1070 Val Phe Thr Gin Phe Leu Ala Asp Asn His His Gin Val Arg Met Leu 1075 1080 1085 Ala Ala Glu Ser He Asn Arg Leu Phe Gin Asp Thr Lys Gly Asp Ser 1090 1095 1100 Ser Arg Leu Leu Lys Ala Leu Pro Leu Lys Leu Gin Gin Thr Ala Phe 1105 1110 1115 1120 Glu Asn Ala Tyr Leu Lys Ala Gin Glu Gly Met Arg Glu Met Ser His 1125 1130 1135 Ser Ala Glu Asn Pro Glu Thr Leu Asp Glu He Tyr Asn Arg Lys Ser 1140 1145 1150 Val Leu Leu Thr Leu He Ala Val Val Leu Ser Cys Ser Pro He Cys 1155 1160 1165 Glu Lys Gin Ala Leu Phe Ala Leu Cys Lys Ser Val Lys Glu Asn Gly 1170 1175 1180 Leu Glu Pro His Leu Val Lys Lys Val Leu Glu Lys Val Ser Glu Thr 1185 1190 1195 1200 Phe Gly Tyr Arg Arg Leu Glu Asp Phe Met Ala Ser His Leu Asp Tyr 1205 1210 1215 Leu Val Leu Glu Trp Leu Asn Leu Gin Asp Thr Glu Tyr Asn Leu Ser 1220 1225 1230 Ser Phe Pro Phe He Leu Leu Asn Tyr Thr Asn He Glu Asp Phe Tyr 1235 1240 1245 Arg Ser Cys Tyr Lys Val Leu He Pro His Leu Val He Arg Ser His 1250 1255 1260 Phe Asp Glu Val Lys Ser He Ala Asn Gin He Gin Glu Asp Trp Lys 1265 1270 1275 1280 Ser Leu Leu Thr Asp Cys Phe Pro Lys He Leu Val Asn He Leu Pro 1285 1290 1295 Tyr Phe Ala Tyr Glu Gly Thr Arg Asp Ser Gly Met Ala Gin Gin Arg 1300 1305 1310 Glu Thr Ala Thr Lys Val Tyr Asp Met Leu Lys Ser Glu Asn Leu Leu 1315 1320 1325 Gly Lys Gin He Asp His Leu Phe He Ser Asn Leu Pro Glu He Val 1330 1335 1340 Val Glu Leu Leu Met Thr Leu His Glu Pro Ala Asn Ser Ser Ala Ser 1345 1350 1355 1360 Gin Ser Thr Asp Leu Cys Asp Phe Ser Gly Asp Leu Asp Pro Ala Pro 1365 1370 1375 Asn Pro Pro His Phe Pro Ser His Val He Lys Ala Thr Phe Ala Tyr 1380 1385 1390 He Ser Asn Cys His Lys Thr Lys Leu Lys Ser He Leu Glu He Leu 1395 1400 1405 Ser Lys Ser Pro Asp Ser Tyr Gin Lys He Leu Leu Ala He Cys Glu 1410 1415 1420 Gin Ala Ala Glu Thr Asn Asn Val Tyr Lys Lys His Arg He Leu Lys 1425 1430 1435 1440 He Tyr His Leu Phe Val Ser Leu Leu Leu Lys Asp He Lys Ser Gly 1445 1450 1455 Leu Gly Gly Ala Trp Ala Phe Val Leu Arg Asp Val He Tyr Thr Leu 1460 1465 1470 He His Tyr He Asn Gin Arg Pro Ser Cys He Met Asp Val Ser Leu 1475 1480 1485 Arg Ser Phe Ser Leu Cys Cys Asp Leu Leu Ser Gin Val Cys Gin Thr 1490 1495 1500 Ala Val Thr Tyr Cys Lys Asp Ala Leu Glu Asn His Leu His Val He 1505 1510 1515 1520 Val Gly Thr Leu He Pro Leu Val Tyr Glu Gin Val Glu Val Gin Lys 1525 1530 1535 Gin Val Leu Asp Leu Leu Lys Tyr Leu Val He Asp Asn Lys Asp Asn 1540 1545 1550 Glu Asn Leu Tyr He Thr He Lys Leu Leu Asp Pro Phe Pro Asp His 1555 1560 1565 Val Val Phe Lys Asp Leu Arg He Thr Gin Gin Lys He Lys Tyr Ser 1570 1575 1580 Arg Gly Pro Phe Ser Leu Leu Glu Glu He Asn His Phe Leu Ser Val 1585 1590 1595 1600 Ser Val Tyr Asp Ala Leu Pro Leu Thr Arg Leu Glu Gly Leu Lys Asp 1605 1610 1615 Leu Arg Arg Gin Leu Glu Leu His Lys Asp Gin Met Val Asp He Met 1620 1625 1630 Arg Ala Ser Gin Asp Asn Pro Gin Asp Gly He Met Val Lys Leu Val 1635 1640 1645 Val Asn Leu Leu Gin Leu Ser Lys Met Ala He Asn His Thr Gly Glu 1650 1655 1660 Lys Glu Val Leu Glu Ala Val Gly Ser Cys Leu Gly Glu Val Gly Pro 1665 1670 1675 1680 He Asp Phe Ser Thr He Ala He Gin His Ser Lys Asp Ala Ser Tyr 1685 1690 1695 Thr Lys Ala Leu Lys Leu Phe Glu Asp Lys Glu Leu Gin Trp Thr Phe 1700 1705 1710 He Met Leu Thr Tyr Leu Asn Asn Thr Leu Val Glu Asp Cys Val Lys 1715 1720 1725 Val Arg Ser Ala Ala Val Thr Cys Leu Lys Asn He Leu Ala Thr Lys 1730 1735 1740 Thr Gly His Ser Phe Trp Glu He Tyr Lys Met Thr Thr Asp Pro Met 1745 1750 1755 1760 Leu Ala Tyr Leu Gin Pro Phe Arg Thr Ser Arg Lys Lys Phe Leu Glu 1765 1770 1775 Val Pro Arg Phe Asp Lys Glu Asn Pro Phe Glu Gly Leu Asp Asp He 1780 1785 1790 Asn Leu Trp He Pro Leu Ser Glu Asn His Asp He Trp He Lys Thr 1795 1800 1805 Leu Thr Cys Ala Phe Leu Asp Ser Gly Gly Thr Lys Cys Glu He Leu 1810 1815 1820 Gin Leu Leu Lys Pro Met Cys Glu Val Lys Thr Asp Phe Cys Gin Thr 1825 1830 1835 1840 Val Leu Pro Tyr Leu He His Asp He Leu Leu Gin Asp Thr Asn Glu 1845 1850 1855 Ser Trp Arg Asn Leu Leu Ser Thr His Val Gin Gly Phe Phe Thr Ser 1860 1865 1870 Cys Leu Arg His Phe Ser Gin Thr Ser Arg Ser Thr Thr Pro Ala Asn 1875 1880 1885 Leu Asp Ser Glu Ser Glu His Phe Phe Arg Cys Cys Leu Asp Lys Lys 1890 1895 1900 Ser Gin Arg Thr Met Leu Ala Val Val Asp Tyr Met Arg Arg Gin Lys 1905 1910 1915 1920 Arg Pro Ser Ser Gly Thr He Phe Asn Asp Ala Phe Trp Leu Asp Leu 1925 1930 1935 Asn Tyr Leu Glu Val Ala Lys Val Ala Gin Ser Cys Ala Ala His Phe 1940 1945 1950 Thr Ala Leu Leu Tyr Ala Glu He Tyr Ala Asp Lys Lys Ser Met Asp 1955 1960 1965 Asp Gin Glu Lys Arg Ser Leu Ala Phe Glu Glu Gly Ser Gin Ser Thr 1970 1975 1980 Thr He Ser Ser Leu Ser Glu Lys Ser Lys Glu Glu Thr Gly He Ser 1985 1990 1995 2000 Leu Gin Asp Leu Leu Leu Glu He Tyr Arg Ser He Gly Glu Pro Asp 2005 2010 2015 Ser Leu Tyr Gly Cys Gly Gly Gly Lys Met Leu Gin Pro He Thr Arg 2020 2025 2030 Leu Arg Thr Tyr Glu His Glu Ala Met Trp Gly Lys Ala Leu Val Thr 2035 2040 2045 Tyr Asp Leu Glu Thr Ala He Pro Ser Ser Thr Arg Gin Ala Gly He 2050 2055 2060 He Gin Ala Leu Gin Asn Leu Gly Leu Cys His He Leu Ser Val Tyr 2065 2070 2075 2080 Leu Lys Gly Leu Asp Tyr Glu Asn Lys Asp Trp Cys Pro Glu Leu Glu 2085 2090 2095 Glu Leu His Tyr Gin Ala Ala Trp Arg Asn Met Gin Trp Asp His Cys 2100 2105 2110 Thr Ser Val Ser Lys Glu Val Glu Gly Thr Ser Tyr His Glu Ser Leu 2115 2120 2125 Tyr Asn Ala Leu Gin Ser Leu Arg Asp Arg Glu Phe Ser Thr Phe Tyr 2130 2135 2140 Glu Ser Leu Lys Tyr Ala Arg Val Lys Glu Val Glu Glu Met Cys Lys 2145 2150 2155 2160 Arg Ser Leu Glu Ser Val Tyr Ser Leu Tyr Pro Thr Leu Ser Arg Leu 2165 2170 2175 Gin Ala He Gly Glu Leu Glu Ser He Gly Glu Leu Phe Ser Arg Ser 2180 2185 2190 Val Thr His Arg Gin Leu Ser Glu Val Tyr He Lys Trp Gin Lys His 2195 2200 2205 Ser Gin Leu Leu Lys Asp Ser Asp Phe Ser Phe Gin Glu Pro He Met 2210 2215 2220 Ala Leu Arg Thr Val He Leu Glu He Leu Met Glu Lys Glu Met Asp 2225 2230 2235 2240 Asn Ser Gin Arg Glu Cys He Lys Asp He Leu Thr Lys His Leu Val 2245 2250 2255 Glu Leu Ser He Leu Ala Arg Thr Phe Lys Asn Thr Gin Leu Pro Glu 2260 2265 2270 Arg Ala He Phe Gin He Lys Gin Tyr Asn Ser Val Ser Cys Gly Val 2275 2280 2285 Ser Glu Trp Gin Leu Glu Glu Ala Gin Val Phe Trp Ala Lys Lys Glu 2290 2295 2300 Gin Ser LeU Ala Leu Ser He Leu Lys Gin Met He Lys Lys Leu Asp 2305 2310 2315 2320 Ala Ser Cys Ala Ala Asn Asn Pro Ser Leu Lys Leu Thr Tyr Thr Glu 2325 2330 2335 Cys Leu Arg Val Cys Gly Asn Trp Leu Ala Glu Thr Cys Leu Glu Asn 2340 2345 2350 Pro Ala Val He Met Gin Thr Tyr Leu Glu Lys Ala Val Glu Val Ala 2355 2360 2365 Gly Asn Tyr Asp Gly Glu Ser Ser Asp Glu Leu Arg Asn Gly Lys Met 2370 2375 2380 Lys Ala Phe Leu Ser Leu Ala Arg Phe Ser Asp Thr Gin Tyr Gin Arg 2385 2390 2395 2400 He Glu Asn Tyr Met Lys Ser Ser Glu Phe Glu Asn Lys Gin Ala Leu 2405 2410 2415 Leu Lys Arg Ala Lys Glu Glu Val Gly Leu Leu Arg Glu His Lys He 2420 2425 2430 Gin Thr Asn Arg Tyr Thr Val Lys Val Gin Arg Glu Leu Glu Leu Asp 2435 2440 2445 Glu Leu Ala Leu Arg Ala Leu Lys Glu Asp Arg Lys Arg Phe Leu Cys 2450 2455 2460 Lys Ala Val Glu Asn Tyr He Asn Cys Leu Leu Ser Gly Glu Glu His 2465 2470 2475 2480 Asp Met Trp Val Phe Arg Leu Cys Ser Leu Trp Leu Glu Asn Ser Gly 2485 2490 2495 Val Ser Glu Val Asn Gly Met Met Lys Arg Asp Gly Met Lys He Pro 2500 2505 2510 Thr Tyr Lys Phe Leu Pro Leu Met Tyr Gin Leu Ala Ala Arg Met Gly 2515 2520 2525 Thr Lys Met Met Gly Gly Leu Gly Phe His Glu Val Leu Asn Asn Leu 2530 2535 2540 He Ser Arg He Ser Met Asp His Pro His His Thr Leu Phe He He 2545 2550 2555 2560 Leu Ala Leu Ala Asn Ala Asn Arg Asp Glu Phe Leu Thr Lys Pro Glu 2565 2570 2575 Val Ala Arg Arg Ser Arg He Thr Lys Asn Val Pro Lys Gin Ser Ser 2580 2585 2590 Gin Leu Asp Glu Asp Arg Thr Glu Ala Ala Asn Arg He He Cys Thr 2595 2600 2605 He Arg Ser Arg Arg Pro Gin Met Val Arg Ser Val Glu Ala Leu Cys 2610 2615 2620 Asp Ala Tyr He He Leu Ala Asn Leu Asp Ala Thr Gin Trp Lys Thr 2625 2630 2635 2640 Gin Arg Lys Gly He Asn He Pro Ala Asp Gin Pro He Thr Lys Leu 2645 2650 2655 Lys Asn Leu Glu Asp Val Val Val Pro Thr Met Glu He Lys Val Asp 2660 2665 2670 His Thr Gly Glu Tyr Gly Asn Leu Val Thr He Gin Ser Phe Lys Ala 2675 2680 2685 Glu Phe Arg Leu Ala Gly Gly Val Asn Leu Pro Lys He He Asp Cys 2690 2695 2700 Val Gly Ser Asp Gly Lys Glu Arg Arg Gin Leu Val Lys Gly Arg Asp 2705 2710 2715 2720 Asp Leu Arg Gin Asp Ala Val Met Gin Gin Val Phe Gin Met Cys Asn 2725 2730 2735 Thr Leu Leu Gin Arg Asn Thr Glu Thr Arg Lys Arg Lys Leu Thr He 2740 2745 2750 Cys Thr Tyr Lys Val Val Pro Leu Ser Gin Arg Ser Gly Val Leu Glu 2755 2760 2765 Trp Cys Thr Gly Thr Val Pro He Gly Glu Phe Leu Val Asn Asn Glu 2770 2775 2780 Asp Gly Ala His Lys Arg Tyr Arg Pro Asn Asp Phe Ser Ala Phe Gin 2785 2790 2795 2800 Cys Gin Lys Lys Met Met Glu Val Gin Lys Lys Ser Phe Glu Glu Lys 2805 2810 2815 Tyr Glu Val Phe Met Asp Val Cys Gin Asn Phe Gin Pro Val Phe Arg 2820 2825 2830 Tyr Phe Cys Met Glu Lys Phe Leu Asp Pro Ala He Trp Phe Glu Lys 2835 2840 2845 Arg Leu Ala Tyr Thr Arg Ser Val Ala Thr Ser Ser He Val Gly Tyr 2850 2855 2860 He Leu Gly Leu Gly Asp Arg His Val Gin Asn He Leu He Asn Glu 2865 2870 2875 2880 Gin Ser Ala Glu Leu Val His He Asp Leu Gly Val Ala Phe Glu Gin 2885 2890 2895 Gly Lys He Leu Pro Thr Pro Glu Thr Val Pro Phe Arg Leu Thr Arg 2900 2905 2910 Asp He Val Asp Gly Met Gly He Thr Gly Val Glu Gly Val Phe Arg 2915 2920 2925 Arg Cys Cys Glu Lys Thr Met Glu Val Met Arg Asn Ser Gin Glu Thr 2930 2935 2940 Leu Leu Thr He Val Glu Val Leu Leu Tyr Asp Pro Leu Phe Asp Trp 2945 2950 2955 2960 Thr Met Asn Pro Leu Lys Ala Leu Tyr Leu Gin Gin Arg Pro Glu Asp 2965 2970 2975 Glu Thr Glu Leu His Pro Thr Leu Asn Ala Asp Asp Gin Glu Cys Lys 2980 2985 2990 Arg Asn Leu Ser Asp He Asp Gin Ser Phe Asp Lys Val Ala Glu Arg 2995 3000 3005 Val Leu Met Arg Leu Gin Glu Lys Leu Lys Gly Val Glu Glu Gly Thr 3010 3015 3020 Val Leu Ser Val Gly Gly Gin Val Asn Leu Leu He Gin Gin Ala He 3025 3030 3035 3040 Asp Pro Lys Asn Leu Ser Arg Leu Phe Pro Gly Trp Lys Ala Trp Val 3045 3050 3055 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: His Glu Pro Ala Asn Ser Ser Ala Ser Gin Ser Thr Asp Leu Cys 1 5 10 15 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: Cys Lys Arg Asn Leu Ser Asp He Asp Gin Ser Phe Asp Lys Val 1 5 10 15 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: Pro Glu Asp Glu Thr Glu Leu His Pro Thr Leu Asn Ala Asp Asp Gin 1 5 10 15 Glu Cys (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: Cys Lys Ser Leu Ala Ser Phe He Lys Lys Pro Phe Asp Arg Gly Glu 1 5 10 15 Val Glu Ser Met Glu Asp Asp Thr Asn Gly 20 25 (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3607 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (ix) FEATURE: (A) NAME/KEY: 3'UTR (B) LOCATION: 1..3607 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: TCTTCAGTAT ATGAATTACC CTTTCATTCA GCCTTTAGAA ATTATATTTT AGCCTTTATT 60 TTTAACCTGC CAACATACTT TAAGTAGGGA TTAATATTTA AGTGAACTAT TGTGGGTTTT 120 TTTGAATGTT GGTTTTAATA CTTGATTTAA TCACCACTCA AAAATGTTTT GATGGTCTTA 180 AGGAACATCT CTGCTTTCAC TCTTTAGAAA TAATGGTCAT TCGGGCTGGG CGCAGCGGCT 240 CACGCCTGTA ATCCCAGCAC TTTGGGAGGC CGAGGTGAGC GGATCACAAG GTCAGGAGTT 300 CGAGACCAGC CTGGCCAAGA GACCAGCCTG GCCAGTATGG TGAAACCCTG TCTCTACTAA 360 AAATACAAAA ATTAGCCGAG CATGGTGGCG GGCACCTGTA ATCCCAGCTA CTCGAGAGGC 420 TGAGGCAGGA GAATCTCTTG AACCTGGGAG GTGAAGGTTG CTGTGGGCCA AAATCATGCC 480 ATTGCACTCC AGCCTGGGTG ACAAGAGCGA AACTCCATCT CAAAAAAAAA AAAAAAAAAC 540 AGAAACTTAT TTGGATTTTT CCTAGTAAGA TCACTCAGTG TTACTAAATA ATGAAGTTGT 600 TATGGAGAAC AAATTTCAAA GACACAGTTA GTGTAGTTAC TATTTTTTTA AGTGTGTATT 660 AAAACTTCTC ATTCTATTCT CTTTATCTTT TAAGCCCTTC TGTACTGTCC ATGTATGTTA 720 TCTTTCTGTG ATAACTTCAT AGATTGCCTT CTAGTTCATG AATTCTCTTG TCAGATGTAT 780 ATAATCTCTT TTACCCTATC CATTGGGCTT CTTCTTTCAG AAATTGTTTT TCATTTCTAA 840 TTATGCATCA TTTTTCAGAT CTCTGTTTCT TGATGTCATT TTTAATGTTT TTTTAATGTT 900 TTTTATGTCA CTAATTATTT TAAATGTCTG TACCTGATAG ACACTGTAAT AGTTCTATTA 960 AATTTAGTTC CTGCTGTTTA TATCTGTTGA TTTTTGTATT TGATAGGCTG TTCATCCAGT 1020 TTTGTCTTTT TGAAAAGTGA GTTTATTTTC AGCAAGGCTT TATCTATGGG AATCTTGAGT 1080 GTCTGTTTAT GTCATATTCC CAGGGCTGTT GCTGCACACA AGCCCATTCT TATTTTAATT 1140 TCTTGGCTTT AGGGTTTCCA TACCTGAAGT GTAGCATAAA TACTGATAGG AGATTTCCCA 1200 GGCCAAGGCA AACACACTTC CTCCTCATCT CCTTGTGCTA GTGGGCAGAA TATTTGATTG 1260 ATGCCTTTTT CACTGAGAGT ATAAGCTTCC ATGTGTCCCA CCTTTATGGC AGGGGTGGAA 1320 GGAGGTACAT TTAATTCCCA CTGCCTGCCT TTGGCAAGCC CTGGGTTCTT TGCTCCCCAT 1380 ATAGATGTCT AAGCTAAAAG CCGTGGGTTA ATGAGACTGG CAAATTGTTC CAGGACAGCT 1440 ACAGCATCAG CTCACATATT CACCTCTCTG GTTTTTCATT CCCCTCATTT TTTTCTGAGA 1500 CAGAGTCTTG CTCTGTCACC CAGGCTGGAG TGCAGTGGCA TGATCTCAGC TCACTGAAAC 1560 CTCTGCCTCC TGGGTTCAAG CAATTCTCCT GCCTCAGCCT CCCGAGTAGC TGGGACTACA 1620 GGCGTGTGCC AACACGCCCG GCTAATTTTT TGTATTTTTA TTAGAGACGG AGTTTCACCG 1680 TGTTAGCCAG GATGGTCTCG ATCGCTTGAC CTCGTGATCC ACCCTCCTCG GCCTCCCAAA 1740 GTGCTGGGAT TACAGGTGTG AGCCACCGCG CCCGGCCTCA TTCCCCTCAT TTTTGACCGT 1800 AAGGATTTCC CCTTTCTTGT AAGTTCTGCT ATGTATTTAA AAGAATGTTT TCTACATTTT 1860 ATCCAGCATT TCTCTGTGTT CTGTTGGAAG GGAAGGGCTT AGGTATCTAG TTTGATACAT 1920 AGGTAGAAGT GGAACATTTC TCTGTCCCCC AGCTGTCATC ATATAAGATA AACATCAGAT 1980 AAAAAGCCAC CTGAAAGTAA AACTACTGAC TCGTGTATTA GTGAGTATAA TCTCTTCTCC 2040 ATCCTTAGGA AAATGTTCAT CCCAGCTGCG GAGATTAACA AATGGGTGAT TGAGCTTTCT . 2100 CCTCGTATTT GGACCTTGAA GGTTATATAA ATTTTTTTCT TATGAAGAGT TGGCATTTCT 2160 TTTTATTGCC AATGGCAGGC ACTCATTCAT ATTTGATCTC CTCACCTTCC CCTCCCCTAA 2220 AACCAATCTC CAGAACTTTT TGGACTATAA ATTTCTTGGT TTGACTTCTG GAGAACTGTT 2280 CAGAATATTA CTTTGCATTT CAAATTACAA ACTTACCTTG GTGTATCTTT TTCTTACAAG 2340 CTGCCTAAAT GAATATTTGG TATATATTGG TAGTTTTATT ACTATAGTAA ATCAAGGAAA 2400 TGCAGTAAAC TTAAAATGTC TTTAAGAAAG CCCTGAAATC TTCATGGGTG AAATTAGAAA 2460 TTATCAACTA GATAATAGTA TAGATAAATG AATTTGTAGC TAATTCTTGC TAGTTGTTGC 2520 ATCCAGAGAG CTTTGAATAA CATCATTAAT CTACTCTTTA GCCTTGCATG GTATGCTATG 2580 AGGCTCCTGT TCTGTTCAAG TATTCTAATC AATGGCTTTG AAAAGTTTAT CAAATTTACA 2640 TACAGATCAC AAGCCTAGGA GAAATAACTA ATTCACAGAT GACAGAATTA AGATTATAAA 2700 AGATTTTTTT TTGGTAATTT TAGTAGAGAC AGGGTTGCCA TTGTATTCCA GCCTTGGCGA 2760 CAGAGCAAGA CTCTGCCTCA AAAAAAAAAA AAAAAAGGTT TTGCCAAGCT GGAACTCTTT 2820 CTGCAAATGA CTAAGATAGA AAACTGCCAA GGACAAATGA GGAGTAGTTA GATTTTGAAA 2880 ATATTAATCA TAGAATAGTT GTTGTATGCT AAGTCACTGA CCCATATTAT GTACAGCATT 2940 TCTGATCTTT ACTTTGCAAG ATTAGTGATA CTATGCCAAT ACACTGCTGG AGAAATCAGA 3000 ATTTGGAGAA ATAAGTTGTC CAAGGCAAGA AGATAGTAAA TTATAAGTAC AAGTGTAATA 3060 TGGACAGTAT CTAACTTGAA AAGATTTCAG GCGAAAAGAA TCTGGGGTTT GCCAGTCAGT 3120 TGCTCAAAAG GTCAATGAAA ACCAAATAGT GAAGCTATCA GAGAAGCTAA TAAATTATAG 3180 ACTGCTTGAA CAGTTGTGTC CAGATTAAGG GAGATAATAG CTTTCCCACC CTACTTTGTG 3240 CAGGTCATAC CTCCCCAAAG TGTTTACCTA ATCAGTAGGT TCACAAACTC TTGGTCATTA 3300 TAGTATATGC CTAAAATGTA TGCACTTAGG AATGCTAAAA ATTTAAATAT GGTCTAAAGC 3360 AAATAAAAGC AAAGAGGAAA AACTTTGGAC ATCGTAAAGA CTAGAATAGT CTTTTAAAAA 3420 GAAAGCCAGT ATATTGGTTT GAAATATAGA GATGTGTCCC AATTTCAAGT ATTTTAATTG 3480 CACCTTAATG AAATTATCTA TTTTCTATAG ATTTTAGTAC TATTGAATGT ATTACTTTAC 3540 TGTTACCTGA ATTTATTATA AAGTGTTTTT GAATAAATAA TTCTAAAAGC AAAAAAAAAA 3600 AAAAAAA 3607 (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 884 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (ix) FEATURE: (A) NAME/KEY: 5'UTR (B) LOCATION: 1..884 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: TCCTCCTTTT AAACGCCCTG AATTGAACCC TGCCTCCTGC GCATCCTCTT TTTGTGTCAC 60 CTTAGGGTTC AGATTTAACT ACGCGACTTG ACTAGTCATC TTTTGATCTC TCTCTCGTAT 120 TTAGTACTTT TAGTCAGCGA GCATTTATTG ATATTTCAAC TTCAGCCTCG CGGTTAAGAG 180 CTTGGGCTCT GGAATCATAC GGCTGGAATT GGAATTCTGT CAGTCGTGTG GCCGCTCTCT 240 ACTGTCTTGT GAAGATAAGT GAGATAATCT TGACCTGTGG TGAGCACTCG TGAGCGTTAG 300 CTGCTGTATT TACCAGGTAC AGATAAGACA ACTACAGTGG ATGATAATGT ATGTGGTGAT 360 AGGGGAGTAC TCTGATGGTA GAGGAGTGAC TTTGGTTCTC TGCAAACTCA GCCTGAGACT 420 ATCAATTCAG TTTGTGGTGA GACCTCGCAG TGTTACCTTG GCAGATGGTA GAAGCCTTCC 480 AGATGGAAGG AAAAATGCGT GTAAAGGCAC AAAGTGTAGA AGGACCCTGA AGCTCCAGCG 540 TGAGGCCTGG CATTGAATGA AATATATTTT GTGGGTTTTC AGCTGCTGAA GTCATAGGAA 600 TGGATGAGAC CAAGAAAACA AAGCTGTTTT TGAGGTATGA GCGGAAGAAG AGATATCAGG 660 AGACTTTCGA AACAGTCATA ACGGAAGTTA ATATGATCAT TGCTAACATT TGCTGTGTTT 720 CAGGCACTGT AAGCATGTAT ATGGGTCCTT AAAGGGACTC ATAGAGAGGC ATACATCACA 780 ATTTGGAATT ATGCATTGGT TTATCAATTT ACTTGTTTAT TGTCACCCTG CTGCCCAGAT 840 ATGACTTCAT GAGGACAGTG ATGTGTGTTC TGAAATTGTG AACC 884 (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 120 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: AGGTAGCTGC GTGGCTAACG GAGAAAAGAA GCCGTGGCCA CGGGAGGAGG CGAGAGGAGT 60 CGGGATCTGC GCTGCAGCCA CCGCCGCGGT TGATACTACT TTGACCTTCC GAGTGCAGTG 120 (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9620 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (vi) ORIGINAL SOURCE: (A) ORGANISM: Mus musculus (viii) POSITION IN GENOME: (A) CHROMOSOME/SEGMENT: Chromosome 9, Band 9C (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: AGAATGCAGC GGTGAGGATG CATGTTCTGA AATCTTAAAC CATGAGTCTA GCACTCAATG 60 ATCTGCTCAT TTGCTGCCGG CAGTTAGAGC ATGACAGAGC TACAGAAAGA AGGAAAGAAG 120 TGGATAAATT TAAGCGCCTG ATTCAGGATC CTGAAACAGT TCAACATTTA GATAGGCATT 180 CTGATTCCAA ACAAGGAAAA TATCTGAATT GGGATGCTGT TTTCAGGTTT TTACAGAAGT 240 ACATTCAAAA AGAAATGGAA AGTCTGAGAA CAGCAAAATC AAATGTATCA GCCACCACAC 300 AGAGCTCCAG ACAGAAGAAG ATGCAAGAGA TCAGCAGTTT GGTCAGATAC TTCATCAAAT 360 GTGCAAACAA AAGAGCACCC AGGCTAAAAT GTCAAGACCT CTTGAATTAT GTCATGGATA 420 CAGTGAAAGA CTCATCTAAT GGTCTAACGT ATGGAGCTGA CTGTAGCAAC ATACTACTCA 480 AAGACATTCT TTCTGTGAGA AAATACTGGT GTGAAGTATC TCAGCAACAG TGGCTAGAAT 540 TGTTTTCACT GTACTTCAGG CTGTATCTCA AGCCATCACA GGACATTAAT AGAGTTTTAG 600 TGGCTAGAAT AATTCATGCT GTCACCAGAG GATGCTGTTC ACAGACTGAT GGATTACCTT 660 CAAAGTTTTT AGATCTTTTT TCCAAGGCTA TTCAGTATGC CAGACAAGAA AAGAGCTCTC 720 CTGGCTTAAG TCACATCTTA GCAGCCCTTA ACATTTTCCT CAAGTCTCTG GCTGTCAACT 780 TCCGAAAACG GGTGTGTGAA GCAGGAGATG AAATTCTTCC TACCTTACTA TATATTTGGA 840 CTCAACATAG ACTTAATGAT TCTTTAAAAG AAGTAATTAT TGAACTAATT CAACTGCAGA 900 TTTATATCCA TCATCCACAA GGAGCCAGAG CTCCTGAAGA AGGTGCTTAT GAATCCATGA 960 AATGGAAAAG TATCTTGTAC AACTTATATG ACTTGCTAGT GAATGAGATA AGTCATATAG 1020 GAAGCCGAGG GAAATATTCC TCAGGATCTC GTAATATTGC TGTCAAGGAA AATCTGATTG 1080 ACCTGATGGC AGATATCTGT TACCAGCTTT TTGATGCAGA TACCAGATCC GTGGAGATTT 1140 CTCAATCTTA TGTGACACAA AGGGAATCCA CTGATTACAG TGTACCTTGC AAAAGAAGGA 1200 AAATAGACGT AGGCTGGGAA GTGATAAAAG ATTATCTTCA GAAGTCACAG AGTGATTTTG 1260 ATCTCGTGCC TTGGCTACAG ATTACAACCC GATTAATATC AAAATATCCT TCCAGTTTAC 1320 CTAACTGTGA GCTGTCTCCA TTAATACTGA TACTGTACCA GCTTCTGCCT CAACAGCGAC 1380 GTGGAGAACG CATCCCATAT GTGTTACGAT GCCTTAAGGA AGTTGCCTTA TGTCAAGGCA 1440 AGAAATCAAA CCTGGAAAGC TCTCAGAAGT CAGATTTATT GAAACTATGG ATCAAAATTT 1500 GGTCTATTAC CTTTCGTGGT ATAAGTTCTG GACAAACACA AACTGAAAAC TTTGGTTTAC 1560 TTGAGGCCAT CATTCAAGGT AGTTTAGTTG AACTTGACAG AGAATTCTGG AAGTTATTTA 1620 CTGGCTCAGC CTGTAAACCT TCTAGTCCTT CAGTATGCTG CTTGACTTTG GCACTTAGCA 1680 TCTGTGTAGT TCCAGATGCA ATAAAAATGG GAACAGAACA AAGTGTGTGT GAAGCAAATA 1740 GAAGTTTTTC TGTAAAGGAG TCAATAATGA GGTGGCTCTT ATTCTACCAG TTAGAGGATG 1800 ACTTAGAAGA CAGCACAGAG CTGCCTCCAA TTCTTCAGCG TAATTTTCCT CATCTTGTAG 1860 TCGAAAAAAT TCTTGTAAGT CTCACTATGA AAAACTCAAA AGCTGCAATG AAGTTTTTTC 1920 AAAGTGTGCC AGAATGTGAA CAACACTGCG AAGATAAAGA AGAGCCTTCA TTTTCAGAAG 1980 TAGAAGAACT GTTTCTTCAG ACTACTTTTG ACAAGATGGA TTTTTTAACT ACTGTCAAAG 2040 AGTATGCTGT AGAAAAATTT CAGTCTAGTG TTGGCTTCTC TGTCCAGCAA AATCTCAAGG 2100 AATCATTGGA TCACTATCTT CTGGGATTAT CAGAACAGCT TTTAAGTAAT TACTCTTCTG 2160 AGATTACAAG TTCTGAAACC CTTGTCCGGT GTTCAAGTCT TTTGGTGGGT GTTCTTGGCT 2220 GCTATTGTTA CATGGGTATA ATAACTGAAG ACGAAGCCCA TAAATCAGAA TTATTCCAGA 2280 AAGCCAAGTC TCTGATGCAA TGTGCAGGAG AAAGTATCTC TCTGTTTAAA AATAAAACAA 2340 ATGAGGAATC AAGAATTGGT TCATTGAGAA ATGTGATGCA TCTGTGTACA AGTTGCTTGT 2400 GTATACATAC CAAGCATACG CCAAACAAGA TTGCCTCTGG CTTTTTCCTA CGATTATTAA 2460 CATCAAAGCT TATGAATGAC ATTGCAGATA TTTGTAAAAG TTTAGCATCC TGTACGAAAA 2520 AGCCATTGGA TCACGGAGTA CATCCAGGGG AAGATGATGA AGATGGTGGT GGTTGTGACA 2580 GTCTGATGGA GGCAGAGGGT CCATCGTCCA CTGGTCTTTC TACTGCTTAC CCCGCTAGTT 2640 CTGTGAGCGA TGCAAATGAT TATGGAGAGA ACCAGAATGC TGTTGGTGCC ATGAGTCCTT 2700 TAGCTGCCGA CTACCTGTCC AAACAAGATC ATCTTCTCTT AGACATGCTC AGGTTCTTAG 2760 GCCGATCTGT AACTGCATCT CAGAGCCATA CTGTGTCGTT TAGAGGAGCT GACATTAGAA 2820 GAAAATTGTT ACTGTTGCTT GATTCTAGCA TACTCGATCT CATGAAGCCC CTCCACCTGC 2880 ATATGTACTT AGTGCTCCTG AAGGATCTCC CTGGAAACGA GCACTCATTG CCAATGGAAG 2940 ATGTTGTTGA ACTTCTGCAA CCATTATCCC TTGTGTGTTC TCTGCACCGA CGTGACCAAG 3000 ATGTCTGTAA AACGATTCTA AGCAATGTCC TTCATATAGT GACAAACCTA GGCCAGGGCA 3060 GTGTGGACAT GGAGAGCACA CGGATTGCTC AAGGACACTT CCTGACAGTG ATGGGAGCAT 3120 TTTGGCATTT GACAAAGGAA AAGAAATGTG TATTCTCTGT AAGAATGGCA TTAGTAAAGT 3180 GTCTTCAAAC ATTGCTTGAG GCTGATCCAT ATTCCGAATG GGCAATTCTT AATGTAAAAG 3240 GACAAGACTT TCCTGTAAAT GAAGCTTTTT CACAATTTCT TGCTGACGAT CATCATCAAG 3300 TTCGGATGTT GGCTGCAGGG TCAGTCAACA GATTATTTCA GGATATGAGA CAAGGCGATT 3360 TCTCCAGAAG CTTGAAAGCA CTCCCTCTGA AGTTTCAGCA GACATCTTTT AACAATGCAT 3420 ACACGACAGC AGAGGCGGGG ATCAGAGGAC TGTTATGTGA TTCTCAGAAC CCTGATCTGC 3480 TGGATGAGAT CTATAACAGA AAATCTGTAC TACTGATGAT GATAGCTGTG GTCTTGCACT 3540 GTAGCCCAGT CTGTGAAAAG CAGGCTTTGT TTGCTTTATG CAAGTCTGTG AAGGAAAACA 3600 GACTAGAACC TCATCTTGTG AAAAAGGTTT TAGAGAAAGT CTCCGAATCG TTTGGATGTA 3660 GAAGTTTAGA AGACTTCATG ATTTCTCACC TAGACTACCT GGTTTTGGAA TGGCTGAACC 3720 TTCAAGATAC TGAATATAGC TTATCTTCTT TTCCTTTTAT GTTATTAAAC TACACAAGCA 3780 TTGAGGATTT CTATCGGTCT TGTTACAAGA TTTTGATCCC ACATTTGGTA ATCAGAAGCC 3840 ATTTTGATGA GGTGAAGTCC ATTGCTAATC AGATTCAAAA GTGCTGGAAA AGCCTGTTGG 3900 TAGATTGCTT TCCGAAGATT CTTGTGCACA TCCTTCCTTA CTTTGCCTAC GAGGGCACGA 3960 GAGACAGCTA CGTGTCACAG AAAAGAGAGA CTGCTACCAA GGTCTACGAT ACTCTTAAAG 4020 GGGAAGACTT CCTAGGAAAA CAGATTGACC AAGTATTCAT TAGTAATTTG CCAGAGATTG 4080 TGGTGGAGTT GCTGATGACA TTGCATGAGA CAGCTGACTC GGCTGACTCG GACGCCAGTC 4140 AAAGCGCCAC CGCCTTGTGT GATTTTTCAG GGGATTTGGA TCCTGCCCCC AACCCGCCAT 4200 ATTTCCCCTC ACATGTCATT CAGGCAACGT TTGCTTACAT CAGCAACTGT CATAAAACCA 4260 AGTTTAAAAG CATTCTAGAA ATTCTTTCTA AAATCCCCGA TTCCTATCAG AAAATACTTC 4320 TGGCCATTTG TGAACAAGCA GCTGAGACAA ATAATGTCTT TAAAAAGCAC AGAATTCTTA 4380 AAATATATCA CCTGTTTGTT AGTTTATTAC TGAAAGATAT ACAGAGTGGC CTGGGAGGGG 4440 CTTGGGCCTT TGTCCTTCGC GATGTTATTT ATACTCTGAT TCACTACATC AACAAAAGGT 4500 CTTCTCATTT CACAGATGTG TCGTTGCGTA GCTTTTCCCT TTGCTGTGAC CTATTAAGTC 4560 GAGTTTGTCA TACAGCTGTA ACTCAATGTA AGGATGCTCT AGAAAGCCAT CTTCACGTTA 4620 TCGTTGGCAC ACTTATTCCC CTTGTGGATT ATCAGGAAGT TCAAGAACAG GTATTGGACC 4680 TGTTGAAGTA CTTAGTGATA GATAACAAAG ACAATAAAAA CCTCTCTGTC ACAATTAAGC 4740 TTTTGGATCC CTTTCCTGAC CATGTTATTT TTAAGGACTT GCGTCTTACT CAACAGAAAA 4800 TCAAATATAG TGGAGGACCT TTTTCACTCT TAGAGGAAAT AAACCATTTT CTCTCAGTAA 4860 GTGCTTACAA TCCACTTCCG CTGACCAGGC TTGAAGGACT GAAGGATCTT CGAAGACAAC 4920 TGGAGCAACA TAAAGATCAG ATGCTAGATC TTCTGAGAGC GTCTCAAGAT AACCCACAAG 4980 ATGGCATTGT GGTGAAGCTA GTTGTCAGCT TGTTGCAGTT ATCCAAGATG GCAGTGAACC 5040 AGACTGGTGA AAGAGAAGTT TTAGAGGCTG TCGGAAGGTG TTTGGGAGAA ATAGGTCCTC 5100 TGGATTTCTC CACCATAGCT GTCCAGCATA ACAAAGATGT GTCCTATACC AAAGCCTACG 5160 GGTTACCTGA AGACAGAGAA CTTCAGTGGA CCTTGATAAT GCTGACTGCC CTCAACAATA 5220 CCCTGGTAGA GGACAGTGTC AAAATTCGAT CTGCTGCTGC TACCTGTTTG AAAAACATTT 5280 TGGCTACAAA GATTGGACAT ATTTTCTGGG AGAATTATAA GACATCAGCG GATCCAATGC 5340 TGACCTATCT ACAACCTTTT AGAACATCGA GGAAAAAGTT TTTAGAAGTG CCCCGATCTG 5400 TTAAAGAAGA TGTTTTAGAA GGCCTGGATG CTGTGAATCT GTGGGTTCCT CAAAGTGAAA 5460 GTCATGACAT TTGGATAAAG ACACTGACGT GTGCCTTTCT GGACAGTGGA GGCATAAACA 5520 GTGAAATTCT CCAGTTATTA AAGCCAATGT GTGAAGTGAA AACCGACTTC TGTCAGATGT 5580 TGCTGCCATA CTTGATCCAT GATGTTTTAC TGCAAGATAC ACATGAATCG TGGAGAACTC 5640 TGCTGTCTGC GCACGTCCGA GGATTTTTCA CTAGTTGTTT TAAGCATTCC TCCCAAGCAA 5700 GCCGCTCAGC AACTCCTGCA AATTCGGATT CAGAGTCAGA GAACTTTCTC CGATGCTGTT 5760 TGGATAAAAA GTCACAAAGA ACCATGCTTG CTGTTGTCGA CTATCTGAGA AGGCAAAAGA 5820 GACCTTCCTC GGGAACAGCT TTTGATGACG CTTTCTGGCT GGATTTGAAT TATCTTGAGG 5880 TTGCGAAGGT GGCTCAGTCC TGCTCTGCTC ACTTCACGGC CTTGCTCTAC GCAGAGATCT 5940 ATTCAGATAA GAAAAGCACA GACGAGCAAG AGAAAAGAAG TCCAACATTT GAAGAAGGAA 6000 GTCAAGGAAC AACTATTTCT AGTTTGAGTG AAAAAAGTAA AGAAGAAACT GGAATAAGCT 6060 TACAGGATCT TCTCTTAGAG ATCTACAGAA GTATAGGAGA GCCGGACAGC CTGTATGGCT 6120 GTGGAGGAGG GAAAATGTTA CAACCCCTTA CTAGAATACG GACATATGAA CATGAAGCTA 6180 CGTGGGAGAA AGCCTTAGTA ACTTACGACC TGGAGACCAG CATCTCCTCC TCCACCCGCC 6240 AGTCAGGAAT CATCCAGGCC CTGCAGAATT TGGGGCTCTC CCATATCCTG TCTGTCTATC 6300 TGAAAGGATT AGACTATGAA AGACGAGAGT GGTGCGCTGA GCTGCAGGAG CTGCGTTACC 6360 AGGCGGCGTG GAGGAACATG CAGTGGGGCC TCTGCGCTTC TGCCGGCCAA GAAGTAGAAG 6420 GAACCAGTTA CCATGAATCG TTGTATAATG CTCTGCAGTG TCTAAGAAAC AGAGAATTCT 6480 CCACATTTTA TGAAAGTCTC CGATATGCCA GTCTTTTCAG GGTGAAAGAA GTTGAAGAGT 6540 TGAGTAAGGG CAGCCTTGAG TCTGTATATT CGCTGTATCC CACACTTAGT AGATTGCAGG 6600 CAATTGGAGA ACTGGAAAAC AGTGGCGAGC TTTTCTCAAG GTCAGTCACA GACAGAGAGC 6660 GCTCTGAAGC ATACTGGAAG TGGCAGAAGC ACTCCCAGCT TCTGAAAGAC AGCGACTTCA 6720 GCTTTCAGGA GCCTCTCATG GCTCTGCGCA CAGTCATTCT GGAGACCCTG GTACAGAAGG 6780 AAATGGAGCG CTCTCAAGGA GCATGCTCTA AGGACATTCT CACCAAACAC CTCGTTGAAT 6840 TCTCTGTTCT GGCTCGAACC TTCAAGAACA CACAGCTCCC TGAAAGAGCA ATATTCAAAA 6900 TTAAGCAATA TAATTCAGCT ATTTGTGGAA TTTCTGAGTG GCATTTGGAA GAAGCACAAG 6960 TATTCTGGGC AAAAAAGGAG CAGAGTCTTG CTCTGAGTAT TCTCAAGCAG ATGATCAAGA 7020 AGTTGGACTC CAGCTTTAAA GATAAAGAGA ATGATGCAGG TCTCAAAGTC ATATACGCAG 7080 AGTGTCTGAG GGTTTGTGGC AGCTGGCTGG CAGAAACTTG CTTAGAAAAC CCTGCAGTCA 7140 TCATGCAGAC CTATCTAGAA AAGGCGGTGA AGGTTGCTGG AAGTTACGAT GGCAACAGCA 7200 GAGAGCTCAG AAATGGACAG ATGAAGGCCT TTCTCTCGTT GGCAAGGTTC TCTGATACTC 7260 AGTACCAGAG AATTGAAAAC TACATGAAGT CATCAGAATT TGAAAACAAG CAAACTCTCT 7320 TAAAAAGAGC CAAAGAGGAA GTGGGCCTTC TAAGGGAACA TAAAATTCAG ACCAACAGAT 7380 ACACAGTAAA GGTTCAGCGA GAACTGGAGC TGGACGAATG TGCTCTCCGT GCACTGAGAG 7440 AGGATCGCAA GCGCTTCCTG TGTAAAGCAG TGGAGAACTA CATCAACTGC TTACTAAGCG 7500 GGGAAGAACA TGATCTGTGG GTGTTCCGGC TTTGCTCCCT CTGGCTTGAA AATTCTGGAG 7560 TTTCTGAAGT CAATGGCATG ATGAAGAAAG ATGGAATGAA GATTTCATCC TATAAGTTTT 7620 TGCCTCTCAT GTATCAATTG GCTGCTCGAA TGGGGACCAA AATGACGGGA GGCCTAGGAT 7680 TTCACGAAGT CCTCAATAAT CTAATCTCTA GGATTTCACT GGATCACCCC CATCATACTT 7740 TGTTCATTAT ACTGGCCTTA GCAAATGCGA ACAAAGATGA ATTTTTGAGC AAACCAGAGA 7800 CAACAAGAAG GAGTCGAATA ACCAAAAGTA CATCTAAAGA AAACTCTCAC CTTGATGAGG 7860 ATCGAACAGA GGCTGCAACC AGAATCATCC ACTCCATCAG AAGTAAGCGA TGTAAGATGG 7920 TGAAGGACAT GGAGGCGCTC TGCGATGCCT ACATCATCTT GGCAAACATG GACGCCTCTC 7980 AGTGGAGGGC TCAGAGAAAA GGCATCAATA TTCCAGCCAA CCAGCCAATC ACTAAACTGA 8040 AGAATTTAGA AGATGTTGTT GTTCCCACTA TGGAAATTAA GGTTGATCCC ACAGGAGAGT 8100 ATGAAAATCT GGTGACTATA AAATCATTTA AAACAGAATT TCGCTTAGCT GGAGGCTTAA 8160 ATTTACCCAA AATAATAGAT TGTGTGGGTT CTGATGGCAA GGAAAGGAGA CAGCTTGTGA 8220 AGGGCCGTGA TGACCTGAGG CAAGATGCTG TCATGCAGCA GGTCTTCCAG ATGTGCAATA 8280 CACTACTGCA GAGAAACACT GAGACTAGAA AGAGGAAACT GACTATCTGC ACATACAAGG 8340 TGGTTCCCCT TTCTCAGCGA AGCGGTGTTC TCGAGTGGTG CACAGGAACC GTTCCTATTG 8400 GTGAATATCT TGTTAACAGC GAAGACGGTG CACATAGAAG ATACAGGCCA AATGATTTCA 8460 GTGCCAATCA GTGCCAAAAG AAAATGATGG AAGTGCAGAA GAAGTCTTTT GAAGAGAAAT 8520 ATGATACCTT CATGACGATT TGCCAAAACT TTGAACCAGT TTTCCGTTAC TTCTGCATGG 8580 AAAAATTCTT GGACCCAGCT GTTTGGTTTG AGAAACGATT GGCATATACA CGCAGTGTGG 8640 CCACATCTTC TATCGTCGGT TACATCCTTG GACTTGGCGA CAGGCACGTA CAGAATATCT 8700 TGATAAACGA GCAGTCGGCA GAGCTTGTGC ACATAGACCT GGGAGTGGCT TTTGAACAGG 8760 GGAAGATCCT TCCCACTCCA GAAACAGTTC CTTTTAGACT CAGCAGAGAT ATTGTGGACG 8820 GGATGGGCAT CACCGGTGTG GAAGGTGTCT TCAGAAGGTG CTGTGAAAAA ACGATGGAAG 8880 TTATGCGGAG TTCTCAGGAA ACCCTGCTGA CCATTGTAGA GGTTCTTTTG TACGATCCAC 8940 TCTTTGATTG GACTATGAAT CCTTTAAAAG CTCTGTATCT ACAGCAGAGA CCAGAAGATG 9000 AGTCCGACCT CCATTCCACC CCCAATGCAG ATGATCAAGA ATGCAAACAA AGTCTTAGTG 9060 ATACTGACCA GAGTTTCAAC AAAGTAGCTG AGCGTGTCTT GATGAGACTG CAAGAGAAAC 9120 TGAAAGGCGT GGAGGAAGGC ACTGTGCTCA GTGTGGGTGG ACAGGTGAAC TTGCTTATCC 9180 AGCAGGCCAT GGATCCCAAA AATCTCAGCC GACTCTTCCC AGGATGGAAA GCTTGGGTGT 9240 GACCTTCACC CTTAAACTCG AACTTCAGAA ATGACATCTC ACCCACCATA TTTGGACAGG 9300 AATTACTTAA GTGAATAACT GCTTTTGATC CAATTTTCTA CTTGACTGAT CACCACCTAA 9360 ATATTAGTAT TTCTACTCTC TTCTGTTAGA GGTAATGGTC ACTCAAGATC CATTCGTAGG 9420 ATACGTGCTG ACTCTTAGGT CATGCTTGTG CTACTGCAGC AAGACCGCCG CATACACACT 9480 GAACTGCAAA TGGTGGGGGC AGCAGAGTGA GCTTTACTGC TGGTGTACAT GAAGACAAGT 9540 TCGTAACTTC TGCTCTAAAA CAACCTTTAA TTAAAGCATG TTTTCCAGAC TGTGTGTGTG 9600 TGTGTGTGTG TGTGTGTGTG 9620 (2) INFORMATION FOR SEQ ID NO:12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3066 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (vi) ORIGINAL SOURCE: (A) ORGANISM: Mus musculus (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: Met Ser Leu Ala Leu Asn Asp Leu Leu He Cys Cys Arg Gin Leu Glu 1 5 10 15 His Asp Arg Ala Thr Glu Arg Arg Lys Glu Val Asp Lys Phe Lys Arg 20 25 30 Leu He Gin Asp Pro Glu Thr Val Gin His Leu Asp Arg His Ser Asp 35 40 45 Ser Lys Gin Gly Lys Tyr Leu Asn Trp Asp Ala Val Phe Arg Phe Leu 50 55 60 Gin Lys Tyr He Gin Lys Glu Met Glu Ser Leu Arg Thr Ala Lys Ser 65 70 75 80 Asn Val Ser Ala Thr Thr Gin Ser Ser Arg Gin Lys Lys Met Gin Glu 85 90 95 He Ser Ser Leu Val Arg Tyr Phe He Lys Cys Ala Asn Lys Arg Ala 100 105 110 Pro Arg Leu Lys Cys Gin Asp Leu Leu Asn Tyr Val Met Asp Thr Val 115 120 125 Lys Asp Ser Ser Asn Gly Leu Thr Tyr Gly Ala Asp Cys Ser Asn He 130 135 140 Leu Leu Lys Asp He Leu Ser Val Arg Lys Tyr Trp Cys Glu Val Ser 145 150 155 160 Gin Gin Gin Trp Leu Glu Leu Phe Ser Leu Tyr Phe Arg Leu Tyr Leu 165 170 175 Lys Pro Ser Gin Asp He Asn Arg Val Leu Val Ala Arg He He His 180 185 190 Ala Val Thr Arg Gly Cys Cys Ser Gin Thr Asp Gly Leu Pro Ser Lys 195 200 205 Phe Leu Asp Leu Phe Ser Lys Ala He Gin Tyr Ala Arg Gin Glu Lys 210 215 220 Ser Ser Pro Gly Leu Ser His He Leu Ala Ala Leu Asn He Phe Leu 225 230 235 240 Lys Ser Leu Ala Val Asn Phe Arg Lys Arg Val Cys Glu Ala Gly Asp 245 250 255 Glu He Leu Pro Thr Leu Leu Tyr He Trp Thr Gin His Arg Leu Asn 260 265 270 Asp Ser Leu Lys Glu Val He He Glu Leu He Gin Leu Gin He Tyr 275 280 285 He His His Pro Gin Gly Ala Arg Ala Pro Glu Glu Gly Ala Tyr Glu 290 295 300 Ser Met Lys Trp Lys Ser He Leu Tyr Asn Leu Tyr Asp Leu Leu Val 305 310 315 320 Asn Glu He Ser His He Gly Ser Arg Gly Lys Tyr Ser Ser Gly Ser 325 330 335 Arg Asn He Ala Val Lys Glu Asn Leu He Asp Leu Met Ala Asp He 340 345 350 Cys Tyr Gin Leu Phe Asp Ala Asp Thr Arg Ser Val Glu He Ser Gin 355 360 365 Ser Tyr Val Thr Gin Arg Glu Ser Thr Asp Tyr Ser Val Pro Cys Lys 370 375 380 Arg Arg Lys He Asp Val Gly Trp Glu Val He Lys Asp Tyr Leu Gin 385 390 395 400 Lys Ser Gin Ser Asp Phe Asp Leu Val Pro Trp Leu Gin He Thr Thr 405 410 415 Arg Leu He Ser Lys Tyr Pro Ser Ser Leu Pro Asn Cys Glu Leu Ser 420 425 430 Pro Leu He Leu He Leu Tyr Gin Leu Leu Pro Gin Gin Arg Arg Gly 435 440 445 Glu Arg He Pro Tyr Val Leu Arg Cys Leu Lys Glu Val Ala Leu Cys 450 455 460 Gin Gly Lys Lys Ser Asn Leu Glu Ser Ser Gin Lys Ser Asp Leu Leu 465 470 475 480 Lys Leu Trp He Lys He Trp Ser He Thr Phe Arg Gly He Ser Ser 485 490 495 Gly Gin Thr Gin Thr Glu Asn Phe Gly Leu Leu Glu Ala He He Gin 500 505 510 Gly Ser Leu Val Glu Leu Asp Arg Glu Phe Trp Lys Leu Phe Thr Gly 515 520 525 Ser Ala Cys Lys Pro Ser Ser Pro Ser Val Cys Cys Leu Thr Leu Ala 530 535 540 Leu Ser He Cys Val Val Pro Asp Ala He Lys Met Gly Thr Glu Gin 545 550 555 560 Ser Val Cys Glu Ala Asn Arg Ser Phe Ser Val Lys Glu Ser He Met 565 570 575 Arg Trp Leu Leu Phe Tyr Gin Leu Glu Asp Asp Leu Glu Asp Ser Thr 580 585 590 Glu Leu Pro Pro He Leu Gin Arg Asn Phe Pro His Leu Val Val Glu 595 600 605 Lys He Leu Val Ser Leu Thr Met Lys Asn Ser Lys Ala Ala Met Lys 610 615 620 Phe Phe Gin Ser Val Pro Glu Cys Glu Gin His Cys Glu Asp Lys Glu 625 630 635 640 Glu Pro Ser Phe Ser Glu Val Glu Glu Leu Phe Leu Gin Thr Thr Phe 645 650 655 Asp Lys Met Asp Phe Leu Thr Thr Val Lys Glu Tyr Ala Val Glu Lys 660 665 670 Phe Gin Ser Ser Val Gly Phe Ser Val Gin Gin Asn Leu Lys Glu Ser 675 680 685 Leu Asp His Tyr Leu Leu Gly Leu Ser Glu Gin Leu Leu Ser Asn Tyr 690 695 700 Ser Ser Glu He Thr Ser Ser Glu Thr Leu Val Arg Cys Ser Ser Leu 705 710 715 720 Leu Val Gly Val Leu Gly Cys Tyr Cys Tyr Met Gly He He Thr Glu 725 730 735 Asp Glu Ala His Lys Ser Glu Leu Phe Gin Lys Ala Lys Ser Leu Met 740 745 750 Gin Cys Ala Gly Glu Ser He Ser Leu Phe Lys Asn Lys Thr Asn Glu 755 760 765 Glu Ser Arg He Gly Ser Leu Arg Asn Val Met His Leu Cys Thr Ser 770 775 780 Cys Leu Cys He His Thr Lys His Thr Pro Asn Lys He Ala Ser Gly 785 790 795 800 Phe Phe Leu Arg Leu Leu Thr Ser Lys Leu Met Asn Asp He Ala Asp 805 810 815 He Cys Lys Ser Leu Ala Ser Cys Thr Lys Lys Pro Leu Asp His Gly 820 825 830 Val His Pro Gly Glu Asp Asp Glu Asp Gly Gly Gly Cys Asp Ser Leu 835 840 845 Met Glu Ala Glu Gly Pro Ser Ser Thr Gly Leu Ser Thr Ala Tyr Pro 850 855 860 Ala Ser Ser Val Ser Asp Ala Asn Asp Tyr Gly Glu Asn Gin Asn Ala 865 870 875 880 Val Gly Ala Met Ser Pro Leu Ala Ala Asp Tyr Leu Ser Lys Gin Asp 885 890 895 His Leu Leu Leu Asp Met Leu Arg Phe Leu Gly Arg Ser Val Thr Ala 900 905 910 Ser Gin Ser His Thr Val Ser Phe Arg Gly Ala Asp He Arg Arg Lys 915 920 925 Leu Leu Leu Leu Leu Asp Ser Ser He Leu Asp Leu Met Lys Pro Leu 930 935 940 His Leu His Met Tyr Leu Val Leu Leu Lys Asp Leu Pro Gly Asn Glu 945 950 955 960 His Ser Leu Pro Met Glu Asp Val Val Glu Leu Leu Gin Pro Leu Ser 965 970 975 Leu Val Cys Ser Leu His Arg Arg Asp Gin Asp Val Cys Lys Thr He 980 985 990 Leu Ser Asn Val Leu His He Val Thr Asn Leu Gly Gin Gly Ser Val 995 1000 1005 Asp Met Glu Ser Thr Arg He Ala Gin Gly His Phe Leu Thr Val Met 1010 1015 1020 Gly Ala Phe Trp His Leu Thr Lys Glu Lys Lys Cys Val Phe Ser Val 1025 1030 1035 1040 Arg Met Ala Leu Val Lys Cys Leu Gin Thr Leu Leu Glu Ala Asp Pro 1045 1050 1055 Tyr Ser Glu Trp Ala He Leu Asn Val Lys Gly Gin Asp Phe Pro Val 1060 1065 1070 Asn Glu Ala Phe Ser Gin Phe Leu Ala Asp Asp His His Gin Val Arg 1075 1080 1085 Met Leu Ala Ala Gly Ser Val Asn Arg Leu Phe Gin Asp Met Arg Gin 1090 1095 1100 Gly Asp Phe Ser Arg Ser Leu Lys Ala Leu Pro Leu Lys Phe Gin Gin 1105 1110 1115 1120 Thr Ser Phe Asn Asn Ala Tyr Thr Thr Ala Glu Ala Gly He Arg Gly 1125 1130 1135 Leu Leu Cys Asp Ser Gin Asn Pro Asp Leu Leu Asp Glu He Tyr Asn 1140 1145 1150 Arg Lys Ser Val Leu Leu Met Met He Ala Val Val Leu His Cys Ser 1155 1160 1165 Pro Val Cys Glu Lys Gin Ala Leu Phe Ala Leu Cys Lys Ser Val Lys 1170 1175 1180 Glu Asn Arg Leu Glu Pro His Leu Val Lys Lys Val Leu Glu Lys Val 1185 1190 1195 1200 Ser Glu Ser Phe Gly Cys Arg Ser Leu Glu Asp Phe Met He Ser His 1205 1210 1215 Leu Asp Tyr Leu Val Leu Glu Trp Leu Asn Leu Gin Asp Thr Glu Tyr 1220 1225 1230 Ser Leu Ser Ser Phe Pro Phe Met Leu Leu Asn Tyr Thr Ser He Glu 1235 1240 1245 Asp Phe Tyr Arg Ser Cys Tyr Lys He Leu He Pro His Leu Val He 1250 1255 1260 Arg Ser His Phe Asp Glu Val Lys Ser He Ala Asn Gin He Gin Lys 1265 1270 1275 1280 Cys Trp Lys Ser Leu Leu Val Asp Cys Phe Pro Lys He Leu Val His 1285 1290 1295 He Leu Pro Tyr Phe Ala Tyr Glu Gly Thr Arg Asp Ser Tyr Val Ser 1300 1305 1310 Gin Lys Arg Glu Thr Ala Thr Lys Val Tyr Asp Thr Leu Lys Gly Glu 1315 1320 1325 Asp Phe Leu Gly Lys Gin He Asp Gin Val Phe He Ser Asn Leu Pro 1330 1335 1340 Glu He Val Val Glu Leu Leu Met Thr Leu His Glu Thr Ala Asp Ser 1345 1350 1355 1360 Ala Asp Ser Asp Ala Ser Gin Ser Ala Thr Ala Leu Cys Asp Phe Ser 1365 1370 1375 Gly Asp Leu Asp Pro Ala Pro Asn Pro Pro Tyr Phe Pro Ser His Val 1380 1385 1390 He Gin Ala Thr Phe Ala Tyr He Ser Asn Cys His Lys Thr Lys Phe 1395 1400 1405 Lys Ser He Leu Glu He Leu Ser Lys He Pro Asp Ser Tyr Gin Lys 1410 1415 1420 He Leu Leu Ala He Cys Glu Gin Ala Ala Glu Thr Asn Asn Val Phe 1425 1430 1435 1440 Lys Lys His Arg He Leu Lys He Tyr His Leu Phe Val Ser Leu Leu 1445 1450 1455 Leu Lys Asp He Gin Ser Gly Leu Gly Gly Ala Trp Ala Phe Val Leu 1460 1465 1470 Arg Asp Val He Tyr Thr Leu He His Tyr He Asn Lys Arg Ser Ser 1475 1480 1485 His Phe Thr Asp Val Ser Leu Arg Ser Phe Ser Leu Cys Cys Asp Leu 1490 1495 1500 Leu Ser Arg Val Cys His Thr Ala Val Thr Gin Cys Lys Asp Ala Leu 1505 1510 1515 1520 Glu Ser His Leu His Val He Val Gly Thr Leu He Pro Leu Val Asp 1525 1530 1535 Tyr Gin Glu Val Gin Glu Gin Val Leu Asp Leu Leu Lys Tyr Leu Val 1540 1545 1550 He Asp Asn Lys Asp Asn Lys Asn Leu Ser Val Thr He Lys Leu Leu 1555 1560 1565 Asp Pro Phe Pro Asp His Val He Phe Lys Asp Leu Arg Leu Thr Gin 1570 1575 1580 Gin Lys He Lys Tyr Ser Gly Gly Pro Phe Ser Leu Leu Glu Glu He 1585 1590 1595 1600 Asn His Phe Leu Ser Val Ser Ala Tyr Asn Pro Leu Pro Leu Thr Arg 1605 1610 1615 Leu Glu Gly Leu Lys Asp Leu Arg Arg Gin Leu Glu Gin His Lys Asp 1620 1625 1630 Gin Met Leu Asp Leu Leu Arg Ala Ser Gin Asp Asn Pro Gin Asp Gly 1635 1640 1645 He Val Val Lys Leu Val Val Ser Leu Leu Gin Leu Ser Lys Met Ala 1650 1655 1660 Val Asn Gin Thr Gly Glu Arg Glu Val Leu Glu Ala Val Gly Arg Cys 1665 1670 1675 1680 Leu Gly Glu He Gly Pro Leu Asp Phe Ser Thr He Ala Val Gin His 1685 1690 1695 Asn Lys Asp Val Ser Tyr Thr Lys Ala Tyr Gly Leu Pro Glu Asp Arg 1700 1705 1710 Glu Leu Gin Trp Thr Leu He Met Leu Thr Ala Leu Asn Asn Thr Leu 1715 1720 1725 Val Glu Asp Ser Val Lys He Arg Ser Ala Ala Ala Thr Cys Leu Lys 1730 1735 1740 Asn He Leu Ala Thr Lys He Gly His He Phe Trp Glu Asn Tyr Lys 1745 1750 1755 1760 Thr Ser Ala Asp Pro Met Leu Thr Tyr Leu Gin Pro Phe Arg Thr Ser 1765 1770 1775 Arg Lys Lys Phe Leu Glu Val Pro Arg Ser Val Lys Glu Asp Val Leu 1780 1785 1790 Glu Gly Leu Asp Ala Val Asn Leu Trp Val Pro Gin Ser Glu Ser His 1795 1800 1805 Asp He Trp He Lys Thr Leu Thr Cys Ala Phe Leu Asp Ser Gly Gly 1810 1815 1820 He Asn Ser Glu He Leu Gin Leu Leu Lys Pro Met Cys Glu Val Lys 1825 1830 1835 1840 Thr Asp Phe Cys Gin Met Leu Leu Pro Tyr Leu He His Asp Val Leu 1845 1850 1855 Leu Gin Asp Thr His Glu Ser Trp Arg Thr Leu Leu Ser Ala His Val 1860 1865 1870 Arg Gly Phe Phe Thr Ser Cys Phe Lys His Ser Ser Gin Ala Ser Arg 1875 1880 1885 Ser Ala Thr Pro Ala Asn Ser Asp Ser Glu Ser Glu Asn Phe Leu Arg 1890 1895 1900 Cys Cys Leu Asp Lys Lys Ser Gin Arg Thr Met Leu Ala Val Val Asp 1905 1910 1915 1920 Tyr Leu Arg Arg Gin Lys Arg Pro Ser Ser Gly Thr Ala Phe Asp Asp 1925 1930 •^SB 1935 Ala Phe Trp Leu Asp Leu Asn Tyr Leu Glu Val Ala Lys Val Ala Gin 1940 1945 1950 Ser Cys Ser Ala His Phe Thr Ala Leu Leu Tyr Ala Glu He Tyr Ser 1955 1960 1965 Asp Lys Lys Ser Thr Asp Glu Gin Glu Lys Arg Ser Pro Thr Phe Glu 1970 1975 1980 Glu Gly Ser Gin Gly Thr Thr He Ser Ser Leu Ser Glu Lys Ser Lys 1985 1990 1995 2000 Glu Glu Thr Gly He Ser Leu Gin Asp Leu Leu Leu Glu He Tyr Arg 2005 2010 2015 Ser He Gly Glu Pro Asp Ser Leu Tyr Gly Cys Gly Gly Gly Lys Met 2020 2025 2030 Leu Gin Pro Leu Thr Arg He Arg Thr Tyr Glu His Glu Ala Thr Trp 2035 2040 2045 Glu Lys Ala Leu Val Thr Tyr Asp Leu Glu Thr Ser He Ser Ser Ser 2050 2055 2060 Thr Arg Gin Ser Gly He He Gin Ala Leu Gin Asn Leu Gly Leu Ser 2065 2070 2075 2080 His He Leu Ser Val Tyr Leu Lys Gly Leu Asp Tyr Glu Arg Arg Glu 2085 2090 2095 Trp Cys Ala Glu Leu Gin Glu Leu Arg Tyr Gin Ala Ala Trp Arg Asn 2100 2105 2110 Met Gin Trp Gly Leu Cys Ala Ser Ala Gly Gin Glu Val Glu Gly Thr 2115 2120 2125 Ser Tyr His Glu Ser Leu Tyr Asn Ala Leu Gin Cys Leu Arg Asn Arg 2130 2135 2140 Glu Phe Ser Thr Phe Tyr Glu Ser Leu Arg Tyr Ala Ser Leu Phe Arg 2145 2150 2155 2160 Val Lys Glu Val Glu Glu Leu Ser Lys Gly Ser Leu Glu Ser Val Tyr 2165 2170 2175 Ser Leu Tyr Pro Thr Leu Ser Arg Leu Gin Ala He Gly Glu Leu Glu 2180 2185 2190 Asn Ser Gly Glu Leu Phe Ser Arg Ser Val Thr Asp Arg Glu Arg Ser 2195 2200 2205 Glu Ala Tyr Trp Lys Trp Gin Lys His Ser Gin Leu Leu Lys Asp Ser 2210 2215 2220 Asp Phe Ser Phe Gin Glu Pro Leu Met Ala Leu Arg Thr Val He Leu 2225 2230 2235 2240 Glu Thr Leu Val Gin Lys Glu Met Glu Arg Ser Gin Gly Ala Cys Ser 2245 2250 2255 Lys Asp He Leu Thr Lys His Leu Val Glu Phe Ser Val Leu Ala Arg 2260 2265 2270 Thr Phe Lys Asn Thr Gin Leu Pro Glu Arg Ala He Phe Lys He Lys 2275 2280 2285 Gin Tyr Asn Ser Ala He Cys Gly He Ser Glu Trp His Leu Glu Glu 2290 2295 2300 Ala Gin Val Phe Trp Ala Lys Lys Glu Gin Ser Leu Ala Leu Ser He 2305 2310 2315 2320 Leu Lys Gin Met He Lys Lys Leu Asp Ser Ser Phe Lys Asp Lys Glu 2325 2330 2335 Asn Asp Ala Gly Leu Lys Val He Tyr Ala Glu Cys Leu Arg Val Cys 2340 2345 2350 Gly Ser Trp Leu Ala Glu Thr Cys Leu Glu Asn Pro Ala Val He Met 2355 2360 2365 Gin Thr Tyr Leu Glu Lys Ala Val Lys Val Ala Gly Ser Tyr Asp Gly 2370 2375 2380 Asn Ser Arg Glu Leu Arg Asn Gly Gin Met Lys Ala Phe Leu Ser Leu 2385 2390 2395 2400 Ala Arg Phe Ser Asp Thr Gin Tyr Gin Arg He Glu Asn Tyr Met Lys 2405 2410 2415 Ser Ser Glu Phe Glu Asn Lys Gin Thr Leu Leu Lys Arg Ala Lys Glu 2420 2425 2430 Glu Val Gly Leu Leu Arg Glu His Lys He Gin Thr Asn Arg Tyr Thr 2435 2440 2445 Val Lys Val Gin Arg Glu Leu Glu Leu Asp Glu Cys Ala Leu Arg Ala 2450 2455 2460 Leu Arg Glu Asp Arg Lys Arg Phe Leu Cys Lys Ala Val Glu Asn Tyr 2465 2470 2475 2480 He Asn Cys Leu Leu Ser Gly Glu Glu His Asp Leu Trp Val Phe Arg 2485 2490 2495 Leu Cys Ser Leu Trp Leu Glu Asn Ser Gly Val Ser Glu Val Asn Gly 2500 2505 2510 Met Met Lys Lys Asp Gly Met Lys He Ser Ser Tyr Lys Phe Leu Pro 2515 2520 2525 Leu Met Tyr Gin Leu Ala Ala Arg Met Gly Thr Lys Met Thr Gly Gly 2530 2535 2540 Leu Gly Phe His Glu Val Leu Asn Asn Leu He Ser Arg He Ser Leu 2545 2550 2555 2560 Asp His Pro His His Thr Leu Phe He He Leu Ala Leu Ala Asn Ala 2565 2570 2575 Asn Lys Asp Glu Phe Leu Ser Lys Pro Glu Thr Thr Arg Arg Ser Arg 2580 2585 2590 He Thr Lys Ser Thr Ser Lys Glu Asn Ser His Leu Asp Glu Asp Arg 2595 2600 2605 Thr Glu Ala Ala Thr Arg He He His Ser He Arg Ser Lys Arg Cys 2610 2615 2620 Lys Met Val Lys Asp Met Glu Ala Leu Cys Asp Ala Tyr He He Leu 2625 2630 2635 2640 Ala Asn Met Asp Ala Ser Gin Trp Arg Ala Gin Arg Lys Gly He Asn 2645 2650 2655 He Pro Ala Asn Gin Pro He Thr Lys Leu Lys Asn Leu Glu Asp Val 2660 2665 2670 Val Val Pro Thr Met Glu He Lys Val Asp Pro Thr Gly Glu Tyr Glu 2675 2680 2685 Asn Leu Val Thr He Lys Ser Phe Lys Thr Glu Phe Arg Leu Ala Gly 2690 2695 2700 Gly Leu Asn Leu Pro Lys He He Asp Cys Val Gly Ser Asp Gly Lys 2705 2710 2715 2720 Glu Arg Arg Gin Leu Val Lys Gly Arg Asp Asp Leu Arg Gin Asp Ala 2725 2730 2735 Val Met Gin Gin Val Phe Gin Met Cys Asn Thr Leu Leu Gin Arg Asn 2740 2745 2750 Thr Glu Thr Arg Lys Arg Lys Leu Thr He Cys Thr Tyr Lys Val Val 2755 2760 2765 Pro Leu Ser Gin Arg Ser Gly Val Leu Glu Trp Cys Thr Gly Thr Val 2770 2775 2780 Pro He Gly Glu Tyr Leu Val Asn Ser Glu Asp Gly Ala His Arg Arg 2785 2790 2795 2800 Tyr Arg Pro Asn Asp Phe Ser Ala Asn Gin Cys Gin Lys Lys Met Met 2805 2810 2815 Glu Val Gin Lys Lys Ser Phe Glu Glu Lys Tyr Asp Thr Phe Met Thr 2820 2825 2830 He Cys Gin Asn Phe Glu Pro Val Phe Arg Tyr Phe Cys Met Glu Lys 2835 2840 2845 Phe Leu Asp Pro Ala Val Trp Phe Glu Lys Arg Leu Ala Tyr Thr Arg 2850 2855 2860 Ser Val Ala Thr Ser Ser He Val Gly Tyr He Leu Gly Leu Gly Asp 2865 2870 2875 2880 Arg His Val Gin Asn He Leu He Asn Glu Gin Ser Ala Glu Leu Val 2885 2890 2895 His He Asp Leu Gly Val Ala Phe Glu Gin Gly Lys He Leu Pro Thr 2900 2905 2910 Pro Glu Thr Val Pro Phe Arg Leu Ser Arg Asp He Val Asp Gly Met 2915 2920 2925 Gly He Thr Gly Val Glu Gly Val Phe Arg Arg Cys Cys Glu Lys Thr 2930 2935 2940 Met Glu Val Met Arg Ser Ser Gin Glu Thr Leu Leu Thr He Val Glu 2945 2950 2955 2960 Val Leu Leu Tyr Asp Pro Leu Phe Asp Trp Thr Met Asn Pro Leu Lys 2965 2970 2975 Ala Leu Tyr Leu Gin Gin Arg Pro Glu Asp Glu Ser Asp Leu His Ser 2980 2985 2990 Thr Pro Asn Ala Asp Asp Gin Glu Cys Lys Gin Ser Leu Ser Asp Thr 2995 3000 3005 Asp Gin Ser Phe Asn Lys Val Ala Glu Arg Val Leu Met Arg Leu Gin 3010 3015 3020 Glu Lys Leu Lys Gly Val Glu Glu Gly Thr Val Leu Ser Val Gly Gly 3025 3030 3035 3040 Gin Val Asn Leu Leu He Gin Gin Ala Met Asp Pro Lys Asn Leu Ser 3045 3050 3055 Arg Leu Phe Pro Gly Trp Lys Ala Trp Val 3060 3065 (2) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: Cys Arg Gin Leu Glu His Asp Arg Ala Thr Glu Arg Arg Lys Lys Glu 1 5 10 15 Val Glu Lys Phe Lys 20 (2) INFORMATION FOR SEQ ID NO:14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear ( ii) MOLECULE TYPE : peptide (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 14 : Cys Leu Arg He Ala Lys Pro Asn Val Ser Ala Ser Thr Gin Ala Ser 1 5 10 15 Arg Gin Lys Lys 20 (2) INFORMATION FOR SEQ ID NO:15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE : peptide (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 15 : Cys Ala Arg Gin Glu Lys Ser Ser Ser Gly Leu Asn His He Leu Ala 1 5 10 15 Ala (2) INFORMATION FOR SEQ ID NO:16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: Cys Arg Gin Leu Glu His Asp Arg Ala Thr Glu Arg Lys Lys Glu Val 1 5 10 15 Asp Lys Phe (2) INFORMATION FOR SEQ ID NO:17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17: Cys Phe Lys His Ser Ser Gin Ala Ser Arg Ser Ala Thr Pro Ala Asn 1 5 10 15 Ser Asp (2) INFORMATION FOR SEQ ID NO:18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18: Arg Pro Glu Asp Glu Ser Asp Leu His Ser Thr Pro Asn Ala Asp Asp 1 5 10 15 Gin Glu Cys (2) INFORMATION FOR SEQ ID NO:19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 249 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19: Met Ser Leu Val Leu Asn Asp Leu Leu He Cys Cys Arg Gin Leu Glu 1 5 10 15 His Asp Arg Ala Thr Glu Arg Lys Lys Glu Val Glu Lys Phe Lys Arg 20 25 30 Leu He Arg Asp Pro Glu Thr He Lys His Leu Asp Arg His Ser Asp 35 40 45 Ser Lys Gin Gly Lys Tyr Leu Asn Trp Asp Ala Val Phe Arg Phe Leu 50 55 60 Gin Lys Tyr He Gin Lys Glu Thr Glu Cys Leu Arg He Ala Lys Pro 65 70 75 80 Asn Val Ser Ala Ser Thr Gin Ala Ser Arg Gin Lys Lys Met Gin Glu 85 90 95 He Ser Ser Leu Val Lys Phe Tyr He Lys Cys Ala Asn Arg Arg Ala 100 105 110 Pro Arg Leu Lys Cys Gin Glu Leu Leu Asn Tyr He Met Asp Thr Val 115 120 125 Lys Asp Ser Ser Asn Gly Ala He Tyr Gly Ala Asp Cys Ser Asn He 130 135 140 Leu Leu Lys Asp He Leu Ser Val Arg Lys Tyr Trp Cys Glu He Ser 145 150 155 160 Gin Gin Gin Trp Leu Glu Leu Phe Ser Val Tyr Phe Arg Leu Tyr Leu 165 170 175 Lys Pro Ser Gin Asp Val His Arg Val Leu Val Ala He He His His 180 185 190 Ala Val Thr Lys Gly Cys Cys Ser Gin Thr Asp Gly Leu Asn Ser Lys 195 200 205 Phe Leu Asp Phe Phe Ser Lys Ala He Gin Cys Ala Arg Gin Glu Lys 210 215 220 Ser Ser Ser Gly Leu Asn His He Leu Ala Ala Leu Thr He Phe Leu 225 230 235 240 Lys Thr Leu Ala Val Asn Phe Arg He 245 (2) INFORMATION FOR SEQ ID NO:20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 210 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20: Gly Phe Ser Val His Gin Asn Leu Lys Glu Ser Leu Asp Arg Cys Leu 1 5 10 15 Leu Gly Leu Ser Glu Gin Leu Leu Asn Asn Tyr Ser Ser Glu He Thr 20 25 30 Asn Ser Glu Thr Leu Val Arg Cys Ser Arg Leu Leu Val Gly Val Leu 35 40 45 Gly Cys Tyr Cys Tyr Met Gly Val He Ala Glu Glu Glu Ala Tyr Lys 50 55 60 Ser Glu Leu Phe Gin Lys Ala Asn Ser Leu Met Gin Cys Ala Gly Glu 65 70 75 80 Ser He Thr Leu Phe Lys Asn Lys Thr Asn Glu Glu Phe Arg He Gly 85 90 95 Ser Leu Arg Asn Met Met Gin Leu Cys Thr Arg Cys Leu Ser Asn Cys 100 105 110 Thr Lys Lys Ser Pro Asn Lys He Ala Ser Gly Phe Phe Leu Arg Leu 115 120 125 Leu Thr Ser Lys Leu Met Asn Asp He Ala Asp He Cys Lys Ser Leu 130 135 140 Ala Ser Phe He Lys Lys Pro Phe Asp Arg Gly Glu Val Glu Ser Met 145 150 155 160 Glu Asp Asp Thr Asn Gly Asn Leu Met Glu Val Glu Asp Gin Ser Ser 165 170 175 Met Asn Leu Phe Asn Asp Tyr Pro Asp Ser Ser Val Ser Asp Ala Asn 180 185 190 Glu Pro Gly Glu Ser Gin Ser Thr He Gly Ala He Asn Pro Leu Ala 195 200 205 Glu Glu 210 (2) INFORMATION FOR SEQ ID NO:21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 448 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21: Gly Phe Ser Val His Gin Asn Leu Lys Glu Ser Leu Asp Arg Cys Leu 1 5 10 15 Leu Gly Leu Ser Glu Gin Leu Leu Asn Asn Tyr Ser Ser Glu He Thr 20 25 30 Asn Ser Glu Thr Leu Val Arg Cys Ser Arg Leu Leu Val Gly Val Leu 35 40 45 Gly Cys Tyr Cys Tyr Met Gly Val He Ala Glu Glu Glu Ala Tyr Lys 50 55 60 Ser Glu Leu Phe Gin Lys Ala Asn Ser Leu Met Gin Cys Ala Gly Glu 65 70 75 80 Ser He Thr Leu Phe Lys Asn Lys Thr Asn Glu Glu Phe Arg He Gly 85 90 95 Ser Leu Arg Asn Met Met Gin Leu Cys Thr Arg Cys Leu Ser Asn Cys 100 105 110 Thr Lys Lys Ser Pro Asn Lys He Ala Ser Gly Phe Phe Leu Arg Leu 115 120 125 Leu Thr Ser Lys Leu Met Asn Asp He Ala Asp He Cys Lys Ser Leu 130 135 140 Ala Ser Phe He Lys Lys Pro Phe Asp Arg Gly Glu Val Glu Ser Met 145 150 155 160 Glu Asp Asp Thr Asn Gly Asn Leu Met Glu Val Glu Asp Gin Ser Ser 165 170 175 Met Asn Leu Phe Asn Asp Tyr Pro Asp Ser Ser Val Ser Asp Ala Asn 180 185 190 Glu Pro Gly Glu Ser Gin Ser Thr He Gly Ala He Asn Pro Leu Ala 195 200 205 Glu Glu Tyr Leu Ser Lys Gin Asp Leu Leu Phe Leu Asp Met Leu Lys 210 215 220 Phe Leu Cys Leu Cys Val Thr Thr Ala Gin Thr Asn Thr Val Ser Phe 225 230 235 240 Arg Ala Ala Asp He Arg Arg Lys Leu Leu Met Leu He Asp Ser Ser 245 250 255 Thr Leu Glu Pro Thr Lys Ser Leu His Leu His Met Tyr Leu Met Leu 260 265 270 Leu Lys Glu Leu Pro Gly Glu Glu Tyr Pro Leu Pro Met Glu Asp Val 275 280 285 Leu Glu Leu Leu Lys Pro Leu Ser Asn Val Cys Ser Leu Tyr Arg Arg 290 295 300 Asp Gin Asp Val Cys Lys Thr He Leu Asn His Val Leu His Val Val 305 310 315 320 Lys Asn Leu Gly Gin Ser Asn Met Asp Ser Glu Asn Thr Arg Asp Ala 325 330 335 Gin Gly Gin Phe Leu Thr Val He Gly Ala Phe Trp His Leu Thr Lys 340 345 350 Glu Arg Lys Tyr He Phe Ser Val Arg Met Ala Leu Val Asn Cys Leu 355 360 365 Lys Thr Leu Leu Glu Ala Asp Pro Tyr Ser Lys Trp Ala He Leu Asn 370 375 380 Val Met Gly Lys Asp Phe Pro Val Asn Glu Val Phe Thr Gin Phe Leu 385 390 395 400 Ala Asp Asn His His Gin Val Arg Met Leu Ala Ala Glu Ser He Asn 405 410 415 Arg Leu Phe Gin Asp Thr Lys Gly Asp Ser Ser Arg Leu Leu Lys Ala 420 425 430 Leu Pro Leu Lys Leu Gin Gin Thr Ala Phe Glu Asn Ala Tyr Leu Lys 435 440 445 (2) INFORMATION FOR SEQ ID NO:22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 216 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22: Leu Gin Asp Thr Glu Tyr Asn Leu Ser Ser Phe Pro Phe He Leu Leu 1 5 10 15 Asn Tyr Thr Asn He Glu Asp Phe Tyr Arg Ser Cys Tyr Lys Val Leu 20 25 30 He Pro His Leu Val He Arg Ser His Phe Asp Glu Val Lys Ser He 35 40 45 Ala Asn Gin He Gin Glu Asp Trp Lys Ser Leu Leu Thr Asp Cys Phe 50 55 60 Pro Lys He Leu Val Asn He Leu Pro Tyr Phe Ala Tyr Glu Gly Thr 65 70 75 80 Arg Asp Ser Gly Met Ala Gin Gin Arg Glu Thr Ala Thr Lys Val Tyr 85 90 95 Asp Met Leu Lys Ser Glu Asn Leu Leu Gly Lys Gin He Asp His Leu 100 105 110 Phe He Ser Asn Leu Pro Glu He Val Val Glu Leu Leu Met Thr Leu 115 120 125 His Glu Pro Ala Asn Ser Ser Ala Ser Gin Ser Thr Asp Leu Cys Asp 130 135 140 Phe Ser Gly Asp Leu Asp Pro Ala Pro Asn Pro Pro His Phe Pro Ser 145 150 155 160 His Val He Lys Ala Thr Phe Ala Tyr He Ser Asn Cys His Lys Thr 165 170 175 Lys Leu Lys Ser He Leu Glu He Leu Ser Lys Ser Pro Asp Ser Tyr 180 185 190 Gin Lys He Leu Leu Ala He Cys Glu Gin Ala Ala Glu Thr Asn Asn 195 200 205 Val Tyr Lys Lys His Arg He Leu 210 215 (2) INFORMATION FOR SEQ ID NO:23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 286 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23: Gly Val Ser Glu Trp Gin Leu Glu Glu Ala Gin Val Phe Trp Ala Lys 1 5 10 15 Lys Glu Gin Ser Leu Ala Leu Ser He Leu Lys Gin Met He Lys Lys 20 25 30 Leu Asp Ala Ser Cys Ala Ala Asn Asn Pro Ser Leu Lys Leu Thr Tyr 35 40 45 Thr Glu Cys Leu Arg Val Cys Gly Asn Trp Leu Ala Glu Thr Cys Leu 50 55 60 Glu Asn Pro Ala Val He Met Gin Thr Tyr Leu Glu Lys Ala Val Glu 65 70 75 80 Val Ala Gly Asn Tyr Asp Gly Glu Ser Ser Asp Glu Leu Arg Asn Gly 85 90 95 Lys Met Lys Ala Phe Leu Ser Leu Ala Arg Phe Ser Asp Thr Gin Tyr 100 105 110 Gin Arg He Glu Asn Tyr Met Lys Ser Ser Glu Phe Glu Asn Lys Gin 115 120 125 Ala Leu Leu Lys Arg Ala Lys Glu Glu Val Gly Leu Leu Arg Glu His 130 135 140 Lys He Gin Thr Asn Arg Tyr Thr Val Lys Val Gin Arg Glu Leu Glu 145 150 155 160 Leu Asp Glu Leu Ala Arg Leu Ala Leu Lys Glu Asp Arg Lys Arg Phe 165 170 175 Leu Cys Lys Ala Val Glu Asn Tyr He Asn Cys Leu Leu Ser Gly Glu 180 185 190 Glu His Asp Met Trp Val Phe Arg Leu Cys Ser Leu Trp Leu Glu Asn 195 200 205 Ser Gly Val Ser Glu Val Asn Gly Met Met Lys Arg Asp Gly Met Lys 210 215 220 He Pro Thr Tyr Lys Phe Leu Pro Leu Met Tyr Gin Leu Ala Ala Arg 225 230 235 240 Met Gly Thr Lys Met Met Gly Gly Leu Gly Phe His Glu Val Leu Asn 245 250 255 Asn Leu He Ser Arg He Ser Met Asp His Pro His His Thr Leu Phe 260 265 270 He He Leu Ala Leu Ala Asn Ala Asn Arg Asp Glu Phe Leu 275 280 285 (2) INFORMATION FOR SEQ ID NO:24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 236 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24: TGCTTTTTTG GACAGTGGAG GCACAAAATG TGAAATTCTT CAATTATTAA AGCCAATGTG 60 TGAAGTGAAA ACTGACTTTT GTCAGACTGT ACTTCCATAC TTGATTCATG ATATTTTACT 120 CCAAGATACA AATGAATCAT GGAGAAATCT GCTTTCTACA CATGTTCAGG AATTTTTCAC 180 CAGCTGTCTT CGACACTTCT CGCAAACGAG CCGATCCACA ACCCCTGCAA ACTTGG 236

Claims: CLAIMS 1. A purified, isolated and cloned nucleic acid sequence encoding a gene, designated ATM, mutations in which cause ataxia-telangiectasia and polymorphisms thereof. 2. A nucleic acid sequence as set forth in claim 1 having a cDNA sequence set forth in SEQ ID Nos:3, 8, 9. 3. A purified, isolated and cloned nucleic acid sequence according to claim 1 wherein the nucleic acid is mRNA. 4. The nucleic acid sequence of claim 1 wherein a mutation event selected from the group consisting of point mutations, deletions AND insertions has occurred such that the resulting sequence is altered imparting ataxia- telangiectasia. 5. The nucleic acid sequence of claim 1 wherein a mutation event selected from the group consisting of point mutations, deletions AND insertions has occurred such that the resulting amino acid sequence is altered imparting ataxia-telangiectasia. 6. The nucleic acid sequence of claim 1 wherein a mutation event selected from the group consisting of point mutations, deletions, insertions and rearrangements has occurred within the flanking sequences of ATM such that regulation of ATM is altered imparting ataxia- telangiectasia. 7. The nucleic acid sequence of claim 1 wherein a mutation event selected from the group consisting of point mutations, deletions, insertions and rearrangements has occurred within the regulatory sequences of ATM such that regulation of ATM is altered imparting ataxia- telangiectasia. 8. A vector comprising an expression control sequence operatively linked to the nucleic acid sequence of claim 1. 9. A vector comprising an expression control sequence operatively linked to a nucleic acid sequence as set forth in claim 2. 10. A host cell, wherein the host cell is selected from the group of suitable eucaryotic and procaryotic cells, which is transformed with the vector of claim 8. 11. A host cell, wherein the host cell is selected from the group of suitable eucaryotic and procaryotic cells, which is transformed with the vector of claim 9. 12. An expression vector according to claim 8 which has a DNA sequence encoding a human phosphatidyllinositol 3- kinase or biologically active derivatives thereof. 13. A host cell, wherein the host cell is selected from the group of suitable eucaryotic and procaryotic cells, which is transformed with the vector of claim 12. 14. The host cell of claim 13 wherein it is E. coli . 15. A purified protein as encoded by the nucleic acid as set forth in claim 1. 16. A purified amino acid sequence selected from the group consisting of SEQ ID No:3 and analogs thereof and mutations of SEQ ID No:3 which cause ataxia-telangiectasia. 17. The purified amino acid sequence as set forth in claim 15 further characterized by signature motifs of signal transduction proteins. 18. The purified amino acid sequence as set forth in claim 16 having signal transduction activity. 19. The purified amino acid sequence as set forth in claim 16 wherein the protein is a phosphatidylinositol 3- kinase. 20. An antibody which specifically binds to a polypeptide of the amino acid sequence of claim 16. 21. An antibody of claim 20 selected from the group consisting of monoclonal and polyclonal antibody. 22. An antibody of claim 21 conjugated to a detectable moiety. 23. A peptide amino acid sequence isolated from the amino acid sequence as set forth in claim 16 having immunogenic properties. 24. A peptide as set forth in claim 23 selected from the sequences set forth as SEQ ID Nos:4 to 7 and 16-23. 25. An antibody which specifically binds to a peptide of the amino acid sequence of claim 23. 26. An antibody of claim 25 selected from the group consisting of monoclonal and polyclonal antibody. 27. An antibody of claim 26 conjugated to a detectable moiety. 28. An antibody which specifically binds to a peptide of the amino acid sequence of claim 24. 29. An antibody of claim 28 selected from the group consisting of monoclonal and polyclonal antibody. 30. An antibody of claim 29 conjugated to a detectable moiety. 31. A non-human transgenic mammal or cell lines containing the expressible nucleic acid sequence of claim 1. 32. A non-human transgenic mammal or cell lines containing the expressible nucleic acid sequence of claim 2. 33. A non-human transgenic mammal or cell lines containing the expressible nucleic acid sequence of claim 4. 34. A non-human transgenic mammal or cell lines containing the expressible nucleic acid sequence of claim 5. 35. A non-human transgenic mammal or cell lines containing the expressible nucleic acid sequence of claim 6. 36. A non-human transgenic mammal or cell lines containing the expressible nucleic acid sequence of claim 7. 37. A non-human eucaryotic organism in which the equivalent nucleic acid sequence of claim 1 is knocked out. 38. A non-human eucaryotic organism in which the equivalent nucleic acid sequence of claim 2 is knocked out. 39. A mouse in which the nucleic acid sequence set forth in SEQ ID No:11 is knocked out. 40. A method for detecting carriers of the defective gene which causes ataxia-telangiectasia, said method comprising the steps of : a) isolating genetic material from an isolated cell sample from a patient; c) hybridizing the genetic material with molecular probes complementary to the DNA sequence of the defective ataxia-telangiectasia gene in order to detect carriers of the mutant gene; and d) detecting the presence of the defective gene which causes ataxia-telangiectasia. 41. A method as set forth in claim 40 wherein the genetic material isolated from the cell sample is DNA. 42. A method as set forth in claim 40 wherein the cell is a lymphocyte. 43. A method as set forth in claim 40 wherein the sample is amniotic fluid. 44. A method as set forth in claim 40 wherein the cell sample is chorionic villi. 45. A method of detecting the polypeptides set forth in claim 16 which cause ataxia-telangiectasia including the steps of: isolating polypeptides from a specimen; and assaying for the polypeptides selected from the group consisting of SEQ ID No:3, analogs of SEQ ID No:3 and mutant sequences of SEQ ID No:3 with an assay selected from the group consisting of immunohistochemical and immunocytochemical staining, ELISA, RIA, immunoblots, immunoprecipitation, Western blotting, functional assays and protein truncation test. 46. A method of detecting a mRNA complementary to the nucleic acid sequence of claim 1 and polymorphisms and mutations thereof including the steps of: isolating mRNA from a specimen; and assaying for complementary mRNA with an assay selected from the group consisting of in si tu hybridization, Northern blotting and reverse transcriptase - polymerase chain reaction. 47. A method of detecting a nucleic acid sequence of claim 1 and polymorphisms and mutations thereof including the steps of: isolating from a specimen nucleic acid; and assaying the nucleic acid with an assay selected from the group consisting of in si tu hybridization, Southern blotting, single strand conformational polymorphism, restriction endonuclease fingerprinting (REF) , PCR amplification and DNA-chip analysis using nucleic acid sequence of claim 1 and polymorphisms and mutations thereof specific primers. 48. A method of screening for homozygous or heterozygous carriers of ATM mutant genes for genetic counseling including the step of: assaying an isolated specimen from a patient for mutations of the ATM gene. 49. A method of claim 48 wherein the specimen is selected from the group consisting of polypeptides and nucleic acids. 50. A kit for detecting a defective gene causing ataxia-telangiectasia, said kit comprising: a molecular probe complementary to genetic sequences of a defective gene which causes ataxia- telangiectasia and detection means for detecting hybridization of said molecular probe and the defective gene thereby indicating the presence of the defective gene. 51. A kit for detecting a defective gene product associated with ataxia-telangiectasia, said kit comprising: an antibody which recognizes mutant epitopes on the ATM gene product which are associated with ataxia- telangiectasia and detection means for detecting the binding of the antibody thereby indicating the presence of the defective gene product. 52. A purified amino acid sequence as set forth in SEQ ID No:3 and analogs thereof. 53. A method of screening subjects presenting with "partial A-T phenotypes" for ATM mutant genes for genetic counseling including the steps of: (a) isolating a specimen from a subject presenting with a "partial A-T phenotype"; and (b) assaying the specimen for mutations of the ATM gene wherein a nucleic acid sequence of claim 1 and polymorphisms and mutations thereof are identified by restriction endonuclease fingerprinting (REF) .

Inventors: COLLINS FRANCIS S, SHILOH YOSEF, TAGLE DANILO A, COLLINS, FRANCIS, S., SHILOH, YOSEF, TAGLE, DANILO, A.
Applicants: COLLINS FRANCIS S, SHILOH YOSEF, TAGLE DANILO A, UNIV RAMOT, US HEALTH, COLLINS, FRANCIS, S., RAMOT-UNIVERSITY AUTHORITY FOR APPLIED RESEARCH AN, SHILOH, YOSEF, TAGLE, DANILO, A., UNITED STATES OF AMERICA, REPRESENTED BY THE SECRE
Application year: 1996
Main classification: C12N5
IPC codes: A01K67, A61K38, C07K14, C07K16, C12N1, C12N5, C12N15, C12P21, C12Q1, G01N33, G01N37